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CHAPTER I 
 
PEPTIDE-MEDIATED SYNTHESIS OF MATERIALS 
 
Introduction 
 The existing types of synthesis methods and applications related to nanoparticles 
are as varied as the types of nanoparticles themselves.  Whether it be the properties 
associated with the materials or the components and mechanism that drive their 
formation, nanoparticles are rapidly becoming integrated in all parts of society.  Of all 
these connections, however, none is more important or interesting than the relationship 
that exists between nanoparticles and biology.   
 Mother Nature has long been recognized as one of the leading researchers in 
materials chemistry.  Biology has developed complex mechanisms available to many 
types of organisms with which to synthesize and utilize materials under the most ambient 
of conditions.  Unfortunately, the task of recognizing these mechanisms and converting 
them to a laboratory setting has been far from trivial.  As a result, an entire area of 
research has emerged devoted to identifying and better understanding this relationship, 
termed “biomimetics.”   
 The following dissertation is dedicated to a similar task: a better understanding of 
the relationship between biology and nanomaterials.  Specifically, how to apply biology 
in ways that will affect and influence nanomaterials, and how to apply nanomaterials in 
ways that will affect and influence biology will be addressed.  Chapter I begins by 
focusing on the most fundamental of these concepts, seeking to offer a glimpse into how 
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to manipulate one of the most basic units of biology, a peptide, to direct the synthesis and 
assembly of nanoparticles.  Subsequent chapters then proceed to examine other various 
aspects related to this bio/nanomaterial interface.  Only Chapter II deviates from this 
theme, offering an opportunity to explore nanoparticle synthesis in the absence of 
biology.  Magnetic FePt nanoparticles were synthesized from a single-source molecular 
precursor by sonochemical means.  The particles were then well characterized and shown 
to possess remarkable magnetic properties.  Chapter III resumes the bionanomaterial 
theme by focusing on the design and synthesis of an antigenic mimic of the Ebola virus 
glycoprotein.  Antigen mimicry was achieved by complete mapping and nanoparticle 
presentation of an Ebola virus glycoprotein epitope.  Quantitation of the interaction of 
this mimic with a monoclonal antibody was then accomplished and compared with 
similar data from the native protein.  Chapter IV continues this study by more intimately 
examining the interaction between this epitope and antibody.  Altered nanoparticle 
presentation schemes were considered with hopes of achieving improved antigenicity.  
Chapter V concludes by investigating further a non-specific binding interaction 
encountered along the way.  Additional minor research efforts are then presented in the 
Appendices. 
 
Biomineralization 
Since the pioneering work of Lowenstam et al., biomineralization has provided an 
impetus for the bottom-up assembly of many types of inorganic materials.1  Biological 
systems are capable of exerting a remarkable level of control over the size, shape, and 
composition of matter on both the micro- and nanoscale.2  One has but to look at the 
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microstructure of an oyster shell or the complex patterns of SiO2 in the frustules of a 
diatom to appreciate the mastery that biological systems exert over materials synthesis.  
The idea that researchers might also be able to achieve a similar level of control in the 
laboratory through solid-state bioinorganic synthesis has propelled the development of 
the burgeoning field of biomimetic materials science. 
 Biomineralization can be cast as a three-step process involving the 
supramolecular preorganization of a template, the interfacial molecular recognition of 
crystal nuclei and the cellular processing of resultant aggregates.3 The first-order 
assembly of biomacromolecular matrices such as protein and lipid networks provides a 
foundation for the second-order assembly of inorganic species.  Typically, these 
frameworks have functionalized surfaces that behave as templates for inorganic 
nucleation and are governed by electrostatic, structural and stereochemical 
complementarity at the organic-inorganic interface.  Without cellular intervention to 
control the flux of metal ions, crystal nuclei would continue to grow along these 
scaffolds, proceeding to their bulk state.  Clearly, such unconstrained growth represents a 
danger to cellular integrity.  The final stage of biomineral construction is that of cellular 
processing, often the distinguishing step between native biomineral morphology and that 
of its synthetic analogues.  The intra- or extracellular environment in which a crystal 
grows ultimately impacts its crystallographic structure and morphology and ensures the 
function of the cell.4 To understand how the biomolecule templates can affect their 
control, a more detailed discussion on particle formation is necessary. 
The classic understanding of the formation of an inorganic material can be 
divided into two stages; formation of a stable nuclei and subsequent growth of the 
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particle.5 Perturbation of either stage can produce drastic changes to the resulting 
material.  Nucleation of a material is dominated by the concept of supersaturation.  In 
solution, there is constant formation and dissolution of small clusters of the dissolved 
ions or molecules resulting from the effects of Brownian motion.6  As the concentration 
increases, the formation of the particles reaches a certain size, referred to as the critical 
nucleus, after which spontaneous nucleation occurs.  At this point, crystal growth begins 
to dominate and may proceed via one of two routes.  Growth occurs via diffusion and 
addition of the solute to the surface of the nuclei.  Alternatively, growth may also take 
place through the aggregation of pre-formed crystal nuclei.  Both pathways are 
influenced by reaction rates as well as mass transport mechanisms that determine both 
size and shape of the resulting crystal.   
 The inclusion of a biomolecule during either stage of nanoparticle formation can 
have a drastic effect on the resulting material.  It is thought that nuclei formation 
proceeds analogous to a chemical reaction, in which an activation energy barrier must be 
overcome in order for the reaction to occur.6  If another solid or an impurity exists in 
solution with the ions or molecules, nucleation occurs at, or on, the site of the impurity.  
Thus, a biomolecule in solution could be considered an impurity at which the nucleation 
can occur.  The inclusion of this impurity then lowers the activation barrier by inducing 
nucleation.  This can also affect the size and structure of the crystal.  By increasing the 
local concentration of solute at the site of the impurity, the number of nucleation sites 
present also increases.  The increase in material required for these sites leaves less 
material for growth, resulting in smaller particles.6  Biomolecules have also been shown 
to affect the growth stage of crystal particles.  For example, if an impurity has an affinity 
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for a specific facet of the growing crystal, growth along that facet could either be 
hindered or promoted, thereby affecting the morphology of the resulting crystal.        
There are several different types of biomolecules capable of mediating the 
formation of biological materials, including nucleic acids, proteins, and lipids.  The major 
focus of this chapter, however, will be on peptide-mediated synthesis of nanomaterials.  
Peptides are known to mediate the formation of materials.  The focus on peptides is of 
particular interest because, unlike many other types of biomolecules (e.g. nucleic acids, 
lipids, or proteins), they are easily synthesized in the laboratory, thus allowing translation 
from the realm of biology to the materials science benchtop. 
The biomimetic synthesis of silica is a classic example of how the study of 
biomineralization strategies of organisms can lead to the development of ambient 
synthesis methodologies for inorganic materials.  Diatoms are unicellular algae that 
possess a distinct cell wall composed of nanostructured biogenic silica.7 It had long been 
hypothesized that the diatom cell wall was composed of an organic matrix that served as 
a mediator of the biosilicification process.8 Thorough examination of the cell wall 
composition of the diatom Cylindrotheca fusiformis, led to the isolation of a set of 
polycationic peptides which generated networks of silica nanospheres in vitro in the 
presence of monosilicic acid at an optimal pH of 6.5.9  Silaffin-1A was shown to be 
comprised of a mixture of two similar peptides, silaffin-1A1 and -1A2, both of which had 
structures similar to that of silaffin-1B.  All three peptides contained polyamine modified  
lysines and phosphorylated serines.9, 10 Sequence analysis of silaffin-1B revealed seven 
homologous repeating units located near the C-terminus of the protein.  A synthetic, non-
modified analog of this repeating unit, termed R5 (H2N-SSKKSGSYSGSKGSKRRIL-
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CO2H), could also precipitate silica in the presence of monosilicic acid, with a maximal 
activity near pH 7.9  Functional analysis of the non-modified R5 peptide revealed the 
importance of the RRIL motif in silica precipitation.11  Several truncates, as well as site-
directed mutants, identified the RRIL motif as a critical component in the self-assembled 
peptide structure necessary to drive the polycondensation of silicic acid.  Further research 
involving the R5 peptide has focused on developing a higher degree of control over the 
silica structure during synthesis, and the usage of the peptide for the synthesis of metal 
oxides with different compositions (e.g. TiO2).12-14
 Researchers have also begun to adopt the principles of biomineralization systems 
to the synthesis of completely abiological materials.  Primary efforts have been directed 
at developing methods that mimic the recognition and specificity of the interactions 
between a biological template and a material.  To discover such templates, combinatorial 
peptide-display approaches have been used to identify the biomolecule with the highest 
degree of specificity for a given material.  The results of this work have led to the 
development of phage-display and cell surface display peptide libraries as screening tools 
for peptides that recognize and bind inorganic materials (Section 2).  These methods have 
expanded the potential of peptide-mediated synthesis to include a far wider variety of 
materials.15-17  
The idea that a peptide has the ability to direct the growth of a material is what 
makes biomimetics such an intriguing strategy.  Although the earliest work in this field 
appears over 25 years ago, only the last 5 years will be examined here.  The control 
exhibited by peptides free in solution and the ability of researchers to address and alter 
that control will be discussed.  Likewise, the effects demonstrated as a result of 
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immobilizing the peptide to a surface will be considered.  Finally, the adaptation of these 
peptide-associated materials into functional devices is presented.   
 
Ligand Discovery 
The application of peptide display methods has fundamentally enabled the 
development of peptide-based materials synthesis.  Peptide display libraries offer a means 
to screen for high affinity peptide binders to a number of different types of materials.18 
Peptide display is based on a combinatorial library of peptides genetically engineered to 
be displayed on the surface of a host, whether it be fused to the coat protein of a 
bacteriophage or displayed on the surface of a microorganism.16, 19 These libraries can 
generate as many as ~1011 discrete peptides.  The process of determining which library 
element binds to a particular substrate is called “biopanning”.  After incubation with the 
target material only phage or bacteria displaying peptide that bind to the material are 
eluted and collected.  Typical methodologies call for repeated cycles of exposure of the 
peptide library to the substrate material and subsequent elution under increasingly 
stringent conditions to select for the strongest binding ligands.  The phage or bacteria 
showing the highest degree of binding can then be isolated and have their DNA 
sequenced in order to determine the peptide sequence that was displayed on their surface.  
Peptide display has proven to be useful for the selection of biomolecules that bind to a 
variety of materials including; metal and metal oxide nanoclusters, metal alloys, and 
nanotubes.15-17, 20-30 A number of these sequences have been highlighted in Table 1.25  
The random sequences are generated through the synthesis of “degenerate 
nucleotides” which encode for the different peptides.  Splicing this genetic sequence into 
 7
the DNA region responsible for encoding one of the outer proteins leads to the synthesis 
of the protein with the random sequence fused to its N-terminus, thus displayed on the 
outer coat of the phage of bacteria.  Typical display methods utilize sequences ranging 
from 7-14 amino acids that are displayed in either a linear or cyclic fashion.  While a 
library displaying longer peptides is capable of generating more overall sequences, a 
higher percentage of the total possible sequences is represented via the shorter sequence 
library.  This is based solely on the number of possible outcomes resulting from the 20 
naturally occurring amino acids. 
The most customary form of peptide display involves the M13 bacteriophage.31  
The M13 bacteriophage is a type of filamentous phage composed of a single DNA strand 
surrounded by a capsid comprised of five different proteins.  Five copies each of the pIII 
and pVI proteins are located at one end of the phage, with five copies each of the pVII 
and pIX located at the other.  The capsid itself is composed of ~2700 copies of the fifth 
protein, pVIII.  Random peptide sequences can be genetically engineered to be displayed 
on any of the five peptides, but are typically expressed on either the pIII or pVIII 
proteins.  These phage libraries are then panned against the target material of interest. 
Traditional panning methods, as described above, result in the identification of 
several peptides capable of interacting with a material.  Often, it is the peptide with the 
strongest affinity for the material that is desired.  Naik et al. suggested that many of  
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Table 1. Examples of polypeptide sequences exhibiting affinity for various inorganics. 
 
Material Sequences Size pI MW Charge Display Type Ref. 
MHGKTQATSGTIQS 14 8.52 1446.60 + 1 
SKTSLGQSGASLQGSEKLTNG 21 8.31 2050.21 + 1 Au 
QATSEKLVRGMEGASLHPAKT 21 8.60 2211.52 + 1 
CSD 17, 24 
        
DRTSTWR 7 9.60 920.98 + 1 
QSVTSTK 7 8.75 749.82 + 1 Pt 
SSSHLNK 7 8.49 771.83 + 1 
PD 25 
        
SVTQNKY 7 8.31 838.92 + 1 
SPHPGPY 7 6.46 753.81 0 Pd 
HAPTPML 7 6.74 765.93 0 
PD 25 
        
AYSSGAPPMPPF 12 5.57 1221.39 0 
NPSSLFRYLPSD 12 6.09 1395.53 0 Ag 
SLATQPPRTPPV 12 9.47 1263.46 + 1 
PD 20 
        
MSPHPHPRHHHT 12 9.59 1470.63 + 1 
RGRRRRLSCRLL 12 12.30 1541.89 + 6 SiO2
KPSHHHHHTGAN 12 8.78 1359.43 + 1 
PD 26 
        
VKTQATSREEPPRLPSKHRPG 21 10.90 2371.68 + 3 Zeolites 
MDHGKYRQKQATPG 14 9.70 1616.82 + 2 
CSD 27 
        
NTRMTARQHRSANHKSTQRA 20 12.48 2351.59 + 4 ZnO 
YDSRSMRPH 9 8.75 1148.26 + 1 
CSD 28 
        
HTQNMRMYEPWF 12 6.75 1639.87 0 CaCO3 DVFSSFNLKHMR 12 8.75 1480.70 + 1 
PD 29 
        
WRPKAATN 9 11.00 955.13 + 2 Cr2O3 RIRHRLVGQ 9 12.30 1134.35 + 3 
CSD 27 
        
Fe2O3 RRTVKHHVN 9 12.01 1146.32 + 3 CSD 16 
        
AQNPSDNNTHTH 12 5.97 1335.31 0 
RLELAIPLQGSG 12 6.00 1253.46 0 GaAs 
TPPRPIQYNHTS 12 8.44 1410.55 + 1 
PD 15 
        
ZnS NNPMHQN 7 6.74 853.91 0 PD 30 
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these high-affinity binders were missed as a result of certain elution procedures and 
sought a method by which to identify these ligands.32  Naik’s group observed that some 
phage peptides bound to the material with such a great affinity that they were never 
eluted, and thus were never isolated.  As these peptides might be more effective as 
binders than the peptides that were actually being isolated, there was a need for the 
development of a new method to identify these peptides.  A polymerase chain reaction 
(PCR)-driven phage display method was employed to alleviate this problem (Figure 1).  
PCR is designed to exponentially amplify fragments of DNA.  After incubation with the 
material and subsequent acid elution the remaining nanoparticles were added to a lysis 
buffer designed to disrupt the phage coat, thus releasing the DNA of any phage that 
remained bound to the material.  The isolated DNA is  amplified by PCR and sequenced 
for the determination of peptides that otherwise would have been overlooked by 
conventional phage display methods.  When applied to the identification of peptides 
having a high affinity for Ag, 14 new sequences were determined that had previously 
gone undetected by standard phage-display method. 
 To evaluate the effectiveness of the new method relative to other panning 
conditions, a series of isolations were utilized to obtain cobalt binding peptides.  High 
affinity cobalt binders were determined using a series of three methods.  Set I involved 
typical acid elution, to remove bound phage from the material, followed by PCR to 
amplify the resulting DNA.  Set II skipped the acid elution step, thus amplifying the 
DNA of bound phage immediately after the washing steps.  Set III involved the common 
procedure of acid elution without any DNA amplification.  It was expected that the 
sequences obtained in Set II should be equal to the sum of the sequences from Sets I and 
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 Figure 1.  Schematic illustration of regular and polymerase chain reaction-driven 
biopanning to determine high affinity binders for inorganic materials.32   
 
 
 
III, however, some sequences were observed that were unique to Set II.  This new group 
of sequences indicates that some potential peptides were, in fact, lost during the 
traditional elution process.  Naik concluded that for a thorough analysis of all the 
potential binders for a material, a non-acid elution PCR-based method would be the best 
approach. 
 While phage display is a more common manner of peptide display, cell-surface 
display has developed in parallel as both a powerful complement and alternative to phage 
display.  Cell-surface display operates in a manner similar to phage display, in which a 
large number of peptides are randomly displayed on the surface of the cell.  Systems have 
been developed for a number of cell types, including Escherichia coli, Gram-positive 
bacteria, and yeast.33-35 A major advantage associated with cell-surface display libraries is 
the ability to fluorescently label the cells enabling high-throughput screening processes.  
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This method of quantitation allows for the improved identification of high affinity 
binders as well providing a means by which to optimize the screening process.33, 34  
 Yeast surface display has emerged as the primary form of cell-surface display.  
Yeast has one primary advantage over E. coli and phage display systems in the fact that it 
lacks an expression bias that is often observed with E. coli systems.35 In E. coli, larger 
peptides and proteins, or proteins involving disulfide bonds can be lost to the screening 
process due to the inability of the bacteria to express these proteins properly.  Yeast 
display systems are simply more robust and are consequently used to express larger 
proteins such as antibodies.  Smaller peptides, however, have been successfully expressed 
in both types of systems, and a number of examples highlighting this technology are 
covered in later sections.     
 The use of these peptide-display libraries has opened the door to countless 
materials synthesis applications.  These peptides often allow for the room temperature 
biomimetic synthesis of a number of different materials that once were only thought 
possible via high temperature or high pressure methods.  Many of the peptide sequences 
highlighted in the following sections were generated using the peptide display methods as 
described above, thus underscoring the valuable impact that can be achieved via the 
convergence of biotechnology and materials science. 
 
Unconstrained Peptide Templates 
 By examining biomineralization systems, researchers understand how peptides 
interact with different materials to direct the resulting size, morphology, or properties 
associated with the material.  The translation of these systems to materials not typically 
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under biological control provides researchers with new approaches for their synthesis.  
New peptides capable of interacting with abiological materials are key to expanding the 
repertoire of obtaining materials.  In recent years, the use of such peptides has led to an 
ever expanding variety of different materials including; metal oxides, metal nanoclusters, 
calcium carbonates, and other nanostructures, all of which have interesting magnetic, 
optical, and electronic properties.3, 25, 36   
 
Metal Oxide Synthesis 
 In recent years, the biomimetic synthesis of metal oxides, such as SiO2, has 
received considerable attention.  Inspired from the peptides found in the cell wall of the 
diatom Cylindrotheca fusiformis, one of the first methods developed for the in vitro 
synthesis of silica was the R5 peptide-mediated condensation of monosilicic acid.9  The 
synthetic R5 peptide is thought to self-assemble with the terminal RRIL motif serving to 
direct this organization.  As a result, a highly cationic complex is formed from the four 
unmodified lysine residues found throughout each R5 peptide.  These cation assemblies 
serve to create localized concentrations of silicic acid whose condensations is driven by a 
general acid/base catalyst mechanism.37  Poly-l-lysine (PLL) has also been used to mimic 
the condensation chemistry of the R5 peptide.  These peptide systems are still studied 
today in an attempt to gain a better understanding of how to control size and morphology 
of the resulting particles as well as determining what other potential materials might fall 
under the control of these peptides.  Table 2 lists these sequences, as well as all others 
discussed in the following section, which have been shown to direct the formation of 
metal oxides. 
 13
 Controlling Size and Morphology of Silica Nanostructures 
 Typical R5 or PLL promoted condensation of silica resulted in fused structures of 
nanospheres having diameters on the order of 200-700 nm.9, 11, 12, 38 Additional control 
over the growth and resulting nanostructure of biomimetic silica can be achieved by 
capitalizing on regulated changes of the three-dimensional structure of the poly-L-lysine 
peptide template.39 The secondary structure of short-chain PLL (PLL20) is a random coil 
conformation regardless of the pH or buffer used.  The resulting silica is typically 
spherical with diameters of approximately 500 nm.  As the molecular weight of PLL 
increases, the formation of crystalline hexagonal platelets of silica is observed.  This 
occurs as a result of a conformational change in longer-chain PLL from the random coil 
configuration to a helical conformation in the presence of phosphate ions.  The helical 
long-chain PLL can then pack into hexagonal lattices that serve as templates for the 
growth of hexagonal-shaped silica.40 A second conformational change can be induced by 
heating the polymer then cooling to room temperature.  This thermal cycling changes the 
polymer’s structure from helical to β-sheet structure, accompanied by a morphological 
change in the resulting silica to an assembly of nanospheres rather than the hexagonal 
platelets (Figure 2).41
 Hawkins et al. examined the porosity associated with silica produced by PLL as a 
function of the template’s conformation.42 Nitrogen adsorption data indicated that silica 
produced from PLL with an α-helical structure contained pores with an average volume 
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 Figure 2.  SEM images of SiO2 nanostructures formed via (left) α-helical and (right) β-
sheet PLL mediation.41
 
 
 
of 0.26 cm3/g compared with a value of 0.03 cm3/g for PLL in a β-sheet structure at the 
same concentration.  The total pore volume for each sample was shown to be similar 
(0.28 and 0.26 cm3/g respectively) indicating a higher degree of surface area associated 
with the silica produced by the α-helical PLL.  In comparison, low-molecular weight 
PLL, which fails to adopt any configuration other than a random coil, showed very little 
porosity in the silica samples. 
 Certain additives may also interact with the condensation mechanism, thus 
affecting the resulting morphology.  Rodriguez et al. showed one example when studying 
the effect of alcohol additives upon peptide-mediated silica condensation.43  When 
synthesized in the presence of hydroxyl containing compounds, such as alcohols and 
carbohydrates, the overall morphology was shown to shift from the commonly observed 
network of nanospheres toward a more sheet-like complex.  This sheet-like complex was 
composed of spheres with diameters of approximately 80 nm.  This effect was observed 
using both R5 and PLL as well as a third peptide, Si4-1 (H2N-MSPHPHPRHHHT-
COOH), which had been identified from a phage-display method.  Several potential 
mechanisms for this shift were proposed, all of which center around the idea that the 
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inclusion of the –OH groups couple to one of the reactants (peptide or Si(OH)4), thus 
slowing particle growth. 
 
 
Table 2. Peptide sequences used in formation of metal oxides. 
 
Peptide Name (if 
applicable) Sequence Material Reference 
PLL p-(Lys)n
SiO2, TiO2, 
GeO2
13, 39, 41, 42, 
43, 44 
R5 SSKKSGSYSGSKGSKRRIL SiO2, TiO2 13, 43 
Si4-1 MSPHPHPRHHHT SiO2 43 
 Phe7-PEG135-Phe7 SiO2 45 
Ti-1 RKKRTKNPTHKLGGGW TiO2 46 
Ge2 TSLYTDRPSTPL GeO2 21 
Ge8 SLKMPHWPHLLP GeO2 21 
Ge34 TGHQSPGAYAAH GeO2 21, 47 
BT1 HQPANDPSWYTG BaTiO3 48 
BT2 NTISGLRYAPHM BaTiO3 48 
ZnO-1 EAHVMHKVAPRP ZnO 49 
CN225 RHTDGLRRIAAR Cu2O 50 
CN85 RTRRQGGDVSRD Cu2O 50 
CN86 RPRRSAARGSEG Cu2O 50 
CN46 ADRTRGRIRGNC Cu2O 50 
CN44 NTVWRLNSSCGM Cu2O 50 
CN88 EKWGMHQECYRH Cu2O 50 
CN93 TMEPRWWCNPIN Cu2O 50 
CN179 RIGHGRQIRKPL ZnO 50 
CN155 VRTRDDARTHRK ZnO 50 
CN120 PASRVEKNGVRR ZnO 50 
CN146 MRHSSSGEPRLL ZnO 50 
CN111 PAGLQVGFAVEV ZnO 50 
CN185 RTDDGVAGRTWL ZnO 50 
CM1 AAPNSPWYAYEY CaOMoO3 51 
CM2 SWSPAFFMQNMP CaOMoO3 51 
CM3 YESIRIGVAPSQ CaOMoO3 51 
CM4 DSYSLKSQLPRQ CaOMoO3 51 
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Aside from PLL, other polypeptides have been used to mediate the formation of 
SiO2.  Liu et al. studied the ability of a triblock copolymer, poly(L-phenylalanine)-b-
poly(ethylene glycol)-b-(L-phenylalanine) (Phe7-PEG135-Phe7) to mediate silica 
formation in an organic solvent system.45  Reaction of the peptide with aniline-methyl 
triethoxy silicane (AMTS) and tetraethoxysilane (TEOS) in a dioxane/benzyl alcohol 
solution with subsequent heating (80 oC for 10 min.) yielded an extremely unique 
macroporous morphology (Figure 3) which was not observed in the absence of AMTS.  
This structure forms as a result of the formation of an organic network, which is likely 
attributed to the π-stacking that occurs between the phenylalanine residues of the peptide 
and the aniline groups of the AMTS precursor.  Such a mechanism was also previously 
proposed by Tamaki et al. for the formation of silica gel polymer hybrids using 
polystyrene and phenyl-containing silicates under similar conditions (i.e. organic solvent 
and elevated temperature).52  
 
 
Figure 3.  SEM image of interconnected layers of SiO2 from reaction of Phe7-PEG135-
Phe7 with AMTS and TEOS.45
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  The ability of external forces to control silica formation has also been examined.  
Physical influences such as electrostatic and hydrodynamic fields have been studied in 
relation to their effect on silica morphology.43  An electrostatic field of -1.0 potential was 
applied to a solution of PLL for 20 min, after which the cathode was removed and 
immersed in a silicon-reagent containing solution.  Silica deposition was concentrated on 
the surface of the electrode, indicating the ability of the electric field to control the 
positioning of the peptide at the electrode surface.  The morphology of the resulting silica 
shifted from sphere-like particles to a fibrous structure as the electric field was applied to 
increasing molecular weight PLL.  When under the influence of a variable hydrodynamic 
field, achieved by cycling a fixed volume of R5 peptide through a Tygon tube, a complex 
of three-dimensional rope-like structures was observed.  It was hypothesized that these 
were the results of bubbles inside the tubing created localized gradients located at the air-
liquid interface, thus influencing the formation of the silica. 
 
Formation of Non-silica Containing Metal Oxides 
 Both the R5 and PLL peptides have shown the ability to control the formation of 
metal oxides compositionally similar to that of SiO2.  Sewell and Wright first reported the 
ability of these peptides in mediating the formation of titania (TiO2).13  The condensation 
of TiO2 was observed using reaction conditions similar to that of the polycondensation of 
silica.  A titanium-containing precursor, titanium(IV) bis(ammonium lactate)-dihydroxide 
(TiBALDH), in the presence of peptide produced TiO2 in less than 5 min.  Reactions 
using R5 peptide produced nanospheres of titania with diameters on the order of 50 nm.  
PLL induced the formation of somewhat larger particles, ~140 nm.  It is interesting to 
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note that in the R5 case, condensation proceeded in the absence of phosphate ions, which 
had not been observed for SiO2.  It is thought, as with the formation of silica, that the 
peptide serves to concentrate the anionic precursor through a variety of interactions, 
while acting as an acid/base catalyst in promoting hydrolysis.  The use of PLL to produce 
germania (GeO2) in a similar manner has also been reported.44
 R5 and PLL are only two of the peptides that have shown the ability to direct the 
formation of metal oxides.  Ken Sandhage’s group has utilized phage-display peptide 
libraries to detect peptides that recognize and promote the precipitation of both TiO2 and 
GeO2.21, 46, 47 Twenty different peptides were identified that bound to one of the major 
facets of rutile TiO2: the (100), (110), and (001) facets.46  However, only one peptide, Ti-
1 was capable of binding to all three.  The peptides were shown to be enriched in lysine, 
arginine, and histidine residues, which is to be expected considering the other 
polycationic biomolecules (R5 and PLL) that biomineralize TiO2.   In a separate study, 
three major germanium binding peptides were identified, two of which induced the rapid 
precipitation of GeO2 when added to a solution containing the Ge-containing compound 
tetramethoxygermanium (TMOG).21 The precipitation is sequence specific throughout a 
group of peptides with successful precipitations resulting from peptides containing 
histidine residues and a high-degree of hydroxyl-containing residues.  The TiO2 and 
GeO2, like SiO2, was produced in the form of interconnected networks of spherical 
particles having diameters between 50-100 nm.   
One of the peptides, Ge34 (TGHQSPGAYAAH), was later used to precipitate 
amorphous germania particles that would later serve as a matrix from which to grow 
magnetic CoPt nanoparticles.47 The germania acts as a support capable of both the 
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immobilization as well as the determination of the size of the CoPt nanoparticles on the 
basis of the pores in the matrix.  CoPt formation and immobilization was accomplished 
by reducing Co and Pt salts with NaBH4 in the presence of the GeO2 matrix.  The 
diameters of the resulting CoPt particles (~8-9 nm) were in agreement with values 
obtained from the average pore diameter of the GeO2 nanospheres (10.59 nm).       
 Combinatorial peptide display methods have been used to identify peptides that 
bind to a variety of other metal oxide materials.  Two prime examples include the use of 
phage display to identify and isolate peptides showing an affinity for the ferroelectric 
material BaTiO3 and the fluorescent semiconductor ZnO.48, 49  Typically, the synthesis of 
tetragonal BaTiO3 is accomplished via high temperature routes (>500 oC) or requires 
prolonged annealing under extremely basic conditions.  Using combinatorial display 
technologies, two peptides were identified that were capable of precipitating tetragonal 
BaTiO3 at room temperature.48 The resulting material exhibited polarization hysteresis (a 
property common amongst ferroelectric materials) consistent with materials synthesized 
via high temperature methods.  Thus, the bioenabled formation of the material represents 
an obvious advantage for the future synthesis of BaTiO3.   
 Umetsu et al. identified a number of ZnO-binding peptides from phage display.  
The best binder, ZnO-1, contained an increased number of basic and hydrophobic 
residues relative to other panned ligands and showed a 100-fold greater binding affinity.49  
To determine the specificity of this interaction, the peptide was modified with a glycine-
linker (GGGS) and terminal cysteine residue at the C-terminus and bound to a gold plate 
through the Au-Cys interaction.  The Au plate was then incubated at room temperature in 
a solution of fluorescent ZnO particles.  The fluorescing particles were colocalized on the 
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portions of the plate previously immersed in peptide solution, indicating the ability of the 
peptide to recognize and bind the material to the Au surface.  The same peptide was also 
tested for its role in the biomineralization of the semiconducting material.  The ZnO-1 
peptide, when combined with a zinc hydrate solution showed no precipitation; however, 
the linker-modified peptide described above promoted a small amount of precipitation 
observable after 3 days.  The recognition between the peptide and the material was 
brought about by the ZnO-1 peptide, but the dehydration of the Zn(OH)2 was actually 
initiated through interaction with the cysteine residue.  The linker, when tested on its 
own, failed to precipitate ZnO.  The precipitate, when observed through SEM, consisted 
of an unusual flower-type morphology previously unknown for ZnO (Figure 4). 
 
 
Figure 4.  Flower-type morphology observed from the peptide-mediated 
biomineralization of ZnO.49
 
 
 
   Often, in an effort to better control the size or shape of the nanoparticles 
produced, the peptides are used to form a nanoreactor, within which the material is 
synthesized and the size and shape constrained to that of the reactor.  In solution, 
bolaamphiphile peptide monomers self-assemble into doughnut-like structures.53 The 
peptide-assemblies, when reacted with GaCl3 at pH = 10 for 1 month promoted the 
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hydrolysis of the precursor to produce monodisperse particles of the kinetically 
unfavored monoclinic phase of β-Ga2O3.54  The particles had diameters of 50 nm with 
narrow size distributions.  The degree of mineralization was significantly reduced when 
the pH was lowered to 7.  This was thought to weaken the hydrogen bonding associated 
with the carboxyl- and amine termini of the doughnut assemblies by protonating the 
carboxyl group.  It was this site at which the hydrolysis was hypothesized to occur, thus 
explaining the reduction of mineralization at the lower pH. 
However, simply being able to control the size or shape of a resulting nanoparticle 
does not necessarily constitute a complete understanding of how a peptide interacts with 
a material.  In an effort to characterize the peptide/metal oxide interaction, Thai et al. 
attempted a compositional analysis of metal oxide-binding peptides.50 A cell-surface 
display method was used to determine peptides with an affinity for the semiconducting 
metal oxides Cu2O and ZnO.  These peptides were then analyzed for the occurrence of 
specific residues with the anticipation of positional or chemical trends that could provide 
insight into the interaction between the peptides and the metal oxides.  Approximately 30 
different binding clones were randomly selected for each material and sequenced to 
determine the amino acid sequence for the peptides responsible for binding.  The number 
of occurrences of individual amino acids were totaled and put into categories based on 
their functionalities.  Throughout the identified high-affinity binders, two distinct classes 
of binders were determined for Cu2O.  The peptides were either highly basic, Arg-Arg 
containing, hydrophilic peptides with a net charge of +2 or were hydrophobic tryptophan-
containing peptides with a neutral or +1 net charge.  ZnO-binding peptides, on the other 
hand, exhibited hydrophilic peptides with common Arg-Lys pairs.  Hydrophobic peptides 
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with an increased number of leucine and valine residues were also fairly widespread for 
the ZnO material.  Molecular dynamic simulations confirmed the probability of these 
residue pairs (Arg-Arg for Cu2O and Arg-Lys for ZnO) serving as contact points with 
their respective material. 
So far, this discussion has only included the use of peptide display methods to 
identify peptides that bind to a single-component material; however, the identification of 
multicomponent binders is also applicable.  Ahmad et al. used a commercially available 
phage-display method to attain peptides that would recognize and induce precipitation of 
the photoluminescent material powellite, CaO•MoO3.51  Four major binders were 
identified, all of which induced precipitation at room temperature when reacted with two 
metal precursors, calcium acetate and ammonium paramolybdate, at neutral pH.  
Interestingly, the precursors, which were in solution at a molar ratio of 2.8:1 (Mo:Ca) 
generated a product that was 1:1 in molybdenum and calcium.  In order to further study 
the potential binding mechanism, mutational analysis was used to evaluate the 
importance of individual amino acids and their influence on the mineralization of the 
material.  It was determined that mineralization was very specific with respect to the 
positioning of the amino acids, as well as the serine content of the peptide, evidenced by 
an approximate 30% decrease in amount of powellite mineralized when serines were 
replaced with alanines.  This result was consistent with previous studies showing serine 
residues to play an important role in the binding and complexation of molybdenum.55
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Encapsulation Using Biomimetic Silica 
 The main focus of biomimetically produced metal oxides has been directed 
towards controlling the structure.  However, some work has been done to expand the 
applicability of these materials.  One such application is the encapsulation of materials 
using biomimetically produced silica.  Such a technique has sparked particular interest 
due to its potential in drug-delivery systems, as well as for the preservation of 
biomolecules in harsh environments.56, 57 Luckarift et al. used biogenic silica to entrap the 
enzyme butyrylcholinesterase and characterized the resulting composite.56 A solution of 
R5 peptide, silicon precursor, and enzyme were reacted for 5 min. at room temperature.  
A typical network of silica particles was observed by scanning electron microscopy 
(SEM).  Ninety percent of the initial enzyme activity was retained in the silica-enzyme 
complex (the remaining 10% was observed in the wash supernatants), compared to 10% 
activity observed using traditional sol-gel immobilization techniques.  In order to 
ascertain whether the enzyme was actually entrapped in the silica rather than absorbed to 
the surface, a second solution of silica particles was prepared sans enzyme, and later 
added to a solution of enzyme to test for adsorption to the silica surface.  No significant 
activity was observed, indicating the entrapment of the enzyme in the nanospheres.  Naik 
et al. also reported the entrapment of enzymes in silica nanospheres, but expanded the 
technique to include nanoparticles.57 They showed that the inclusion of preformed CoPt 
nanoparticles or quantum dots (QDs) to a silica-precipitating reaction mixture could lead 
to the entrapment of the particles (Figure 5). 
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Figure 5.  TEM of entrapped CoPt nanoparticles in a silica matrix.57 
 
Biomineralization of Calcium Carbonate 
 CaCO3 is one of the most common biological minerals.  It exists in six different 
phases: calcite, aragonite, vaterite, calcium carbonate monohydrate, calcium carbonate 
hexahydrate, and an amorphous form.2  The most common of these forms are the calcite 
and aragonite phases.  A great deal of work has been published on attempting to direct 
and control the growth of CaCO3 in vitro, some of which has included using metal ion 
and carboxylic acid additives.58, 59 Most of the previous work involving peptide-mediated 
formation of CaCO3 has involved either the selection of certain faces of the growing 
crystal to induce formation of a particular phase, or the use of acidic peptides as growth 
templates.60-63 Table 3 presents a few examples of peptide sequences used to mediate the 
formation of CaCO3. 
The outer shell of the mollusk Mytilus californianus is composed of calcium 
carbonate and is usually found in the calcite or aragonite phases.  This hard, protective 
shell is grown with the help of an organic matrix.1  The isolated matrix proteins involved 
in shell formation were enriched in aspartic acid residues.64 Many published reports 
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suggest these acidic proteins are responsible for the phase selection of the growth CaCO3, 
calcite or aragonite.65-67 Acidic peptides are still being studied for their role in vivo in 
calcite morphology mediation.  Volkmer et al. used peptides containing alternating 
hydrophilic (Asp) and hydrophobic (Phe) residues to create β-sheet formations designed 
to imitate the acidic proteins normally thought to control calcite formation.68  The two 
peptides used, H-(Phe-Asp)2-OH and H-(Phe-Asp)4-OH, are known to interact with  
 
Table 3. Peptide sequences used in the formation of CaCO3. 
Sequence Material Reference 
FDFD CaCO3 68 
FDFDFDFD CaCO3 68 
PEG110-(Asp)10 CaCO3 69 
PEG110-(Asp)16 CaCO3 69 
PEG110-(Glu)6 CaCO3 69 
PEG110-(Glu)10 CaCO3 69 
PEG110-(Glu)16 CaCO3 69 
PEG110-(Glu)20 CaCO3 69 
PEG110-(Glu)25 CaCO3 69 
RREEWWDDRREEWWDD CaCO3 70 
KKEEWWDDKKEEWWDD CaCO3 70 
RREEWWDDPRREEWWDD CaCO3 70 
KKEEWWDDPKKEEWWDD CaCO3 70 
KKEEWWDDGKKEEWWDD CaCO3 70 
KKAEEAWWADDPKKAEEAWWADD CaCO3 70 
KEKEWDWDKEKEWDWD CaCO3 70 
 
 
 
distinct crystal faces of calcite.  Carbon dioxide and ammonia were slowly diffused into a 
solution containing calcium chloride and the peptide to induce the formation of the 
crystals.  The crystals were shown to have grown with a preference toward the {01.2} 
and {11.0} faces in the presence of both aspartic acid-rich peptides, a commonly 
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observed growth habit in biology for calcite crystals.  At the time, this represented the 
first example of the use of a synthetic peptide to induce the same growth habits for 
natural peptides isolated from organisms. 
 This idea that acidic peptides can act as growth modifiers for calcium carbonate 
has led to the study of the effects of poly-aspartic acids and poly-glutamic acids and the 
role that the structure of the peptides might play in growth modification.  Kasparova et al. 
examined the concentrational effect displayed by block copolymers rich in aspartic and 
glutamic acid residues.69  They determined that PEG-ylated block copolymers (PEG-b-
poly(L-Asp) and PEG-b-poly(L-Glu)) possessing a random coil conformation at elevated 
pH (~8) could control the morphology of the resulting crystal as a function of polypeptide 
concentration.  Additionally, increasing concentrations of copolymer exhibited a much 
greater effect on the resulting morphology leading to the formation of spherical particles.  
This deviates for more rigid cubic-like particles observed under small concentrations of 
polypeptide (0.05 g/L) (Figure 6). 
 
 
Figure 6.  CaCO3 crystallized in the presence of PEG-b-poly(Asp) at concentration (a) 
0.001 g/L; (b) 0.008 g/L; (c) 0.05 g/L; and (d) 1 g/L.  Crystals grown in (a) and (b) more 
closely resemble CaCO3 crystals grown in the absence of peptide.69
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 While the discussion of CaCO3 crystallization control has been dominated by 
peptides containing acidic residues, other non-acidic residues can impact CaCO3 
formation.  In the process of attempting to mimic the function of eggshell matrix proteins, 
Ajikumar et al. developed a series of peptides capable of directing CaCO3 
mineralization.70 They developed three sets of peptides containing multiplets of charged 
residues.  The importance of multiplets of charged residues in influencing biomineral 
formation had previously been demonstrated.71 They were able to examine the role of the 
residues on the crystal formation within these peptides.  The first group of peptides 
simply observed the effect of replacing one charged residue with another (arginine vs. 
lysine): (R2E2W2D2)2 vs. (K2E2W2D2)2.  For the second group of peptides, a proline was 
inserted into the center of the peptides from the first group in order to limit the 
conformational flexibility of the peptides.  The final group of peptides involved the 
incorporation of glycine and alanine residues as a way of disrupting any secondary 
structure the peptides were capable of forming.  Crystals formed using peptides from the 
first two groups showed a concentration dependent control of morphology, with crystals 
produced from the lysine-containing peptides exhibiting sizes twice that of the arginine-
containing peptides.  Polycrystalline aggregates of CaCO3 were observed with sizes 
increasing with concentration.  The peptides from the third group failed to exhibit any 
control of the CaCO3 formation, suggesting not only importance of the primary structure 
of the peptide, but also the secondary structure and spatial arrangement of the important 
residues. 
 A few of the acidic matrix proteins isolated from mollusk shells were also shown 
to be enriched in phosphorylated serine residues relative to other non-acidic amino 
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acids.72, 73  Having previously studied the ability of phosphorylated serine residues to 
control the morphology of CaCO3, Hayashi et al. set out to study the effect of other 
potentially phosphorylated residues, specifically Thr(PO3H2).74, 75  Morphological control 
was observed relative to the ratio corresponding to the threonine residue and calcium ion 
concentrations.  Spherical particles of CaCO3 were observed when the [Ca2+]/[Thr] ratio 
was between 60-100.  When the ratio was increased to greater than 120, a brushlike 
morphology was observed, and when 40 or below, crystals failed to precipitate. 
 
Metal Nanocluster Synthesis 
 The peptide-mediated formation of metal oxides was spawned directly in relation 
to the natural biological formation of these materials; however, the methods and 
techniques associated with these syntheses methods can be applied to the formation and 
assembly of non-natural inorganic materials as well, including metals, semiconductors, 
zeolites, and carbon nanostructres.15, 17, 20, 23, 25, 30, 76 Peptide-display methods make 
practically any material amenable to study, thereby developing avenues to new materials 
that were previously unrealized.  Some of the peptide sequences used to mediate the 
formation of inorganic nanoclusters are listed in Table 4.  Metal nanoparticles are of 
particular interest due to the promising optical and electronic properties associated with 
these materials. 
 The synthesis and assembly of Au nanoparticles has been given significant 
attention as a result of the material’s optical properties.  Slocik et al. synthesized gold 
nanoparticles with the help of a multifunctional peptide capable of both reducing gold 
ions in solution and passivating the surface of the nanoparticles, thus stabilizing them in 
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Table 4. Peptide sequences used in the formation of inorganic nanoparticles. 
Peptide name Sequence Material Reference 
A3 AYSSGAPPMPPF Au 77 
Flg DYKDDDDK Antibodies 77 
A3-Flg AYSSGAPPMPPFPDYKDDDDK Au-Antibodies 77 
Flg-A3 DYKDDDDKPAYSSGAPPMPPF Antibodies-Au 77 
GBP-1 MHGKTQATSGTIQS Au 78, 79 
TBP-1 RKLPDAPGMHTW Ti 80 
 
 
 
 
aqueous solution.77  The peptide A3 (AYSSFAPPMPPF), previously shown to bind gold 
and silver surfaces, contains a tyrosine residue, which acts as the reductant to promote the 
formation of nanoparticles.  Replacing the tyrosines with serine residues prevents the 
gold nanoparticle formation.  A similar reaction with Ag+ ions, which also bind to the A3 
peptide, showed no reduction.  This result is expected considering the standard reduction 
potential of a Ag+ ion is much less than that of a Au3+ (0.80 V vs. 1.52 V, respectively), 
and thus would likely need a stronger reducing agent than tyrosine.  The fact that the 
peptides also stabilize the particles in solution should not be overlooked, as passivation 
makes the particles amenable to further functionalization.  In the same report, Slocik and 
coworkers incorporated the sequence of a common biomolecular recognition peptide, the 
Flg sequence (DYKDDDDK), into the sequence of the A3 peptide.  Two forms of the 
new sequence were studied, A3-Flg and Flg-A3, for their recognition by an antibody that 
binds the Flg peptide.  Both sequences showed the ability to induce formation of gold 
nanoparticles and be recognized by immobilized anti-Flg antibodies via the Flg portion of 
the sequence.  The multifunctionality associated with these peptides could potentially 
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lead to their use in biosensing applications and the use of antibodies to pattern the 
specific placement of the nanoparticles on a solid surface. 
 In order to gain a better understanding of how these peptide/metal interactions 
occur, Kulp et al. investigated peptide-mediated gold nanoparticle formation at the 
molecular level.78  An E. coli cell-surface display method had previously identified a 42 
a.a. peptide, gold-binding protein-1 (GBP-1), that consisted of three repeats of the 
following 14 a.a. sequence: MHGKTQATSGTIQS.  Kulp concluded that in the presence 
of Au ions, the peptide adopts an unfolded random coil structure, confirmed by circular 
dichroism and NMR measurements.  This structure allows for the middle portion of the 
peptide, -KTQATS-, to interact specifically with the metal ions, a phenomenon validated 
by Au-adduct mass spectrometry studies.  Previous mechanisms had suggested folding of 
the peptide to serve as a template for the formation of the Au nanocrystals.  Kulp, in turn, 
postulates a template is less accurate, and that the formation more likely proceeds with 
the peptide playing a vital role in the nanocrystal formation. 
 In addition to driving the synthesis of nanomaterials, the peptides can also direct 
the assembly of preformed nanostructure units.  Peptides previously shown to bind 
metals, or metal nanoparticles, have been used in the patterning of particles onto desired 
substrates.  Zin et al. explored the possibility of using the gold-binding peptide described 
above, GBP-1, as a means to both chemically and physically pattern Au nanoparticles 
onto a metal substrate through the use of microcontact printing techniques.79 Their 
“chemical patterning” technique consisted of reacting GBP-1 to a self-assembled 
monolayer of an aldehyde-containing compound with the help of a 
poly(dimethylsiloxane) (PDMS) stamp (Figure 7A).  The “physical patterning” technique 
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used the PDMS stamp to transfer GBP-1 to a gold surface through the Au-binding 
interaction of the peptide (Figure 7B).  After pipetting preformed gold nanoparticles onto 
the GBP-1 patterns, both methods of surface preparation directed the assembly of the 
nanoparticles at the sites containing the peptide.  The fidelity of the pattern was  
 
 
Figure 7. Schematic of patterning of Au nanoparticles using two different methods. (A) 
Chemical patterning by covalently attaching GBP-1 through –CHO functionality of a 
self-assembled monolayer.  (B) Physical patterning of GBP-1 onto Au-surface using the 
Au-recognition motif of the peptide.79
 
 
 
confirmed by atomic force microscopy (AFM) images.  The chemically patterned sample 
showed a much greater degree of coverage of the nanoparticles throughout the pattern 
compared to the physically patterned sample.  This suggests that the forced 
immobilization of the peptide on the gold surface (the physically patterned technique) 
could have resulted in the loss of recognition to other gold surfaces, or in this case, the 
nanoparticles. 
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 While considerable effort has been directed towards the use of Au-binding 
peptides, these lessons have been expanded to include other types of nanoparticles.  Sano 
et al. studied the interactions and specificity of a peptide shown to bind titanium surfaces, 
TBP-1.80 After determining the amino acids primarily responsible for the peptide’s 
binding via site-directed mutagenesis, it was established that the peptide most likely 
interacted through an ionic attraction via the hydroxyl groups of the oxidized Ti surface.81 
The question was asked whether or not this binding was universal to any metal with an 
oxidized surface, or if the peptide showed specificity to the Ti surface.  Sano tested a 
phage displaying TBP-1 (RKLPDAPGMHTW) for its interactions with other metal 
surfaces:  Ti, Si, Ag, Au, Cr, Pt, Sn, Zn, Cu, and Fe.  The phage-displayed TBP-1 bound 
the Ti, Si, and Ag surfaces equally, whereas all other surfaces showed no binding.  
According to Sano and coworkers, mutational analysis at the Arg-1, Pro-4, and Asp-5 
positions significantly impaired the binding of TBP-1 to the titanium surface.81  A similar 
study with the silicon and silver surfaces also showed dramatic reductions in binding 
when one of these residues was replaced with an alanine residue.  TBP-1 was also tested 
for its role in the biomineralization of the new metals.  TBP-1 was shown to be active in 
the mineralization of AgNO3 to Ag nanoparticles, as well as in the formation of SiO2.  
Noting that both the isoelectric points and crystal structures of titanium, silver, and 
silicon are markedly different, Sano proposed that the TBP-1 must recognize some 
similar local electrochemical geometry evident on the oxide surface. These findings 
allowed the authors to speculate that, while obviously different, some similarities must 
occur in the chemical structure of Ti, Si, and Ag at the nanoscale level.   
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 An alternative method for directing the size and morphology of a resulting 
material is to confine the area within which the material is formed.  One way this is 
accomplished is through the design of peptide nanoreactors, which assemble the material 
within a spatially confining core.53 This practice has been adapted for the formation of 
metal nanoclusters.  The same bolaamphiphile peptide monomers mentioned earlier to 
induce the formation of metal oxide nanospheres inside peptide nano-doughnuts were 
also used to synthesis gold nanocrystals.  The peptide monomer, bis(N-α-amido-
glycylclycine)-1,7-heptane dicarboxylate, self-assembles into nano-doughnuts in 
solution.  Gold ions are reduced in the presence of the nano-doughtnuts, which serve as 
nanoreactors, by UV irradiation for approximately 20 minutes.  Extended UV irradiation 
(>10 h) was used to remove the peptide coating (Figure 8).  The nano-doughtnuts form 
with an outer diameter of ~50 nm and an inner diameter of ~12 nm, which are visible by 
both scanning force and transmission electron microscopies.  The resulting gold 
nanocrystals had diameters consistent with the inner diameter of the doughnuts.  When 
the gold ions were reduced with a stronger reducing agent, nanoparticles were formed 
without the formation of a nano-doughnut.  The resulting particles had larger, more 
disperse diameters, indicating the importance of the doughnuts in limiting the size of the 
nanoparticles. 
 Ryadnov used peptide self-assembly properties for the creation of a 
polynanoreactor, within which multiple nanoparticles of monodisperse sizes are 
formed.82 The polynanoreactor is formed from a dendrimer-like assembly of leucine 
zipper peptide sequences.  This assembly contained numerous nanosized cavities capable 
of serving as nucleation sites, with the growing nanoparticle size governed by the size of  
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 Figure 8.  Schematic of peptide nano-doughnut formation and subsequent Au 
nanoparticle crystallization.53
 
 
the cavities.  AgNO3 was reduced by sodium citrate in the presence of the nanoreactor.  
Ag nanoparticles with an average diameter of 5.2±0.5 nm were observed by transmission 
electron microscopy (TEM), which was consistent with the inner diameter size of the 
nanoreactor cores (4.6±0.7 nm). 
Peptide hydrogels have also been utilized as a form of nanoreactor.83 Simple 
cationic tryptophan-containing peptide amphiphiles can self-aggregate in aqueous 
solution in the form of a hydrogel.84 Tryptophan is one of a number of amino acids that 
has proven capable of reducing gold ions in solution.  Consequently, reduction of 
chloroaurate ions in the presence of these tryptophan-containing hydrogels produced gold 
nanoparticles whose size and shape were governed by the self-assembling properties of 
the hydrogel.  Lamellar, wire-shaped, octahedral, and decahedral particles were all 
observed depending on the peptide composition utilized for hydrogelation.  It was 
proposed that the 3D matrix imposed by the hydrogelator acts to trap the gold ions, 
allowing for reduction by tryptophan residues.  The space within the hydrogel then serves 
to stabilize and determine the size and shape of the growing nanoparticles.  These 
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hydrogels present an interesting case in which various shapes and sizes of nanoparticles 
can be produced by varying the peptide used for gelation; however, the ability to tune the 
properties of the peptides to achieve specific sizes remains a concern.  The properties of 
the resulting nanoparticles are determined on a case by case basis, rather than through 
some predictive property of the peptide. 
 
Computational Studies 
 In order to fully realize the potential of peptides in mediating the formation of 
inorganic materials, a better understanding of the mechanisms involved in the peptide-
material interaction and binding is necessary.  Often, these types of studies are 
accomplished with computer simulations of the interaction and modeling of the binding 
sites.  The attempt to understand the self-assembly associated with silica formation is a 
prime example of these types of studies.  The ability of diatom-isolated peptides to 
induce silica formation has long been thought to proceed via self-assembly mechanisms 
in which the peptide serves as a scaffold.38  Using Brownian dynamics computer 
simulations, Lenoci and Camp set out to determine how this self-assembly occurs.85 They 
concluded that distinct clusters of silica begin to form at lower peptide densities (< 5% 
w/v) and strands of gel-like structures most likely begins to occur as the peptide density 
increases (~15% w/v).  At higher densities (>25% w/v), these strands merge to form more 
concentrated and defined structures.  The simulations led the group to predict that at low 
peptide concentrations, aggregates of peptide form, providing a nucleation site for silica, 
which grows outward from the center point of the peptide aggregate.  At higher 
concentrations, a peptide-network forms which serves to constrict the growth of the 
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silica.  Their simulations were performed using silaffin models, but the group believes the 
theories can be aptly applied to both R5 peptide and poly-L-lysine models. 
Other simulation studies have attempted to ascertain the importance of certain 
residues in the recognition and binding process.  The binding of peptides to platinum has 
been commonly used as a model system.  A number of sequences examined to gain 
insight into the dynamics of a peptide-metal interaction are listed in Table 5.  Kantarci et 
al. have utilized molecular dynamics simulations to analyze the interactions of  a 
common Pt-binding motif.86 The threonine-serine-threonine (TST) sequence is a motif 
found to be conserved amongst a number of Pt-binding peptide.25  In an attempt to 
determine what makes the TST sequence such an efficient binder, the molecular 
dynamics simulations were performed on cyclic, TST-containing peptides and were 
compared with a non-TST containing peptide considered to be a weaker binder.  The 
TST-containing peptides showed a higher propensity to form hydrogen bonds with 
surrounding water molecules in the absence of a metal surface compared to the weaker 
binders.  This indicates that the functional groups from these residues are more exposed 
to the solvent and thus likely to be exposed in the presence of a metal.  Weaker binding 
peptides lack these exposed residues and are therefore less likely to interact with a metal 
surface.  The TST region of the peptides corresponded to the most flexible region of the 
peptide indicating the importance of flexibility in platinum surface binding. 
 Seker et al. performed a similar study on the effect of a constraint peptide on 
metal binding.87  A comparative study monitored the metal binding differences between 
the cyclic and linear forms of a Pt-binding peptide (PTSTGQA), with the cyclic form 
providing the constraint.  Surface plasmon resonance was used to monitor binding events 
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between the peptide and solid platinum surface.  Kinetic and equilibrium values were 
shown to be 20 times greater for the cyclic peptide than the linear form.  Circular 
dichroism measurements showed that in the presence of the metal surface, the linear 
peptide is able to adopt a conformation that is a combination of a helical and random coil 
structures.  The cyclic peptide attempts to do the same, but is conformationally inhibited 
by the loop structure.  The flexibility associated with the linear peptide leads to slower 
adsorption behavior because of the increased conformations it is able to adopt.  The  
 
 
Table 5. Peptide sequences studied in computational analyses of peptide-metal 
interaction. 
 
Peptide name (if 
applicable) Sequence Material Reference 
 CPTSTLQAC Pt 86 
 CQSVTSTKC Pt 86 
 CVRTSTWRC Pt 86 
 CIMRDGPMC Pt 86 
 PTSTGQA Pt 87 
 CPTSTGQA Pt 87 
SD152 PTSTGQA Pt 88 
SD60 QSVTSTK Pt 88 
SD128 LGPSGPK Pt 88 
SD1 APPLGQA Pt 88 
SD60 LNDGHNY Pt 88 
 
 
opposite holds true for the cyclic peptide.  The stability provides favorable interactions 
between side chains responsible for binding, thus resulting in a higher affinity constant. 
Another study involving Pt-binding peptides focused on the conformation adopted 
by the peptide during the binding process.  Oren et al. analyzed the crystallographic 
surface recognition of three types of peptides representing different levels of affinity for 
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the metal: strong, moderate, and weak binders.88  Using computer modeling studies, they 
were able to determine that the peptides adopt certain molecular architectures during a 
binding event.  These architectures contain protrusions designed to increase the 
interaction with the metal surface.  It was proposed that the physical recognition observed 
between a peptide and a metal surface is a result of a protrusion-metal surface structure 
match.  Binding, on the other hand, is more likely a consequence of interactions between 
the specific functional groups (i.e. electrostatic or polarity effects) located on these 
protrusions and the metal surface, rather than a spatial complement.  
The types of reactions and simulations previously discussed are only relevant if 
the peptides can adopt any imaginable conformation, which is true for peptides free in 
solution.  As the degrees of freedom become restricted, interactions and binding 
mechanisms begin to change.  These changes result in alterations in the way in which the 
peptide can influence the formation of a material.  Thus, immobilizing the peptide within 
a larger structure opens up new opportunities for mediating material synthesis. 
 
Materials-Immobilized Peptide Templates 
 Immobilizing a peptide onto the surface of a nanomaterial is one approach a 
researcher has for directing the synthesis of a material.  This technique offers an 
innovative alternative to simply dissolving a peptide in solution with the hopes that the 
peptide achieves the desired result.  Peptide constraint allows for the tailoring of the 
synthesis for a variety of applications including direction of a particular morphology of 
resultant nanocrystal, the forced adoption of a certain conformation, or simply as a means 
for enhancing the interactions necessary between the peptide and material to drive the 
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formation of the biomineral.  While there are currently a number of peptide-
immobilization scaffolds herein the focus will be solely on peptides immobilized onto the 
surface of nanostructured materials.  The peptide sequences in the following sections can 
be found in Table 6.   
 
Table 6. Peptide sequences used as materials-bound templates. 
 
Peptide 
name Sequence Material Ref. 
Flg-A3 DYKDDDDKPAYSSGAPPMPPF Pd, Au 89 
A3-Flg AYSSGAPPMPPFPDYKDDDDK Au, Pd 89 
 SGDLENEVAQLEREVRSLEDEAAELEQKVSRLKNEIEDLKAE Au 90 
 SGDLKNKVAQLKRKVRSLKDKAAELKQEVSRLENEIEDLKAK Au 90 
E5 CGGEVSALEKEVSALEKEVSALEKEVSALEKEVSALEK Au 91 
K5 CGGKVSALKEKVSALKEKVSALKEKVSALKEKVSALKE Au 91 
JR2EC NAADLEKAIEALEKHLEAKGPCFAAQLEKQLEQAFEAFERAG Au 92, 93 
 HPGAH Pt 94 
HG12 HGGGHGHGGGHG Ni 95 
M1 VCATCEQIADSQHRSHRQMV ZnS 96 
P1 HSSYWYAFNNKT SWNT 97 
P1R5 SSKKSGSYSGSKGSKRRILGGGGHSSYWYAFNNKT 
SWNT, 
SiO2
97 
AG3 AYSSGAPPMPPF Ag 98 
GBP-1 MHGKTQATSGTIQS Au 99 
PLL p-(Lys)n SiO2 100 
 
 
 
Nanoparticle-Bound Peptides 
 Using preformed peptide-nanoparticle complexes to direct the assembly of 
particles into higher-order structures, or for the synthesis of bimetallic nanostructures, is a 
logical extension of the peptide-mediated synthesis of nanomaterials discussed above.  
Slocik et al. used this strategy to expand the applicability of their multifunctional peptide 
to synthesize Au-Pd bimetallic structures that were capable of serving as catalysts in the 
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hydrogenation of alcohols.89 Their multifunctional peptide, A3-Flg, was capable of 
forming these bimetallic structures with the A3 portion of the peptide, thus inducing the 
formation of Au nanoparticles, followed by the reduction of Pd+ ions in the presence of 
the peptide-nanoparticle complex.  What makes this second particle formation possible is 
the affinity of the Flg sequence for palladium surfaces.  The Flg peptide (DYKDDDDK) 
consists of three major residues known to bind palladium: aspartic acid, lysine, and 
tyrosine.  During the reduction of Pd+ ions, the Flg portion of the fused peptide directs the 
assembly of forming palladium nanoparticles at the surface of the Au nanoparticles, 
where the peptide is attached.  The resulting structure consists of smaller palladium 
nanoparticles attached to the surface of larger Au nanoparticles.  TEM analysis showed 
the Au-A3-Flg particles to have diameters of 10.7 nm and 15.5 nm for the final Au-A3-
Flg-Pd particles. 
 Another common method for the assembly of nanoparticles is the use of leucine 
zipper-like peptides that dimerize in solution to form coiled-coils.  Leucine zipper 
peptides typically contain six heptad repeats (a-b-c-d-e-f-g) that form right-handed α-
helical conformations.  When associated with the same domain from another peptide, the 
two dimerize, leading to the formation of a left-handed coiled-coil.  As these helices 
begin to pack, they are held together through hydrophobic interactions brought about by 
the presence of leucine residues.  Additional stabilization can also occur due to 
electrostatic interactions between residues in the e and g positions.   
Stevens et al. examined using this strategy for nanoparticle assembly by 
functionalizing two such peptides (one acidic and one basic) onto the surface of gold 
nanoparticles.90 The acidic peptide contained glutamic acid residues in both the e and g 
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positions throughout the heptad repeat.  As a result, favorable interactions at pH below 
the pKa of glutamic acid allowed for association of the peptides as described above.  As 
the pH is increased, the glutamic acid residues become deprotonated, and thus the 
repulsion from the COO- functionalities results in a loss in peptide helicity.  
Functionalization of the peptide onto the gold nanoparticle was achieved through the 
inclusion of a terminal cysteine residue, which bound the gold via the thiol functionality.  
After functionalization, aggregation of the nanoparticles was observed at low pH that had 
not been previously observed with the un-functionalized particles.  The peptide coiled-
coil association brought about the aggregation of the nanoparticles, thus creating an 
assembly of nanoparticles.   
Binary nanoparticle assemblies can also be formed by functionalizing the acid 
peptide onto the surface of small nanoparticles (8.5 nm) and the basic peptide, which 
contained a large number of lysine residues in the e and g positions, onto larger particles 
(53 nm).  These lysine-glutamate pairs added stabilization and promoted the formation of 
heteromer particles, resulting in structures containing two different sized particles.  At 
neutral pH, the smaller particles were observed to form satellites around the larger 
particles (Figure 9A).  This pH falls favorably between the pKa’s of glutamic acid and 
lysine, resulting in the charged form of both residues and increasing the likelihood of 
association.  Lowering the pH induced the formation of larger assemblies through the 
added interactions associated with the acidic peptides (Figure 9B). 
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 Figure 9.  Assemblies formed through coiled-coil formations at (A)neutral and (B) low 
pH.90
 
 
 In addition to controlling coiled-coil assembly via pH, photothermal methods 
have also been employed.  Slocik et al. developed both nanoshell-nanoshell and 
nanoshell-quantum dot complexes that were capable of responding to near-IR light.91 For 
nanoshell-nanoshell complexes, preformed Au nanoparticles were functionalized with 
two different matching antiparallel coiled-coil sequences containing terminal cysteine 
residues.  The same peptides were functionalized onto the surface of CdSe/ZnS quantum 
dots through disulfide linkages for the purpose of the nanoshell-QD complexes.  When 
incubated together, assemblies of nanoparticles formed that were robust to common 
thermal and chemical methods of protein denaturation.  If these complexes were exposed 
to near-IR irradiation, the photothermal nature of the gold nanoshells induced the 
temperature-mediated unfolding of the coiled peptides resulting in the disassembly of the 
complexes.  This phenomenon was observed for both types of interfaces.  Removing the 
light brought about the reassembly of the particles.  The reversibility of optical 
responsivity makes these peptide-nanoshell complexes candidates for a variety 
photothermal applications. 
 Nanostructure assembly can occur through methods other than coiled-coil peptide 
interactions.  Scientists have exploited numerous peptide interactions to induce 
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nanoparticle aggregation and assembly.  Aili et al. designed a glutamic acid-rich 42 a.a. 
peptide (JR2EC) that undergoes a conformation change in response to the lowering of 
pH.92, 93  At neutral pH, the nanoparticle-bound peptides remain in an unfolded 
conformation brought about by the repulsive charges from multiple glutamic acid 
residues.  As the pH is lowered closer to the pKa of glutamic acid (~4), the residues 
become protonated.  As a result, the repulsion is eliminated, and the peptides undergo a 
folding.  The JR2EC peptide contains an intentional helix-loop-helix secondary structure 
that dimerizes in solution upon folding.  Thus, when functionalized on the surface of a 
nanoparticle, this folding induces dimerization of the peptides and brings about the 
aggregation of the nanoparticles (Figure 10).  Hydrogen-bonded assemblies have also 
been produced by carboxylating the free terminus of nanoparticle-bound peptides.101 
Gold nanoparticles have been functionalized and assembled by lowering the pH of the 
solution to acidic conditions to induce hydrogen-bonding through the carboxylate 
functionality.  This hydrogen bonding has been confirmed by infrared spectroscopy and 
is shown to increase as pH is lowered even further, thus increasing the degree of 
assembly.  Large assemblies of nanoparticles spanning micrometer ranges have been 
confirmed by TEM analysis. 
     
 
Figure 10.  Schematic representation of pH-driven peptide folding used to induce 
nanoparticle aggregation.92
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Nanotube-Bound Peptide Templates 
 Nanoparticles offer valuable methods for assembly but are limited in potential 
morphology by their generally spherical shape.  To achieve non-spherical morphologies, 
other nanostructured materials must be explored.  One such example is the use of 
nanotube-bound peptides to direct the formation of the resulting structure of a material.  
Peptides can be attached to the surface of a nanotube by a variety of different methods, 
each depending on the composition of the nanotube.  For example, peptides have been 
attached to peptide nanotubes through amide-amide hydrogen-bonding interactions.  
Attaching peptides to carbon nanotubes, on the other hand, often occurs through some 
type of covalent modification.  Once attached to the surface of a nanotube, the peptides 
are capable of mediating the formation of the material at or on the surface of the 
nanotube, typically resulting in an overall nanotube/nanowire shape.  This has been used 
as an alternative to other nanowire production methods as a means of better controlling 
the final shape and surface coverage of material.   
One example can be found in the work of Yu et al., in which histidine-rich 
peptides were bound to peptide nanotubes and used to nucleate platinum to cover the 
surface of the nanotube.94 Peptide nanotubes arise from self-assembled bolaamphiphile 
peptide monomers.  Generally, the peptides are linked via an amide bond with a 
carboxylic acid linker, which then self-assemble into nanotubes via hydrogen bonding.  
The histidine-rich peptide His-Pro-Gly-Ala-His had previously been shown to bind 
platinum ions as a function of pH.  Analysis of the mechanism of interaction revealed that 
under acidic conditions, the peptide binds platinum ions via the carboxylate oxygen of the 
C-terminal histidine residue.  Under basic conditions, however, binding is controlled by 
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the imidazole group of the histidine residues and amide groups of the alanine and glycine.  
After immobilization of the peptide through backbone amide-amide hydrogen bonding, 
these important binding sites are free to interact with the metal ions.  By reducing 
platinum ions in the presence of the peptide-immobilized nanotubes, they were able to 
nucleate platinum nanocrystals on the surface.  The surface coverage of resulting 
nanocrystals is pH dependent, with more nucleation occurring in basic pH.  The greater 
degree of binding associated with the histidine/alanine/glycine interaction in basic 
solution is thought to increase the concentration of platinum ion at the surface of the 
peptide, thus leading to a greater extent of surface coverage. 
 Using pH to control direct growth has been observed in other materials as well.  
pH control of peptide-bound nanotubes has been used to direct the synthesis of magnetic 
nickel particles as well as semiconducting ZnS particles.95, 96 In both cases, peptides 
shown to mineralize the desired material were bound to peptide nanotubes, but adjusting 
the solution pH had different effects on each material.  For the nickel particles, pH was 
used to control the size of the resulting nanocrystals during the reduction of nickel ions.95  
Monodisperse particles having diameters of ~30, 50, and 100 nm were observed on the 
surface of the nanotubes at pH 4, 6, and 8, respectively (Figure 11a-c).  In the absence of 
a peptide template, a small amount of nanocrystals were still observed on the nanotubes, 
but the sizes were extremely polydisperse, having diameters ranging from 10-100 nm 
(Figure 11d).  It was suggested that aggregation of peptide occurs on the surface of the 
nanotube at higher pH, possibly allowing more space for crystal formation and growth. 
 Adjusting the pH during formation of the ZnS particles controls crystallographic 
morphology of the resulting material.  A pH range of 5-10 was studied.  For lower pH 
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solutions, pH = 5.5-7.4, monodisperse crystalline wurtzite ZnS was formed on the 
peptide nanotube.  For pH levels >8, amorphous ZnS was observed.  The conformation of 
the ZnS binding peptide is thought to play a major role in this compositional control.  The 
ZnS-binding peptide, M1 (VCATCEIADSQHRSHRQMV), constitutes a portion of the  
 
 
 
Figure 11. TEM images of Ni nanocrystal formation on peptide nanotubes at pH (a) 4, (b) 
6, (c) 8, (d) and in the absence of peptide template.  Inset: Electron diffraction peak of 
resulting nanocrystals.95
 
 
 
larger influenza virus matrix protein, M1.  Within this protein, the M1 peptide undergoes 
an unfolding of its helical backbone as the solution pH is increased.  As this unfolding 
occurs, a Cys2His2 region emerges that is capable of increasing the intake of zinc ions.  
The nature of this binding was characterized by Raman spectroscopy.  Throughout the 
lower portion of the pH region, this intake in dominated by a His-Zn2+ chelation which 
shifts to a His-Zn2+-His chelation throughout the higher pH region, evidenced by the 
appearance of a new Raman peak 1561 cm-1 at high pH (~ 10.0).  The different chelation 
configurations of the peptide fixes the Zn2+ ions at different spacings.  These spacings 
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affect the way in which incoming S2- ion interact, causing the formation of different 
phases.  
 Peptide-bound carbon nanotubes have also been used in directing material 
synthesis.  Pender et al. utilized the multifunctionality of a single-wall carbon nanotube 
(SWNT)-binding peptide to both suspend the nanotubes in solution and direct the 
formation of silica and titania to coat the nanotube.97 A phage-display peptide library was 
used to identify a peptide with an affinity for SWNTs.  One dominant peptide emerged, 
P1 (HSSYWYAFNNKT), which contained four aromatic residues, a functionality known 
to aid in dispersing SWNT in aqueous solutions.  The multifunctionality was achieved by 
synthesizing a fusion peptide consisting of the P1 peptide and the silica precipitating R5 
peptide, separated by a glycine linker: 
SSKKSGSYSGSKGSKRRILGGGGHSSYWYAFNNKT.  The resulting peptide now 
possessed both the functionality of binding to SWNTs, thus dispersing them in solution 
and precipitating metal oxides on the surface of the nanotubes.  In the presence of silicic 
acid, the P1R5-coated nanotubes precipitate silica in the form of a matrix of nanospheres.  
However, these appear to agglomerate during silica formation, as bundles of SWNTs can 
be seen coated with silica.    
 
Metal Surface and Thin Film-Bound Peptides 
 One of the major goals associated with peptide-mediated materials synthesis is the 
ability to unequivocally direct the growth of the material and specifically pattern a 
material.  To obtain such command of the placement of a synthesized material would 
open up countless patterning and device fabrication opportunities.  To realize this goal, 
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materials synthesis has expanded to the formation and attempted patterning of materials 
on solid surfaces and thin films.  Peptides offer the distinct advantage of both providing a 
means of attachment between the material and the surface, and the ability to play a key 
role in mediating the synthesis of the desired material.  If a peptide is known to bind or 
precipitate a particular material, the major issue with synthesizing that material on a 
surface is attaching the peptide to the surface so that its functionality may be maintained.   
Several methods, both chemical and physical have been developed for this task.  
Xu et al. immobilized the silver-binding peptide AG3, AYSSGAPPMPPF, onto a 
polymer film to direct the synthesis of silver crystallites.98  A poly(ethylene terephthalate) 
(PET) surface was modified with an amine functionality.  At neutral pH, the AG3 peptide 
was then coupled to the surface of the film through this amine functionality.  Exposure to 
a solution of AgNO3 led to the formation of silver crystallites on the polymer film 
ranging in size from 1-4 μm, with the peptide providing both the recognition of the 
material and the means of reduction.   
A frequent alternative to chemically attaching the peptide to a surface is the use of 
the recognition aspect associated with the peptide.  For instance, Zin et al. immobilized a 
biotinylated Au binding peptide onto a gold surface through Au-interaction properties of 
the peptide.99 The Au-recognition property yielded the ability to bind to a gold surface, 
while the biotin-functionality was able to bind the dots.  This strategy was used to direct 
the self-assembly of quantum dots on the metal surface as a means to study surface 
plasmon-enhanced luminescence properties as a function of QD-to-metal distance.  
Microcontact printing was used to pattern the biotinylated peptides to the gold surface, 
and the streptavidin-coated nanoparticles were subsequently bound to the peptides.  Two 
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methods were used to vary the overall quantum dot-to-metal surface distance.  The first 
method involved direct attachment of the peptide to the gold surface, utilizing the 
peptide’s gold recognition capabilities, and binding the nanoparticles to the peptide.  The 
second method covalently attached the peptides to a carbonyl terminated linker which 
was bound to the gold surface via a thiol functionality.  This linker increased the distance 
between the metal surface and the peptide-bound quantum dots.  A total height difference 
of approximately 1.3 nm was observed between the two methods.  These patterned arrays 
were in turn used to investigate the associated luminescence properties relative to QD-to-
metal distance.  Fluorescence measurements revealed a significant decrease in emission 
intensity of the surface attached peptide-QD compared to the linker attached assembly.  
This result was not surprising, given metal surfaces have been shown to quench 
fluorescence.   
It is not completely understood, however, whether this quenching occurrs as a 
result of the linker distance or as a function of QD density differences between the two 
methods.  To investigate, atomic force microscopy was used to determine QD coverage 
of the arrays.  An increase in coverage of approximately 30% was observed for the linker 
attached dots.  This likely occurs as a result of the gold binding peptides desire to 
maximize interactions with the gold surface in the absence of a covalent linker, somewhat 
restricting the streptavidin-QD access to the biotin.  Zin and coworkers noted an overall 
increase in fluorescence of ~27% between the two methods and spatially resolved 
spectral measurements allowed them to attribute a 5% of this difference per dot.  
Therefore, the conclusion was made that while both linker distance and QD densities 
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affect the overall fluorescence, this effect is dominated by the average QD attachment 
density.          
Another method used to pattern peptide templates is through electrical deposition.  
Glawe et al. have successfully electrically deposited poly-L-lysine (PLL) on an indium 
tin oxide (ITO) surface, which were then used in the formation of silica nanoparticles.100 
Through the use of an electric field, Glawe et al. was able to deposit a gradient of PLL on 
an ITO cathode, the PLL was then reacted with silicic acid to induce to formation of 
SiO2.  An area of greatest density of peptide occurred at the spot closest to the anode tip, 
corresponding to the area of the greatest electric field intensity.  This was evident due to 
the deposition of silica which occurred only in areas containing PLL.  Density of peptide 
decreased as the electrostatic field expanded outward away from the central tip resulting 
in a decrease in silica deposition along this gradient.  After deactivation of the electric 
field, the peptide-coated ITO cathode was exposed to a solution of silicic acid.  The 
resulting morphology of the silica nanospheres were observed solely as platelets with 
their long axis oriented parallel to the ITO surface.  This growth most likely originates as 
a result of the PLL orientation of the cathode surface.  Infrared spectroscopy suggests the 
PLL is believed to be primarily in a β-sheet, compared to a random coil conformation in 
solution, possibly initiating this unique structure. 
The inherent design of many of the methods discussed, from the inspiration for 
the reactions to the materials being produced, suggests their compatibility with biological 
systems.  Biological-based scaffolds have emerged to aid in the identification of 
functional peptide templates.  The successful integration of these peptide templates 
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provides an important route for the introduction of functioning nanoscale materials in 
living systems. 
 
Biological Peptide Scaffolds 
 When designing scaffolds for peptide-mediated material synthesis, a common tact 
is to find the ideal nanoscale material to serve as a scaffold and devise methods to 
incorporate the peptide into the material.  Arguably, the most readily available peptide 
scaffolds are those on which the peptides are immobilized for surface display panning 
methods.  These virus and cell-based display methods are perfect examples of how this 
peptide-immobilization concept can be used in materials synthesis.  Although surface 
display methods represent one use of the biological scaffolds, their expanded applications 
in materials synthesis are being explored.  Herein, we will focus on three exemplars of 
such scaffolds for peptide presentation: viral display, cellular display, and protein-cages.  
Table 7 presents some of the sequences of interest for these types of applications. 
 
Virus-based Scaffolds 
 Virus particles have routinely been used in materials synthesis.102, 103 They have 
the distinct advantage of being amenable to both chemical and genetic modifications that 
allow them to serve a variety of purposes.  They can be thought of as having three 
potential interaction interfaces available for modification, compared to most materials 
which use their outer surface as the primary interface.  The exterior, interior, and protein 
subunit interfaces have all been utilized as interaction sites for different applications 
(Figure 12). 
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 Figure 12.  Schematic of the three different types of sites amenable to modification in 
most types of virus particles.104 
 
 
 
 While it is true that materials synthesis has made significant advancements via the 
help of virus-based display methods, the use of viruses for peptide display goes far 
beyond the identification of high affinity peptides.  Viruses can be used to display a high 
concentration of peptides capable of synthesizing materials that are extremely difficult to 
obtain by conventional methods.  This was most certainly the case for the work of Angela 
Belcher’s group involving the biological synthesis of magnetic nanoparticles.105, 106 The 
metal alloys FePt and CoPt have both been shown to have desirable magnetic properties 
for magnetic storage devices.  Traditional means of synthesizing the crystalline L10 phase 
of the ferromagnetic FePt, typically involve the synthesis of a chemically-disordered 
phase which must be annealed at high temperatures post-synthesis.  In order to simplify  
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Table 7. Peptide sequences used for biological-scaffold applications. 
 
Peptide name 
(if applicable) Sequence Material Reference 
FP12 HNKHLPSTQPLA FePt 22, 105 
 SVSVGMKPSPRP FePt 105 
 VISNHRESSRPL FePt 105 
 KSLSRHSHIHHH FePt 105 
 EPGHDAVP CoPt 106 
CP7 CNAGDHANC CoPt 22 
A7 CNNPMHQNC ZnS 22 
J140 SLTPLTTSHLRS CdS 22 
p8#9 VSGSSPDS Au 107 
S1 SWDPYSHLLQHPQ Streptavidin 107, 108 
 AHHHHHH Ni(II) complex 108 
D01 HDYRGHIHGHSQHGTEQPD CdS 109 
D07 DVHHHGRHGAEHADI CdS 109 
E01 DVHHHGRHGAEQAEI CdS 109 
 CCCCCC Au, ZnSe, ZnS 110 
 HHHHHH 
Au, ZnSe, ZnS, 
CdSe, CdS 110 
 MMMMMM Au, ZnS 110 
 WWWWWW Au, ZnSe, ZnS 110 
 XHXHXHX  110 
 XXHHHXX  110 
 EEGnHHHGnEE  110 
Z1 KHKHWHW CdS, ZnS, Au 110 
Z2 RMRMKMK Au 110 
Z3 PHPHTHT ZnS 110 
D6 DDDDDD Ag 111 
E6 EEEEEE Ag 111 
T59 THRTSTLDYFVI PPyCl 112 
 GRGDS Cellular proteins 112 
AG4 NPSSLFRYLPSD Ag 113 
TBP-1 RKLPDAAPGMHTW Ti, SiO2 114 
RGD-4C CDCRGDCFC Cellular proteins 115 
 KTHEIHSPLLHK CoPt 116 
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the synthesis methods, efforts to eliminate the high temperature annealing step are being 
made.  Reiss’s work provides one of the first examples of the room temperature synthesis 
of such a material.105  An M13 phage display library was panned against preformed FePt 
particles in order to identify a peptide capable of binding the crystalline L10 phase of 
FePt.  One major sequence was identified as having the greatest affinity 
(HNKHLPSTQPLA).  The peptide, expressed on either the pIII or pVIII proteins, was 
then used in an attempt to mineralize the material via the reduction of both platinum and 
iron salts.  For phage displaying peptide via the pIII protein at the end of the virus, FePt 
was produced in a number of disordered phases, suggesting the five copies of displayed 
peptide were not sufficient to induce the formation of the ordered phase.  The same 
experiment using pVIII-expressed peptides (of which there are ~2700 copies) produced 
nanoparticles with an average diameter of 5 nm covering the surface of the virus.  The 
nanoparticles proved to be the desired, kinetically unfavored L10 phase.  The approximate 
2700 copies of the genetically displayed peptide were able to provide a coordinating 
environment for the Fe and Pt ions sufficiently high to promote the nucleation of the 
crystallographically-ordered particles. 
This material-coated virus technology has been used to direct the formation of 
materials with a specific morphology.  For instance, Mao et al. capitalized on the 
filamentous nature of the M13 bacteriophage for the formation of magnetic and 
semiconducting nanowires.22  Peptides were screened for the ability to bind both 
magnetic (FePt and CoPt) and semiconducting (ZnS and CdS) materials, and were 
expressed on the pVIII coat protein of the bacteriophage.  Incubating the virus with metal 
salt precursors led to the nucleation of the material on the surface of the virus in the form 
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of nanocrystals.  Annealing at temperatures ranging from 350-500 oC brought about the 
formation of single crystal nanowires throughout the length of the virus.  During the 
annealing, fusion of individual particles of magnetic or semiconductor materials occurred 
on the surface of the virus, resulting in a morphology mimicking that of the virus.       
By increasing the complexity of the virus functionality, higher-order structures 
are attainable.  The different proteins that comprise the capsid of the M13 bacteriophage 
structure allow for the formation of higher-order architectures.  The different 
functionalities associated with each of the proteins can be altered in a way that brings 
about the formation of a material, but also allows the networking of individual virus 
particles to give higher-order structures.  Such structures can be obtained by expressing 
different peptides on the different proteins.  For instance, Au-binding peptides expressed 
on the pVIII coat protein bind and nucleate gold particles, while streptavidin-binding 
peptides expressed on the pIII protein (found at one end of the virus) are able to 
recognize and bind streptavidin-coated nanoparticles.107, 108  These nanoparticles thus 
serve as “attachment points” capable of binding multiple viruses to give a variety of 
nanostructures (Figures 13 and 14). 
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 Figure 13. TEM images of virus architectures.  Gold-coated virus particles are attached to 
streptavidin-coated gold nanoparticles via streptavidin-binding located at the pIII protein 
of the virus (indicated by the arrows).107
 
 
 
 
 
Figure 14.  AFM images of virus nanoring structures.  Rings are formed by modifying 
one virus end with a streptavidin-binding peptide and the other with a peptide-
nanoparticle/streptavidin complex.108
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Cel- surface display  
The use cell surface display systems has been employed for a number of reasons, 
including their enhanced ability to quantitate peptide binding.  Peelle et al. have used cell 
surface display to study the principles governing peptide-inorganic materials interactions 
in two separate reports.  In both cases, a yeast cell-surface display method was used to 
determine high affinity binders to the II-IV semiconductor CdS.109, 110 In the first 
example, three major histidine-rich peptides were identified as high-affinity binders to 
CdS.  A fluorescence-based cell binding assay was used in an effort to quantitate the 
degree of binding after a series of mutational analyses.  This analysis revealed the 
importance of histidine residues in the binding of Cd+ ions.  Removal of any one histidine 
residue in any of the peptides significantly reduced binding, suggesting a cooperative 
binding mechanism with respect to the five histidine residues that were found on each 
peptide.  The second study expanded on these results by studying the peptide-inorganic 
materials interaction at the amino acid functional group level.110 The materials studied 
were expanded to include CdSe, ZnS, ZnSe, and Au, as well as the CdS semiconductor 
used in the first study.   Homohexamers of each of the 20 natural amino acids were 
displayed on the surface of yeast cells and studied for their ability to bind each of the 
materials.  Peptide binding was determined as a result of cell coverage assays in which 
peptide-bound cells were observed via optical microscopy.  Quantitation was determined 
by the percent coverage of the material displayed by the cells.  The results indicated that 
residues containing aromatic secondary nitrogen or sulfur atoms were able to selectively 
bind a number of the materials.  The histidine-containing homohexamer was the only 
residue observed to bind all five materials.  Further studies observed binding changes 
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with respect to amino acids directly adjacent to histidine residues.  Specific patterns were 
observed and characterized for each type of material.  Consequently, the authors were 
able to devise a proof of design method in which potential high-affinity peptides for 
specific materials were predicted as a result of the evidence observed in the binding 
studies.  
Yeast display has also been used in the formation of crystalline silver 
nanoparticles.111 Homohexamers of aspartic and glutamic acids (D6 and E6) were 
genetically engineered to be displayed on the outer surface of yeast cells.  The cells, 
when in the presence of silver acetate and visible light, promoted the reduction of the 
silver ions, resulting in 10-20 nm crystalline silver nanoparticles coating the yeast cell 
wall.  It was proposed that this reduction was made possible due to the combinatorial 
effects of both the carboxylic acids of the peptides and ambient light.  Carboxylic acid-
bound silver ions reduce easier than free ions.  This study helps to support that claim and 
goes as far as to show an increased reduction possible with glutamic acid-containing 
peptides over aspartic acid-containing peptides.  Structural studies suggested that a more 
folded conformation, relative to the fairly linear D6, results in a higher local concentration 
of carboxylic acids.  This increased concentration leads to more localized silver ions, 
resulting in an increased overall reduction potential amongst the clusters. 
While these reports show cell-surface display to be a suitable technique for high 
affinity peptide selection, they fail to utilize the cell-binding aspect to expand the value of 
the method. The ability of peptides to bind cells is highly conducive for their 
incorporation into biological nanomaterials.  The ability to adapt a nanomaterial into a 
biological system renders endless possibilities for medical diagnostics and therapeutics 
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simply by accessing the nanoscale.  Nanomaterials have already proven to be useful for a 
variety of biomedical applications, including drug delivery systems, biosensors, and 
imaging agents, among other things.117 One method frequently employed to elicit this 
cell-binding behavior from peptides is the inclusion of a cell adhesion sequence.  The 
arginine-glycine-aspartic acid (RGD) sequence is a common amino acid sequence known 
to bind to protein receptors found on the surface of many cell types.118 Modifying a 
material-specific peptide sequence with this motif will impart in the resulting peptide the 
bifunctionality of recognizing and binding both the material and cell surface proteins.  
Sanghvi et al. used this approach to promote cell attachment to a conductive polymer.112  
Their covalent modification of an existing biomaterial represents an improvement over 
previous, unpredictable, non-specific forms of chemical modification for cell adhesion.  
A peptide, T59, shown to bind the electrically conductive polymer, chlorine-doped 
polypyrrole (PPyCl), was modified at the C-terminus with the cell adhesion sequence, 
GRGDS.  PPyCl, alone, does not promote cellular adhesion; however, when modified 
with the bifunctional T59-GRGDS peptide, cellular adhesion is observable via 
fluorescent staining.  This successful functionalization is just one example of using a 
peptide-mediated material for biological applications; in this case the control of 
biomolecular and cellular activity. 
 
Protein cage scaffolds 
 It should be fairly obvious now that if peptides can mediate the synthesis of a 
material then proteins should certainly possess similar abilities.  However, being that this 
review has focused solely on peptide-mediated materials synthesis, we would like to 
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make a clear distinction between protein-mediated synthesis and protein-incorporated 
peptide mediated synthesis, only the latter of which will be discussed here.  Often times, 
proteins possess distinct features considered valuable in materials synthesis.  If 
capitalized upon, these aspects can provide a better means of control during the synthesis 
of a material.  The incorporation of material-binding peptides into the structures of these 
proteins should be generalizable.  For example, the ferritin protein is composed of 24 
subunits, each comprised of two different proteins, a heavy chain (H-chain) and a light 
chain (L-chain), which arrange to form a protein cage possessing an outer diameter of 12 
nm and an inner core diameter of 8 nm.  The cage is capable of both inducing the 
biomineralization of iron oxide as well as maintaining it storage.119, 120 However, it is 
possible to genetically modify the interior of the cage to display peptides specific for non-
iron materials.  These peptides are the capable of directing the formation of monodisperse 
nanoparticles of the material inside the cage.  Kramer et al. genetically engineered a 
silver-binding peptide (AG4) fused to the C-terminus of one of the ferritin subunits.113 
The AG4 peptide is thereby displayed on the surface of the inner cavity of the cage.  
Incubating the protein cages in AgNO3 led to the reduction of silver ions and the 
formation of nanoparticles inside the protein cavity.  The resulting silver nanoparticles 
were shown to have a tight size distribution with a diameter consistent with the diameter 
of the interior of the cage. 
 Similar strategies have been employed to fuse peptides to the exterior of ferritin 
protein cages.  Ferritin can be genetically engineered to assemble in a way that utilizes 
only one of the subunits.  Fusing a peptide to the N-termini of one of the subunits (H- or 
L-chain) and assembling a ferritin cage based solely on that subunit leads to the display 
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of the peptide on the exterior of the protein cage, resulting in the ability of the cage to 
bind to a variety of materials.  This is in contrast to ferritin assembly involving both 
subunits, which displays the peptide on the interior of the cage.  Sano et al. demonstrated 
the binding of protein cages to a metal surface by genetically engineering the fusion of 
Ti-binding peptide using these methods.114 The cages retained the specificity exhibited by 
the free peptide for binding to the surface of a Ti or SiO2 surface, but not a gold surface.  
Uchida et al. performed similar cage exterior modifications, and confirmed that the 
protein cages retain their ability to mineralize iron oxide on the interior of the cage, 
despite the external functionalization.115
 Other proteins, similar to ferritin, have been used for the direction of nanoparticle 
synthesis.  The heat-shock protein MjHsp contains a ferritin-like cage architecture.  
MjHsp assembles via 24 identical subunits into a 12-nm sized cage, amenable to both 
interior and exterior modification.121  The cage contains 3-nm pores which permit access 
to the interior of the cage, allowing the cage to serve as a size-constrained nanoreactor.  
The cage can be modified through site-directed mutagenesis of the subunit protein to 
display peptides on the interior of the cage, similar to the ferritin cage.  By introducing a 
CoPt-binding peptide at the N-terminus of the protein subunits, Klenn et al. was able to 
nucleate and grow CoPt in the kinetically unfavored L10 phase, with well-defined, 
monodisperse sizes.116 After reduction of metal precursors in the presence of pre-
assembled protein cages, nanoparticles were produced with sizes corresponding to the 
interior cage diameter (~6 nm).  The resulting particles were actually proven to be 
composites of CoPt mineral and protein cage, providing evidence that the nanoparticle 
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becomes encapsulated within the cage.  However, despite this encapsulation, the particles 
showed magnetism consistent with the L10 phase. 
 
Applications of Peptide-Associated Materials 
 The substantial progress in the utilization of peptide-directed formation of 
materials is beginning to translate into applications.  As mechanisms of interaction 
between peptides and materials become better understood, the level of control exhibited 
can be further tuned to produce ever more desirable products.  However, the full promise 
of this technology cannot be appreciated until the development of these peptide-mediated 
materials find their way into functional applications and devices.   
 An emerging trend garnering recent attention is the application of functionalized 
bacteriophage.  One example can be found in the formation of virus-based nanofibers.  
Functional 1-D nanofibers have been created using wet and electrospinning techniques 
that have comparable mechanical strength properties to Nylon 6,6 and polystyrene 
fibers.122, 123  A liquid crystalline suspension of the rod-shaped M13 bacteriophage 
blended with polyvinyl pyrolidone (PVP) was electrospun into continuous virus 
nanofibers having diameters ranging from 100-200 nm and lengths on the centimeter 
scale.  Integration of a peptide functionality on the surface of the virus allows for the 
formation of a number of useful materials, including optical, magnetic, semiconducting, 
and electronic fibers.  Lee and Belcher were able to incorporate the streptavidin-tagged 
fluorescent molecule R-phycoerythrin by genetically engineering the streptavidin-binding 
sequence Trp-Asp-Pro-Tyr-Ser-His-Leu-Leu-Gln-His-Pro-Gln (WDPYSHLLQHPQ) to 
be displayed via the pIII protein of the M13 phage.122 This was later expanded by Chiang 
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et al. to display peptides via the pVIII protein, resulting in bound material spanning the 
length of the virus.123  It was shown that functionalization of the fibers was possible both 
before and after the fiber was spun.  A CdSe-binding carboxylic acid-rich sequence was 
used to bind quantum dots (QDs) to the surface of the virus.  Wet-spinning the QD-bound 
virus resulted in fibers which contained QDs throughout the length of the fiber (Figure 
15A).  In contrast, post-spinning functionality was achieved by spinning fibers of virus 
displaying the gold-binding sequence p8#9 (VSGSSPDS).  Subsequent reduction of Au3+ 
ions in the presence of the viral fibers produced gold nanoparticles specifically bound to 
the surface of the fibers (Figure 15B). 
 
 
Figure 15.  M13 bacteriophage fibers displaying peptides that bound (A) quantum dots 
and (B) gold nanoparticles.123
 
 
 
 These versatile material-promoting phage have also been employed in 
manufacturing of functional devices, specifically lithium ion battery electrodes.124  
Tetraglutamate (EEEE) and a Au-binding peptide were randomly incorporated into the 
coat protein (pVIII) of a M13 bacteriophage.  The virus was incubated with preformed 
gold nanoparticles, which bound to the surface of the virus at the points displaying the 
gold-binding peptide.  The gold nanoparticle-displaying viruses were then added to a 
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solution of CoCl2, which was subsequently reduced.  This resulted in the nucleation of 
Co3O4, a compound capable of reacting with lithium and maintaining a large reversible 
storage capacity, onto the surface of the virus.  In this instance, the tetraglutamate served 
at least three purposes: 1) to block the addition of gold nanoparticles from covering the 
entire virus; 2) to provide a nucleation site for the Co3O4 on the virus surface; 3) and to 
provide a negatively charged surface designed to interact with the positively charged 
polymer used in the electrode assembly process.  The virus particles were incorporated 
into the anode of the battery through the formation of two-dimensional layers on 
electrostatically cohesive films of positively charged polymer.  The Au-Co3O4 composite 
layers showed a higher lithium storage capacity than layers composed of just Co3O4 
under electrochemical evaluation.  This enhancement likely results from the catalytic 
effects displayed by the gold particles on the Co3O4/lithium reaction.  However, both 
samples were capable of demonstrating a reversible capacity approximately twice what is 
typically found in carbon-based anodes for Li ion batteries.    
 The idea of engineering proteins to recognize and assemble materials is also 
finding its way into device applications.  Lower et al. have proposed peptide-engineered 
enzymes for use in enzyme-based fuel cells.125  An enzyme-based fuel cell utilizes the 
natural redox activity associated with the enzyme to produce a current by immobilizing 
the enzyme on a metal oxide electrode.  The redox activity catalyzes the reduction of 
metal oxide resulting in a current.  A major problem with this technology, however, is the 
difficulty associated with immobilizing the enzyme to the electrode.  Lower proposes a 
situation in which a metal oxide binding peptide is engineered to be displayed by the 
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enzyme, thus providing an attachment point, however, this technology has yet to be 
implemented. 
 These materials are also beginning to make their way into biomedical 
applications.  One of the more recent developments is the tissue engineering of 
biomaterials for bone regeneration.  The major structure associated with bone involves 
the biomineral hydroxyapatite, Ca5(PO4)3(OH), bound to a collagen protein scaffold.  
There have been a number of reports involving peptides and amino acids involved in the 
inhibition of hydroxyapatite growth, but only a few related to mineral formation.126, 127 
Consequently, a major focus has been to identify a peptide capable of inducing the 
formation of hydroxyapatite.  Roy et al. have used phage display to isolate the 
hydroxyapatite-binding peptide HA 6-1 (SVSVGMKPSPRP), but have yet to utilize the 
peptide for biomineralization studies.128    
 Lee et al. published one of the first reports involving both the in vitro and in vivo 
biomineralization of hydroxyapatite.129  In this report, a peptide based on a collagen 
binding protein known as osteopontin was identified.  This peptide, the collagen-binding 
motif (CBM - GLRSKSKKFRRPDIQYPDATDEDITSHM), was shown to both bind 
collagen protein and induce the formation of hydroxyapatite.  It had previously been 
thought that collagen played a crucial role in the biomineralization of hydroxyapatite.  
However, Lee’s study also showed peptide-induced mineral formation in absence of 
collagen, suggesting the protein behaves solely as a scaffold with little mineralizing 
capability.  They went on to demonstrate this bone formation in vivo by the addition of a 
peptide/collagen matrix to a skull defect of a rabbit.  Four weeks later, bone formation 
 66
was observed as bony spikes directed towards the defect center.  This was in stark 
contrast to control defects in which no matrix or peptide-free matrix was added. 
 
Conclusions 
 In order to realize the potential of directed growth of materials, morphological 
control must be expanded to more desirable and complex, three-dimensional structures.  
For this reason, the biological compatibility of many types of printing and patterning 
techniques will be of concern.  Patterning technologies offer the ability to unequivocally 
direct the placement of a template, albeit in a totally two-dimensional arrangement, and 
subsequently grow the material at that desired position.  The expansion of these 
technologies to incorporate biological templates in a three-dimensional fashion will 
undoubtedly facilitate the growth of peptide-mediated materials synthesis. 
 The goal to improve the experimental control over matter is constantly driving the 
discovery and creation of new functional materials.  Biologically inspired synthetic routes 
will continue to offer an alternative to high cost reactions driven under unfavorable 
conditions (high temperatures and pressures).  The development of peptide-display 
techniques provides a road map, allowing for the expansion of these methods to include 
many materials.  The determination of high-affinity peptide binders aids in the rapid 
identification of potential synthetic templates. The integration of these peptides with 
biological systems will lead to the creation of new hybrid materials combining the unique 
properties of nanoscale materials with the diverse functionality of living organisms.  This 
development will help to bridge the gap between such diverse fields as biotechnology, 
tissue engineering, molecular electronics, and magnetism.  
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CHAPTER II 
 
 
 
SONOCHEMICAL SYNTHESIS OF FEPT NANOPARTICLES HAVING A HIGH 
COERCIVITY 
 
 
 
Introduction 
 
 The size and shape of the particles that compose a material affect the properties 
associated with that material.  A case in point is the recent emergence of the field of 
nanomaterials synthesis, in which unique materials properties are attained simply by 
accessing the nanoscale.  One example of such a property is magnetism, as the magnetic 
saturation associated with a number of materials maximizes with decreasing particle 
size.130 As a result, synthesis methods are constantly being developed to offer 
improvement in the methods used to attain these sizes of materials. 
 The synthesis of magnetic nanomaterials has recently been given considerable 
attention due to their unique size-related properties, which can be tuned for use in a 
number of fields, including data storage, medicine, and separations.131 In recent years, a 
number of metal alloys, such as FePt and CoPt, have emerged as candidates for a variety 
of ultra-high density data storage and high performance permanent magnet related 
applications.  This interest hinges primarily on the exceptional magnetocrytalline 
anisotropy (~7x106 J/m3) and coercivity associated with these alloys.132
 FePt most commonly exists in two major forms: the chemically disordered, 
superparamagnetic, face-centered cubic (fcc) phase, or the ordered, ferromagnetic, face-
centered tetragonal (fct) phase (Figure 16).  Superparamagnetism is a nanoscale-
dependent property that occurs when the magnetic domain of a particle is the size of the 
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particle itself.130 As a result, only a small amount of energy is needed to flip the direction 
of magnetization of the entire particle, leading to constant fluctuations in magnetic spin 
and an average magnetic moment of zero in the absence of an applied external field.  
Ferromagnetism, on the other hand, is described as permanent magnetism even in the 
absence of an applied field.  As a result, this type of magnetism is the desired form for 
data storage and permanent magnet applications.133 The crystallinity of fct FePt, and thus 
the ferromagnetism associated with this phase, is enhanced at the near equal-atomic 
composition, reaching a maximum at a slightly iron-rich composition .134, 135  Therefore, 
the primary synthetic target for FePt alloy particles has typically been near equal-atomic 
clusters (Fe50Pt50) having diameters less than 10 nm.  
 
 
Figure 16.  (A) Chemically disordered, fcc phase with random arrangement of both Fe 
and Pt atoms.  (B) Chemically ordered, fct phase with alternating planes of Fe and Pt 
atoms.   
 
 
 
 Until recently, FePt materials were synthesized using vacuum-deposition 
techniques.  However, wet-chemical techniques have been developed which provide the 
researcher a means by which to tune and control the size and composition of the resulting 
material.133, 136, 137  The most common of these wet-chemistry techniques is the 
reduction/decomposition synthesis first reported by Sun et al.138  In this method, dual 
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precursors are incorporated that require simultaneous reduction of a platinum salt 
(platinum acetylacetonate) and decomposition of a molecular iron species (iron 
pentacarbonyl) in the presence of organic passivating agents (oleic acid and oleylamine).  
When performed in a slight excess of Fe precursor, this synthesis produces 3 nm fcc 
particles with a slightly iron-deficient composition (Fe52Pt48).  Subsequent annealing at 
temperatures greater than 450 oC are necessary to convert the particles to the desired 
ferromagnetic fct phase.  The crystallinity of the resulting particles has been shown to 
maximize with increasing annealing temperatures.  However, particle sintering and 
twinning can occur when particles are annealed at temperatures above 650 oC, leading to 
a decrease in crystallinity. 
 Although reduction/decomposition remains the primary approach for FePt 
nanoparticle synthesis, alternative methods have emerged.  A co-reduction method has 
been developed that eliminates the need for the toxic and volatile Fe(CO)5.139  The 
volatility associated with this molecule has made the task of controlling the final 
composition of the particles difficult.  Co-reduction alleviates this concern by using 
separate Fe (FeCl2) and Pt (Pt(acac)2) salts in the presence of the same organic 
passivating agents.  Methods designed to reduce or eliminate the need for thermal 
annealing through either metal doping or via direct access of the fct phase have also been 
explored.140, 141 These methods, however, all require high boiling point solvents and 
extended reflux.  
 As an alternative to the high-temperature reaction environments of the 
aforementioned syntheses, we have developed a sonochemical synthetic method, that 
utilizes a single-source molecular precursor.  The precursor, Pt3Fe3(CO)15, contains an 
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equal number of Fe and Pt atoms which, when sonicated in the presence of organic 
stabilizing agents, leads to the formation of particles with a near equal-atomic 
composition.  The resulting particles, upon thermal annealing, possess an unusually high 
room temperature coercivity.        
 
 
Experimental 
 
General considerations and materials 
 Air sensitive compounds and reactions were manipulated and performed using 
standard Schlenk techniques under a nitrogen atmosphere.  All ultrasonic irradiations 
were made using a high intensity ultrasonic probe (Branson Digital Sonifer, Model 450, 1 
cm diameter Ti horn, 20 kHz, 160 W). 
 Tris(norbornylene)platinum(0), Pt(C7H10)3, was prepared as described in the 
reactions of Crascall and Spencer.142  Fe(CO)5, 99.5% was purchased from Strem 
Chemicals.  Oleic acid, 99+%, oleylamine, 70%, and [3-(2-aminoethylamino) propyl] 
trimethoxysilane were purchased from Aldrich Chemical Co.  All chemicals were used as 
received without further purification. 
    
Synthesis of Pt3Fe3(CO)15  precursor 
 The FePt precursor, Pt3Fe3(CO)15, was prepared via a slightly modified version of 
the original synthesis reported by Adams et al.143  Tris(norbornylene)platinum(0), 
Pt(C7H10)3 (0.500 g), was reacted at room temperature with Fe(CO)5 (3.5 mL) in 200 mL 
of hexane solvent for ~10 min..  After removal of the solvent under vacuum, thin-layer 
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chromatography with a 3/7 CH2Cl2/hexane solvent mixture resulted in one product which 
was characterized by IR spectroscopy: Pt3Fe3(CO)15 (20 mg, 5%).  IR (ν(CO), cm-1, in 
hexane):  2056 (s), 2009 (m), 1998 (m). 
 
Synthesis of FePt nanoparticles 
 The precursor, Pt3Fe3(CO)15 (60 mg), was dissolved in 2 mL of toluene containing 
oleic acid (0.32 mL) and oleylamine (0.28 mL).  This solution was irradiated under N2 
with a high-intensity ultrasonic probe at 35% maximum intensity for 1 h.  The resulting 
solution was centrifuged at 5100 rpm to remove any unwanted solid that may have 
precipitated.  The nanoparticles were then precipitated by the addition of 20 mL of 
ethanol.  These particles were collected by centrifugation at 5100 rpm.  The yellow-
brown supernatant was discarded and the resulting nanoparticles were dissolved in a 
solution consisting of a 1:1 mixture of hexane and octane containing oleic acid and 
oleylamine as previously described by Chen et al.144 These as-synthesized particles were 
characterized by powder X-ray diffraction spectroscopy and transmission electron 
microscopy. 
 
Linker molecule stabilization and thermal annealing of nanoparticles  
 The linker molecule/Si substrate attachment and nanoparticle stabilization was 
performed as described by Yu et al.145 To attach the linker molecule, a Si wafer substrate  
(Silicon Inc.) was immersed in a toluene solution of [3-(2-aminoethylamino) propyl] 
trimethoxysilane (APTS) linker molecule [0.10 % (v/v)] for 5 min.  The substrate was 
then removed, rinsed with toluene, dried with nitrogen, and baked at 120 oC for 30 min.  
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The substrate/linker molecule was immersed into a hexane dispersion of nanoparticles 
(~1 mg/mL) for 10 min.  The substrate was removed, rinsed with nitrogen, and allowed to 
dry under ambient air at room temperature.  The nanoparticle/linker molecule/substrate 
assembly was then annealed at 775 oC for 3 h under a slightly reducing atmosphere (10% 
H2/90% N2). 
 
Nanoparticle characterization 
 Samples for transmission electron microscopy (TEM) analysis were prepared by 
attaching the nanoparticles to a SiO-coated copper grid (Ted Pella Inc.) previously 
modified with an APTS linker molecule as described above.  Face-centered cubic 
nanoparticles were analyzed as-prepared, while face-centered tetragonal nanoparticles 
were studied after thermal annealing of the nanoparticle/grid assemblies as previously 
described.  Transmission electron microscopy and energy dispersive X-ray spectroscopy 
(EDS) measurements were performed using a Phillips CM20T TEM operating at 200 kV.  
Single-particle high-resolution energy dispersive spectroscopy (HR-EDS) was performed 
using a Philips CM200FEG 200 kV TEM coupled with an Oxford light element EDS 
detector and EMiSPEC Vision data acquisition system.  HR-EDS data was collected in 
nanoprobe mode with an acceleration voltage of 200 kV and a collection time of 100 s for 
each particle. 
Powder X-ray diffraction (XRD) analysis was performed on both the fcc and fct 
nanoparticles using a Scintag X1 θ/θ automated powder X-ray diffractometer with a Cu 
target, a Peltier-cooled solid-state detector, and a zero-background, Si(510) sample 
support.  Magnetic measurements were performed at Oak Ridge National Laboratory 
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using a superconducting quantum interference device (SQUID) with a maximum applied 
field of 6.5 Tesla. 
 
Results and Discussion 
 
Precursor Synthesis  
 Single source precursors have been utilized in the formation of FePt 
nanoparticles.146-148 In each of the previous cases, however, the molecule was either 
composed of a disproportionate number of metal atoms (non-1:1) or contained large 
organic ligands which could affect the final composition or properties of the particles.  
For this reason, the single-source precursor selected for this study would need to 
circumvent both of these challenges.  Pt3Fe3(CO)15 offers advantages over previously 
utilized precursors of equal-atomic metal compositions and thermally labile ligands.  The 
molecule was first reported by Adams et al. and consists of six planar metal atoms: a 
triangle of Pt atoms and a cluster of Fe(CO)4 bridging each of the Pt-Pt bonds.143  The 
molecule also contains one CO ligand bound to each Pt atom located in the same plane as 
the metal atoms(Figure 17). 
 Synthesis of the molecule was accomplished via a modified version of the original 
Adams prep.  Pt3Fe3(CO)15 was synthesized by reacting iron pentacarbonyl, Fe(CO)5, and 
tris(norbornylene)platinum(0), Pt(C7H10)3, in hexane solvent.  The product was purified 
and isolated via thin-layer chromatography and characterized using infrared spectroscopy 
(Figure 18).  The main difference between this synthetic scheme and the original was the 
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Figure 17.  ORTEP drawing of Pt3Fe3(CO)15.143 
 
 
 
inclusion of the tris(norbornylene)platinum(0) precursor rather than bis(1,5-
cyclooctadiene)platinum(0) [Pt(COD)2].  This modification solved two different 
problems that were encountered with the initial synthesis.  First, the reported synthesis of 
Pt(COD)2 called for the conversion of Pt(C7H10)3 to Pt(COD)2, a reaction for which the 
actual yield fell significantly below the reported yield (below 40% vs. 78%, respectively).  
The successful use of Pt(C7H10)3 eliminated this low yield step.  Additionally, 
Pt3Fe3(CO)15 synthesis via Pt(COD)2 precursor led to the formation of three products that 
required separation via thin-layer chromatography.  In contrast, the use of Pt(C7H10)3 
produced one product, the desired Pt3Fe3(CO)15, in similar yield to what was observed 
with Pt(COD)2. 
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Figure 18.  IR of Pt3Fe3(CO)15 indicating characteristic adsorption bands at 2056, 2009 
and 1998 cm-1. 
 
 
Synthesis of face-centered cubic FePt Nanoparticles 
 Sonochemistry has been used to drive the formation of a range of nanoscale 
materials, including metal nanoparticles, magnetic particles, rare earth materials, hollow 
particles, and cube-shaped particles.149-157 Sonochemistry utilizes ultrasound to create 
extremely high local temperatures in a reaction solution.  As acoustic waves come into 
contact with a molecule in solution they induce a vibrational motion in that molecule.  As 
the intensity of the waves increase, the vibrational motion increases, eventually 
overcoming the intramolecular forces holding the structure together, inducing the 
formation of small bubbles at the surface of the molecule.  As these bubbles form, they 
continue to grow in size until a critical size is reached, upon which a violent collapse 
occurs.  This process of bubble formation, growth, and collapse is referred to as 
cavitation.149, 158 Cavitation produces extremely high local temperatures (~5000 oC) and 
pressures (~1000 atm) as a result of this violent collapse, which last for remarkably short 
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lifetimes (<100 nanoseconds).  However, these times are sufficient to provide the energy 
necessary to drive a variety to chemical reactions. 
  FePt nanoparticles were formed via sonication of the Pt3Fe3(CO)15 precursor in a 
contained reactor (Figure 19).  A typical reaction was performed in toluene solvent under 
a flow of N2 gas.  Oleic acid and oleylamine were also present in the reaction mixture as 
they serve to passivate the resulting nanoparticles, preventing particle aggregation and 
rendering them soluble in organic solvents.  Water is generally considered the optimum 
solvent for sonochemical reactions due to the increased cavitation potential resulting 
from its low vapor pressure.  In this case, however, toluene was used in an attempt to aid 
in precursor solubility while still retaining approximately 74% of the cavitation intensity 
typically observed in water.159 The use of nitrogen gas served to maximize cavitation 
intensity relative to sonochemistry performed in ambient air.  The maximum 
temperatures obtained by cavitation are dependent on the specific heat capacity of the gas 
molecules undergoing compression.  Diatomic gases are generally able to release more 
energy than polyatomic gases, resulting in higher cavitation temperatures.160   
 
 
 
Figure 19.  Diagram of sonochemical reactor. 
 77
 The reaction described above produced face-centered cubic FePt nanoparticles.  
Transmission electron microscopy indicated the particles were actually an agglomerated 
network of smaller particles (Figure 20A) likely held together through van der Waals 
interactions between the oleic acid and oleylamine surfactant molecules.  Energy 
dispersive X-ray spectroscopy revealed the particles to be composed of solely Fe and Pt 
atoms (Figure 20B).  Powder X-ray diffraction confirmed the particles to be in the fcc 
phase (Figure 20C). 
 
 
Figure 20.  As-synthesized nanoparticle characterization.  (A) TEM image showing 
agglomerated particles.  (B) EDS spectrum confirming the presence of both Fe and Pt 
atoms.  Cu peaks arise due to the copper grid on which the particles are presented.  (C) 
XRD of face-centered cubic FePt particles with corresponding diffraction file. 
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Conversion to face-centered tetragonal FePt 
 
 Conversion of the as-synthesized fcc particles to the desired fct phase was 
accomplished via thermal annealing.  Significant aggregation of the particles was 
observed after the annealing of the bulk FePt nanoparticle powder, typically due to the 
decomposition of the organic passivating ligands when subjected to such high 
temperatures.  Conversion of the particles to the crystalline face-centered tetragonal 
phase, however, was confirmed via XRD (Figure 21) with excellent differentiation of all 
expectant superlattice peaks, despite this aggregation.  Scherrer’s analysis of the resultant 
XRD spectrum indicated particle size had grown to ~29 nm in diameter during the 
annealing process.   
 
 
 
Figure 21.  XRD of annealed bulk FePt powder with corresponding face-centered 
tetragonal diffraction file. 
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 In an effort to prevent particle aggregation, as-synthesized particles were annealed 
after stabilization of the particles onto a Si wafer via a [3-(2-
aminoethylamino)propyl]trimethoxysilane linker following the protocols established by 
Yu et al.145  Particles were also immobilized and annealed on a SiO-coated TEM grid for 
microscopy purposes.  Previous use of this linker stabilization method has proven to 
prevent both aggregation and particle coalescence which usually occur during the 
annealing step of ferromagnetic FePt nanoparticle synthesis.145, 161, 162 Particle 
crystallinity and resulting magnetic coercivity increase with both annealing time and 
temperature, with all studies indicating a maximum annealing temperature of ~650 oC.138  
Previous annealing beyond this temperature resulted in destruction of particle 
crystallinity from the associated aggregation and coalescence.163  Prohibiting particle 
aggregation through immobilization, however, allows the use of higher temperatures, 
thus potentially giving rise to particles with increased crystallinity and coercivity.145  
Therefore, an annealing temperature of 775 oC was used for this study.  While surfactant 
decomposition certainly still occurs at this temperature, particle immobilization prohibits 
the movement necessary to cause aggregation.   
 TEM analysis of the annealed grid showed high contrast particles with an average 
diameter of 5.8 nm (Figure 22A).  High resolution transmission electron microscopy of 
single nanoparticles revealed lattice fringes with spaces consistent with the known d-
spacings for the (111) and (110) planes of fct FePt (Figure 22B).  On-particle high 
resolution energy dispersive X-ray spectroscopy confirmed a majority of the particles 
possessed the desired slightly-rich Fe composition (Figure 22C).  XRD on the annealed 
wafer showed the emergence of the (001) and (110) superlattice peaks, though the rest of 
 80
the spectrum was either masked by the peaks from the Si wafer or were indistinguishable 
due to the small amount of material bound to the wafer (Figure 22D). 
 
 
 
Figure 22.  Annealed nanoparticle characterization.  (A) TEM image showing high 
contrast particles with an average diameter of 5.8 nm.  (B) HR-TEM image of single 
particle highlighting the presence of (111) and (110) superlattice fringes. (C) On-particle 
HR-EDS.  (D) XRD of annealed Si wafer-immobilized particles with observable (001) 
and (110) superlattice peaks. 
 
 
 
 Si wafer-immobilized particles were then sent to Oak Ridge National Laboratory 
for magnetic measurements.  Experiments were conducted at both room temperature and 
5 K, the results of which are shown in Figure 23.  Magnetic hysteresis loops showed a 
room temperature coercivity of 22.3 kOe, a value on par with some of highest published 
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FePt coercivities to date.162, 164 Measurements taken at 5 K showed increased coercivity 
compared to those taken at room temperature, however magnetic saturation of the sample 
was unable to be achieved at the maximum applied field of 6.5 T. 
 
 
 
 
Figure 23.  Magnetization hysteresis loops at room temperature and 5 K. 
 
 
 
Conclusions 
 
 Near equal-atomic face-centered tetragonal FePt nanoparticles were synthesized 
through sonication of a single-source precursor.  Interestingly, substantial magnetic 
values were attained for the samples prepared by this method.  There are two factors 
unique to this synthesis that could have contributed to this high level of magnetism.  The 
use of a single-source, zero-valent metal cluster has the potential to offer more uniformly 
arranged metal atoms, resulting from the initial 1:1 metal ratio of the precursor and the 
lack of necessary reduction.  The formation of particles via the extreme local 
temperatures created by sonochemical cavitation could also be a contributing factor.  
Both features could aid in the ordering that occurs during the annealing process.   
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CHAPTER III 
 
DESIGN AND SYNTHESIS OF AN ANTIGENIC MIMIC OF THE EBOLA 
GLYCOPROTEIN 
 
 
Introduction 
 The immunological interface that exists between an antigen and an antibody is a 
paradigm for biological interfaces.  It occurs as a highly specific and sensitive interaction 
(Kd ~ 10-6-10-12) and is governed by an assortment of complex, non-covalent forces (e.g. 
electrostatics, hydrophobics, hydrogen bonding).165, 166  The binding observed between a 
protein antigen and an antibody is typically brought about by the antibody’s recognition 
of a specific amino acid sequence presented in a particular conformation by the 
antigen.167  Recapitulation of these binding characteristics using a synthetic antigen 
mimic can provide a new means for studying and manipulating this interface.  
The design and synthesis of immunological mimics could prove useful in a 
number of areas, including vaccine development and sensor technology.  For example, 
current antigen detection strategies often utilize biological simulants as a form of positive 
control for their detection device.  However, in most cases the simulant takes the form of 
an irradiated or killed form of the organism that these devices are attempting to detect 
(for virus or bacteria-based detection).  These techniques, despite their successful 
adaptation, are expensive and potentially life-threatening, thus illustrating the need for 
cost-effective, safe alternatives.  Nanoparticle-based synthetic simulants combine the 
ability to mimic the antigenicity of a biological species with the non-toxicity, as 
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compared to the viral- and bacterial-based methods, and relatively low production cost 
desired for such a material.168-170  
 Successful mimicry involves the determination of the antigenic epitope, the 
region responsible for antibody recognition, and the presentation of that epitope in a 
manner similar to that of the sequence’s native conformation.  Herein, we describe our 
efforts in mimicking the antigenicity of the Ebola glycoprotein.  Specifically, we have 
mapped an epitope region of the glycoprotein based on the 15H10 monoclonal antibody, 
which binds the native protein.  This epitope was then presented in a fashion that allowed 
15H10 to recognize and bind the complex with an affinity similar to that observed with 
the native glycoprotein.  Although our efforts were focused specifically on this one 
antigen, this approach is applicable to most protein-based antigens. 
 
Experimental 
 
Peptide synthesis and characterization   
 All peptides were synthesized via continuous flow fmoc solid phase peptide 
synthesis methods on an Advanced Chemtech peptide synthesizer, purified by reverse-
phase HPLC, and lyophilized as previously described.171  Identification of the peptides 
was confirmed by MALDI mass spectrometry. 
 
Enzyme-linked immunosorbant assays   
 Enzyme-linked immunosorbant assays (ELISAs) were performed in 96-well 
Immulon-coated plates.  For epitope mapping, all peptides were dissolved in 50 mM 
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carbonate buffer and added to the wells at a concentration of 6.4 μM.  These peptides 
were incubated for 1 h at 37 oC.  Three washes were performed after this and each 
subsequent step using phosphate-buffered saline (PBS) containing 0.1% Tween-20.  The 
wells were then blocked using 300 μL of 10% BSA solution for 2 h at 25 oC.  Murine 
monoclonal 15H10 antibody was received as a gift via the Southeast Regional Center for 
Excellence in Biology (SERCEB) and was isolated and purified as previously 
described.172 15H10 antibody was added as primary antibody at 7 μg/mL and incubated 
for 1 h at 37 oC.  Samples were treated with goat anti-mouse horseradish peroxidase 
secondary antibodies (diluted 1:5000 in PBS) and were allowed to incubate for 1 h at 37 
oC.  After addition of TMB substrate, the enzymatic reaction was quenched using 1 M 
H2SO4.  The wells were then measured spectrophotometrically at 450 nm.  Each assay 
was performed in triplicate.  Ebola Zaire glycoprotein, received as a SERCEB gift and 
isolated and purified as previously described, and carbonate buffer were used as a 
positive and negative control, respectively.172  
 
Monolayer-Protected Cluster (MPC) synthesis and characterization 
 Tiopronin-protected gold nanoclusters were synthesized as previously described 
by Templeton et al.173 Briefly, auric acid (2.7 mmol) was dissolved in an 85:15 solution 
of methanol/glacial acetic acid.  N-(2-Mercaptopropionyl)glycine (C5H9NO3S), 
commonly referred to as tiopronin (8.1 mmol), was added in 3-fold excess to the auric 
acid.  Sodium borohydride (54 mmol) was then slowly added in 20-fold excess to reduce 
the Au (III).  After allowing the solution to stir for 30 min., the methanol was removed 
under vacuum.  The pH was adjusted to approximately 1.0 and the clusters were then 
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purified by dialysis.  Dialysis was performed with cellulose ester tubing with a molecular 
weight cut-off of 10,000 Da.  The dialysis tubing was added to 4 L of water and was 
allowed to stir for three days.  The water was exchanged approximately every 12 hours 
over the course of the three day period.  The MPCs were then dried under ambient 
conditions and characterized by transmission electron microscopy (TEM), nuclear 
magnetic resonance spectroscopy (NMR), and thermogravimetric analysis (TGA). 
 
Place exchange reaction     
 All place-exchange reactions were carried out as previously described by 
Hostetler et al.174 In a typical exchange, Au-tiopronin MPC’s were dissolved in a 2 
mg/mL solution of deionized water.  Peptides previously dissolved in 500 μL of 
deionized water were then added to the MPC solution in an approximate 7:1 tiopronin 
ligand-to-peptide ratio.  This solution was allowed to stir at room temperature for three 
days before purification by dialysis as described above.  The extent of exchange was 
determined by analyzing the NMR integration of amino acid peaks from the peptide 
compared with integration of tiopronin peaks. 
 
Determination of antigen-antibody binding by quartz crystal microbalance   
 A typical QCM experiment was performed under continuous flow and focused on 
immobilizing the antibody while flowing across a nanocluster solution to achieve 
binding.  Each experiment involved the use of a 5-MHz quartz crystal with gold 
electrodes plated on both sides.  Each crystal was cleaned with a solution of piranha (3:1 
H2SO4/30% H2O2) before each experiment.  After allowing the system to equilibrate in a 
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pH 7.2, 50 mM phosphate buffer for at least 1 h, the immobilization component (Protein 
A; 4.5 μM in 50:50 phosphate/acetate buffer) was allowed to flow over the crystal until a 
maximum amount of binding had occurred.  A 10 min. phosphate buffer equilibration 
step was performed after this and each subsequent step.  Bovine serum albumin was then 
added to block the remaining sites on the crystal.  Monoclonal 15H10 antibody (300 nM 
in phosphate buffer) was then added and allowed to equilibrate while binding to the 
Protein A, followed by addition of nanocluster mimic solution for 5 min. while binding 
was detected. 
 
Results and Discussion 
 
Epitope Mapping 
The Ebola glycoprotein is a highly glycosylated transmembrane protein thought to 
be responsible for both receptor binding and fusion of the virus with host cells.175 It is the 
only protein expressed on the surface of the virion and exists in multiple forms.176 The 
first form is post-translationally modified by proteolytic processing into two subunits, the 
N-terminal GP1 and C-terminal GP2, which are subsequently linked by disulfide bonds.  
The second form is an unedited form of GP1, sGP, which is secreted from the virus-
infected cell and differs from GP1 in its last 69 amino acids.175, 177 The version of the GP 
that remains with the virus forms spikes on the surface that mediate viral entry into 
cells.175, 178, 179 It is this 676 amino acid form of the glycoprotein that is the focus of this 
study. 
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 The synthesis of an antigenic mimic can be thought of as a two-fold process: 
epitope determination and epitope presentation.  Successful mimicry of a protein’s 
antigenicity occurs when the amino acid sequence responsible for binding the protein to 
an antibody is presented in a fashion similar to that found in the native structure.  Often 
times a crystal structure of the protein antigen can aid in the determination of a binding 
region.  It is in this fashion that Gerdon et al. were able to determine an epitope of the 
anthrax toxin, B. anthracis.170 However, in the absence of such a structure, epitope 
mapping procedures can be employed.  Common methods utilized to explore the binding 
between a particular amino acid sequence and an antibody includes nuclear magnetic 
resonance spectroscopy (NMR), mass spectrometry, and surface plasmon resonance 
spectroscopy (SPR).172, 180, 181  Our method, however, involves enzyme-linked 
immunosorbant assays (ELISA) performed on potential antigenic regions.  
 Possible antigenic regions for the Ebola glycoprotein have previously been 
reported.182 Three principle regions were reported to have a high probability of possible 
antigenic activity (Figure 24): an N-terminal region, 
STDQLKSVGLNLEGSGVSTDIPSATKRWGFRSG (a.a. 59-91); a mid-peptide region, 
DDDAASSRITKGRISDRATRKYSDLVPKNSPG (a.a. 318-349); and a C-terminal 
region, EPHDWTKNITDKINQIIHDFIDNPLPNQDNDD (a.a 611-642).  Yu et al. 
examined the antigenicity of these peptides.183  They found that antibodies raised against 
the C-terminal peptide reacted with the native glycoproteins from both Ebola subtypes 
they studied (the Zaire and Sudan-Gulu subtypes).  Antibodies raised against the N- 
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 Figure 24.  Schematic of Ebola glycoprotein indication the location of the three main 
sections indicated as having possible antigenic activity.  The blue region at the C-
terminus represents the transmembrane portion of the protein. 
 
 
 
terminal and mid-region peptides failed to react with the Ebola Zaire subtype.  The 
degree of reactivity of the C-terminal region suggested it as an epitope foundation for the 
design of an Ebola mimic that would effectively represent two different Ebola subtypes 
(Zaire and Sudan-Gulu). 
In an effort to establish the specific amino acids responsible for binding 15H10, 
overlapping 10 amino acid peptides were determined by sequentially shifting one amino 
acid at a time to create 23 different peptides.  The ability of the antibody to recognize and 
bind each peptide was probed via ELISA.  The signal from the assay is proportional to 
the degree of binding exhibited between the peptide and antibody.  The results from this 
binding assay are shown in Figure 25. 
The highest region of binding was shown to exist near the C-terminus of the 
sequence (a.a. 623-639), centered around one three amino acid sequence (F-I-D).  A 
second fragment located near the N-terminus (a.a. 614-629) showed binding (~0.25-
0.27), though not as significant as the aforementioned C-terminal region.  These peptides 
all contained a common T-D-K motif, separate from the aforementioned F-I-D pattern.  
The fact that binding occurred separately in two different regions suggests the peptides 
contain partial epitopes and that both sequences (TDK and FID) might be responsible for 
complete binding of the antibody.  This type of epitope is commonly referred to as a  
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Figure 25.  ELISA results for overlapping Ebola glycoprotein C-terminal peptides 
highlighting the specific sequences responsible for inducing antibody recognition and 
binding. 
 
 
 
discontinuous epitope.  Such epitopes are composed of discontiguous sequences of amino 
acids brought in a close proximity due to protein folding.167  Consequently, in an effort to 
construct an epitope inclusive of the major binding regions, longer peptides (16-17 a.a.) 
were synthesized; a 17-mer centered around the highest observed region of binding (1. 
INQIIHDFIDNPLPNQD) and two 16-mers (2. TDKINQIIHDFIDNPL and 3. 
IHDFIDNPLPNQDNDD) shifted to both sides of this potential epitope.  Analysis of the 
expanded epitopes by ELISA showed an increased recognition and binding by the 
monoclonal antibody relative to their shorter counterparts (Figure 26), highlighting the 
suitability of these peptides as epitopes for use in the design of an Ebola glycoprotein 
mimic. 
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 Figure 26.  ELISA results of potential Ebola epitopes indicate the suitability for the use of 
these peptides in further mimicry studies. 
 
 
 
Epitope Presentation 
For successful mimicry, the peptide epitope sequence (the primary structure of the 
peptide) must be presented in a manner that allows the peptide to adopt a conformation 
(secondary and tertiary structure) similar to the one adopted by the native protein.  Seeing 
that protein structure is often difficult to predict and therefore practically impossible to 
purposefully mimic, a presentation method that limits the conformational freedom of the 
peptide epitope would go a long way towards achieving this goal.  A method that 
provides the added dimension of multi-valency would also be desirable to increase the 
degree of interaction between the epitope and the antibody.  A few common approaches 
for introducing multi-valency into a presentation method include the use of linear 
mutimeric peptides, multiple-antigenic peptides (MAPs), and the use of nanoparticles.182, 
184, 185  
Nanoparticles, in particular, have been proven a viable presentation scaffold, 
capable of providing a means of recapitulating a three-dimensional structure through 
covalent attachment of the peptide epitope.169, 170, 186-188 Tiopronin-protected gold 
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nanoclusters were used as a presentation scaffold for our Ebola glycoprotein mimic 
system.  The tiopronin ligands act as stabilizing units for the nanoparticles, preventing 
aggregation of the particles and providing enhanced water solubility, thus allowing their 
integration with bio-systems. Synthesis of the particles by literature methods produced a 
monodisperse batch of particles (3.20 ±0.65 nm) and thermogravimetric analysis 
confirmed an organic composition of 20.7%.189 The characterization of these particles is 
shown in Figure 27.  The average particle composition was calculated to be 
approximately Au616Tiopronin195 (MW ~ 152,962 Da).  The monodispersity exhibited by 
the nanoparticles is necessary to ensure uniformity of ligand coverage on the mimic. 
 
 
Figure 27.  Characterization of tiopronin-protected gold nanoclusters: (A) TEM, (B) 
histogram, (C) NMR, (D) TGA. 
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Peptides are functionalized onto the surface of these nanoparticles via “place-
exchange reactions”.174 These well-defined reactions occur when water-soluble thiolate-
protected gold nanoclusters are exposed to another thiol containing molecule, at which 
point the molecule exchanges with one of the tiopronin ligands.174, 187  Each of the 
peptide epitopes were synthesized with an N-terminal cysteine residue to serve as the 
incoming thiol functionality, thus allowing an attachment point for the peptide to the 
nanoparticle.  After place exchange, the resulting particles were characterized by NMR to 
determine the degree of functionalization (Figure 28).  Place exchange involving a 5:1 
tiopronin-to-incoming peptide ratio resulted in approximate final average compositions of 
Au616Tiopronin183Ebola-112 (MW ~ 176,327 Da), Au616Tiopronin171Ebola-224 (MW ~ 
197,052 Da), and Au616Tiopronin183Ebola-313 (MW ~ 176,660 Da) for the three separate 
epitopes 
 
Figure 28.  NMR characterization of place-exchange.  Peak integration allows for the 
determination of the degree of functionalization of the particles.  
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Binding Quantitation 
 
 Multiple analytical techniques are currently available to quantitate the interaction 
between an antigen and antibody, including immnoblotting, immunofluorescence 
analysis, and surface plasmon resonance spectroscopy.189-191  This study relied upon a 
quartz crystal microbalance (QCM) to quantitatively determine the binding between the 
monoclonal antibody and our nanocluster mimic.  QCM operates via an oscillating quartz 
crystal that measures mass adsorption due to a change in oscillation frequency.  The 
QCM chip was prepared by adsorbing an antibody immobilization molecule, Protein A, 
to the gold-plated surface of the quartz crystal.  After immobilization of the antibody to 
the Protein A, the antigenic mimic is introduced to the system (Figure 29).  QCM offers 
sensitivity with respect to multiple layer adsorption that is often difficult to meet with 
other immunological techniques, as nanogram levels of binding are detectable through 
multiple layers.  This sensitivity, coupled with its simplicity of operation makes QCM a 
very advantageous technique for quantitatively measuring these types of interactions. 
 
 
Figure 29. Layer-by-layer assembly demonstrated by the QCM method. 
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 Initial binding studies resulted in some non-specific binding problems for two of 
the potential mimics (Ebola-1 and Ebola-2), rendering them ineffective.  Of greater 
concern, however, was the complete lack of binding exhibited between 15H10 and the 
Ebola-3 mimic, a matter that forced the re-evaluation of the presentation method.  This 
lack of interaction could be due to steric hindrance induced by the combination of the 
nanoparticle and peptide conformation.  The epitope of interest contains two proline 
residues in the middle of the sequence that likely produce a kink in the structure that 
renders crucial portions of the epitope (FID) inaccessible when functionalized on a 
nanoparticle.  To account for this problem, a polyethylene glycol (PEG) linker was 
inserted between the peptide epitope and terminal cysteine anchor.  The linker, consisting 
of six PEG units (PEG6), was designed to project the peptide beyond the tiopronin cloud 
and away from the surface of the nanoparticle.  Functionalization of the PEG-ylated 
epitope onto the surface of a nanoparticle introduces a new found accessibility that 
enhances interaction with an antibody, and does so in a way that maintains the 
stabilization necessary to limit the conformational freedom of the peptide. 
QCM experiments confirmed the successful recognition of the Ebola-3-PEG 
nanocluster complex by the monoclonal antibody (Figure 30).  The control non-
functionalized tiopronin-protected nanoparticles did not bind to the antibody 
functionalized QCM chip (Figure 31A).  To ensure the specificity of the interaction, two 
additional control experiments were performed, the first involving a different non-Ebola 
antibody (anti-hemagglutinin) and the Ebola-PEG-3 cluster (Figure 31B) and the second 
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 Figure 30. QCM experiment showing approximately 200 ng of Ebola-3-PEG nanocluster. 
 
involving the 15H10 anti-Ebola glycoprotein antibody and a cluster functionalized with a 
PEG-ylated sequence (C-PEG-NSELLSLINDMPITNDQKKLMSNN) from the 
Respiratory Syncytial Virus F protein (Figure 31C).  Both controls failed to produce any 
significant binding.  An initial antibody concentration of 300 nM and cluster 
concentration of 14.4 μM gave approximately 200 ng worth of nanocluster mimic 
binding.  This binding confirms the success of the linker molecule in allowing 
accessibility of the antibody to the entire epitope structure.  As a result, this type of 
rational approach should be applied to all future nanoparticle-based mimics in which the 
epitope region finds itself in close proximity to the nanoparticle core. 
 In order to act as an effective simulant, the affinity exhibited between the mimic 
and the antibody must be similar to that of the native protein.  Determination of the 
equilibrium affinity constant, Kd, allows for such a comparison.  Yu et al. reported a Kd 
value of 0.10±0.01 μM as a measure of the affinity between the 15H10 antibody and the 
native Ebola glycoprotein as measured by two independent techniques (QCM and 
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SPR).172 The equilibrium constant for our mimic system was determined via 
concentration dependent binding studies as previously described.168  The total mass of 
  
 
 
 
Figure 31. QCM control experiments:  (a) Au-tiopronin particles and 15H10 antibody, (b) 
Ebola-PEG-3 nanocluster and anti-hemagglutinin antibody, (c) RSV F-protein 
nanocluster and 15H10 antibody.  All three show no significant binding. 
 
 
nanocluster bound to antibody after five minutes was determined and fit to a logarithmic 
curve (Figure 32). 
The total mass begins to reach a constant value at the higher concentrations, indicating 
the formation of a monolayer as all the antibody binding sites become occupied.  When 
fit to a Langmuir adsorption isotherm as previously described, a Kd of (20±1.5) x 10-6 M 
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was obtained (Figure 33).  Adsorption constants can also be calculated via a kinetic 
method.  By determining the kinetic forward (kf) and reverse (kr) rates obtained from 
time-dependent binding curves (Figure 34), Kd can be derived.  These values (kf = 
(7.7±0.4) x 101 M-1s-1; kr = (7.0±1.3) x 10-4 s-1) produced a Kd value for the Ebola-3-
PEG/15H10 monoclonal antibody system of (9.0±0.4) x 10-6 M 
 
 
Figure 32. Logarithmic fit.  Δm plotted vs. [Ebola-3-PEG] showing immunosensor 
saturation at increasing concentrations. 
 
 
 
 The average Kd from the two methods (Langmuir isotherm and kinetic methods), 
as calculated from the reported native glycoprotein data is 0.180 μM.172  The average 
value for our nanocluster mimic (14.5 μM) falls within two orders of magnitude of this 
value.  The lower value indicates a greater affinity of the native protein for the antibody 
compared to the mimic.  A peptide mimic should be expected to bind with the same 
affinity as the native antigen.  Gerdon et al. reported a Kd value for a peptide- 
functionalized nanoparticle-based mimic of the protective antigen of B. anthracis within 
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one order of magnitude of the value obtained for the native protective antigen.170 Peptide 
mimics have also been reported which show increased affinity compared to their native 
counterparts.  Simmons et al. have reported on a peptide mimic of the Plasmodium 
 
 
Figure 33.  Langmuir adsorption isotherm fit.  Plotting Δm vs Δm/[Ebola-3-PEG] 
produces a linear plot, the slope of which allows for the calculation of Kd = (20±1.5) x 
10-6 M. 
 
 
 
falciparum apical membrane antigen-1 (AMA-1) that shows an increased affinity of two 
orders of magnitude compared to the AMA-1 antigen.191  It should be noted, however, 
that the difference observed in the case of the Ebola-3 mimic was somewhat expected as 
it lacked the secondary TDK motif that showed binding in ELISA studies.  This decrease 
in binding can likely be partially attributed to this idea that the epitope, as constructed, 
remains incomplete.  Further investigation will center on the Ebola-2 sequence which 
contained both the TDK and the FID sequences we observed as preferential for binding 
15H10 and novel strategies for the presentation of a discontinuous epitope. 
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 Figure 34. Kinetic plot.  Plotting the time constant, τ, vs [Ebola-3-PEG] allows for the 
determination of kf and kr.  kr/kf = Kd = (9.0±0.4) x 10-6 M. 
 
 
 
Conclusions 
 A nanocluster assembly has been synthesized that was shown to be recognized 
and bound by the anti-Ebola glycoprotein antibody, 15H10.  Control experiments show 
this binding to be specific for the exposed sequence when presented on a nanoparticle.  
QCM detection of this binding produced an average Kd of 14.5x10-6 M when calculated 
by two different methods.  This value falls within two orders of magnitude of the reported 
native glycoprotein Kd (0.10±0.01) x 10-6 M).  Our reported kinetic rate constants of 
(forward rate constant, kf = (7.7±0.4) x 101 M-1s-1; reverse rate constant, kr = (7.0±1.3) x 
10-4 s-1) are within a similar value.  Despite this relatively small difference in binding 
affinities, however, the rational design approach described here has provided a road map 
for future mimicry studies involving protein-based antigens. 
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CHAPTER IV 
 
 
 
ENHANCMENT OF EBOLA MIMIC ANTIGENICITY VIA ALTERED EPITOPE 
PRESENTATION  
 
 
 
Introduction 
 
 One of the fundamental relationships in biology is the immunological interface 
that exists between an antigen and an antibody.  This interface is characterized by a 
variety of interactions that are capable of preserving a high level of sensitivity and 
specificity while maintaining an extreme level of complexity.  While the complete 
mechanisms behind antibody-antigen binding are still not completely understood, a 
number of different types of chemical and physical interactions are known to play a role, 
including hydrophobics, van der Waals effects, and hydrogen bonding.165, 166, 192, 193 These 
interactions give rise to the physical and structural complementarity that govern the 
molecular recognition between the two species.  Consequently, any effort to mimic or 
control the binding that occurs between an antigen and an antibody must be able to 
recapitulate this structural complementarity.   
 The antigen-binding domain of an antibody is composed of a series of β-pleated 
sheets which creates a region of peptide loops at its surface.194 The sequence and 
structure of this region is termed the paratope and serves as the binding site for a specific 
protein antigen.  The corresponding binding site of the antigen is referred to as the 
epitope.  Two primary classifications have emerged for the conceptualization of the types 
of binding that occur for the various types of epitopes.167, 195  Continuous epitopes (i.e., 
linear epitopes), represent the specific linear sequence of amino acids necessary to induce 
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antibody recognition.  Discontinuous epitopes (i.e., conformational epitopes), represent 
either a contiguous or discontiguous sequence of amino acids whose secondary structure 
and conformation govern antibody recognition.  There is a higher level of selectivity 
associated with these epitopes, as the sequence alone is insufficient to bring about 
antibody binding.  These conformations arise due to the folding of the protein chain and 
are more difficult to predict and reproduce in the absence of a protein crystal structure. 
 Epitope mapping procedures such as the one described in Chapter III provide 
convenient methods to determine the sequence responsible for binding an antibody, but 
offer little in regards to structural determination.  As a result, methods must be developed 
that allow for the study of conformational epitopes as well as their linear counterparts.  
Nanoscale antigen mimics are capable of these types of studies, offering the ability to 
incorporate elements such as structure into design of the mimic. 
 The use of nanoparticle scaffolds has emerged as a suitable method for epitope 
presentation, with one recent review touting them as potential “artificial proteins”.196 The 
versatility associated with nanoparticle functionalization allows for the design of variable 
presentation strategies tailored to the peptide or protein of interest.  A number of recent 
publications highlight the extensive applicability of these functionalized particles, 
including their use as cell-targeting agents, their ability to serve as artificial antibodies, or 
the ability to induce peptide folding-mediated particle aggregation.197-199
 As a continuation of the antigen mimicry study presented in Chapter III, altered 
presentation schemes were investigated as a means to improve the antigenicity of a 
nanoscale mimic of the Ebola glycoprotein.  The binding achieved via three different 
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forms of epitope presentation was quantitated using a quartz crystal microbalance 
immunosensor and compared with values obtained for the native protein. 
 
Experimental 
 
Peptide synthesis and characterization   
 All peptides were synthesized via continuous flow fmoc solid phase peptide 
synthesis methods on an Advanced Chemtech peptide synthesizer, purified by reverse-
phase HPLC, and lyophilized as previously described.171  Identification of the peptides 
was confirmed by MALDI mass spectrometry. 
 
Monolayer-Protected Cluster (MPC) synthesis and characterization 
 Tiopronin-protected gold nanoclusters were synthesized as previously described 
by Templeton et al.173 Auric acid (2.7 mmol) was dissolved in an 85:15 solution of 
methanol/glacial acetic acid.  N-(2-Mercaptopropionyl)glycine (C5H9NO3S), commonly 
referred to as tiopronin (8.1 mmol) was added in 3-fold excess to the auric acid.  Sodium 
borohydride (54 mmol) was then slowly added in 20-fold excess to reduce the Au (III).  
After allowing the solution to stir for 30 min., the methanol was removed under vacuum.  
The pH was adjusted to approximately 1.0 and the clusters were purified by dialysis.  
Dialysis was performed with cellulose ester tubing with a molecular weight cut-off of 
10,000 Da.  The dialysis tubing was added to 4 L of water and was allowed to stir for 
three days.  The water was exchanged approximately every 12 hours over the course of 
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the three day period.  The MPCs were then dried under ambient conditions and 
characterized.  
 Transmission electron microscopy (TEM) samples were prepared by dropwise 
addition of an aqueous suspension of particles onto a carbon-coated copper grid (Ted 
Pella, Inc.).  TEM was performed using a Phillips CM20T TEM operating at 200 kV.  
Nuclear magnetic resonance spectroscopy (NMR) samples were prepared by dissolution 
of the particles in a deuterium oxide solvent and was performed on a 300 MHz Bruker 
DPX-300 FT-NMR Spectrometer.  Thermogravimetric analysis (TGA) was performed on 
an Instrument Specialist TGA-1000. 
 
Place-exchange reactions     
 All place-exchange reactions were carried out as previously described by 
Hostetler et al.174 In a typical exchange, Au-tiopronin MPC’s were dissolved in a 2 
mg/mL solution of deionized water.  Peptides previously dissolved in 500 μL of 
deionized water were then added to the MPC solution utilizing various tiopronin ligand-
to-peptide ratios.  This solution was allowed to stir at room temperature for three days 
before purification by dialysis as described above.  The extent of exchange was 
determined by analyzing the NMR integration of amino acid peaks from the 
functionalized peptide compared with integration of tiopronin peaks. 
 
Determination of antigen-antibody binding by quartz crystal microbalance   
 A typical QCM experiment was performed under continuous flow and focused on 
immobilizing the antibody while flowing across a nanocluster solution to achieve 
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binding.  Each experiment involved the use of a 5-MHz quartz crystal with gold 
electrodes plated on both sides.  Each crystal was cleaned with a solution of piranha (3:1 
H2SO4/30% H2O2) before each experiment.  After allowing the system to equilibrate in 
pH 7.2, 50 mM phosphate buffer for at least 1 h, the immobilization component (Protein 
A, 4.5 μM in 50/50 phosphate/acetate buffer) was allowed to flow over the crystal until a 
maximum amount of binding had occurred.  A 10 min. phosphate buffer equilibration 
step was performed after this and each subsequent step.  Bovine serum albumin was then 
added to block the remaining sites on the crystal.  Monoclonal 15H10 antibody (300 nM 
in 50 mM phosphate buffer) received as a gift via SERCEB, was then added and allowed 
to equilibrate while binding to the Protein A, followed by addition of nanocluster mimic 
solution for 5 min. while binding was detected. 
 
Results and Discussion 
  
Monolayer-protected cluster synthesis and functionalization 
 Monolayer-protected gold clusters (MPCs) provide an excellent foundation for 
the development of nanoscale antigen mimics.168-170, 200 Tiopronin-protected gold 
nanoparticles remain the optimal presentation scaffold owing partially to their 
straightforward synthesis and ease of characterization.  The synthesis, as described by 
Templeton et al., produces ~3 nm sized particles capped with thiol-containing tiopronin 
ligands, rendering them within the size regime of small proteins.173 The tiopronin ligands 
bind to surface gold atoms and stabilize the particles by forming “staple” structures over 
the nanoparticle surface.201-203 These motifs arise due to the ability of the sulfur atom to 
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bind more than multiple gold atoms, one of which is lifted off the surface of the 
remaining particle.  This type of binding leads to the formation of linear S-Au-S motifs 
across the structure of the particle (Figure 35).  Functionalization of these particles 
proceeds via  
 
 
Figure 35.  The “staple” motif.  Yellow = gold atoms, blue = sulfur atoms, red and green 
= methyl groups.202
 
 
 
well-characterized “place-exchange” reactions, first described by Hostetler et al.174 Place-
exchange likely occurs at one of these “staple” positions when tiopronin-protected 
clusters are introduced in the presence of other free thiol-containing ligands, typically 
exchanging in a 1:1 ratio.  The degree of exchange can be controlled by varying either the 
molar ratio of incoming thiol-to-bound ligand or the overall reaction time.  
Characterization of the batch of tiopronin-protected gold nanoparticles used in this study 
is presented in Figure 36.  Nanoclusters with an average diameter of 3.45 nm were 
produced with an average composition of Au773Tiopronin226 (MW = 188,911 Da). 
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 Figure 36.  Characterization of Au-Tiopronin nanoparticles: (A) TEM, (B) Histogram, 
(C) NMR, and (D) TGA. 
 
 
 
Linear epitope presentation 
 
 The epitope mapping procedures discussed in Chapter III identified a principal 
region of the glycoprotein as being responsible for binding the anti-Ebola glycoprotein 
antibody, 15H10.  This epitope is comprised of amino acids from spanning residues 620-
635 of the 676 a.a. glycoprotein.  The segment falls within a region identified as one of 
the heptad repeat (HR2) regions of the glycoprotein as determined via the recently 
reported crystal structure of an Ebola glycoprotein-neutralizing antibody (KZ52) 
complex.204  Unfortunately, the region is located within an unresolved, amorphous 
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portion of the structure, so conformational detail related to these sequences is 
unavailable. 
  Three overlapping peptides from this region, Ebola-1 (INQIIHDFIDNPLPNQD), 
Ebola-2 (TDKINQIIHDFIDNPL), and Ebola-3 (IHDFIDNPLPNQDNDD), were 
synthesized and identified as viable candidates for epitope presentation.  Non-specific 
binding issues, however, limited the study to only one of the available sequences, Ebola-
3.  The successful presentation of this sequence resulted in a binding affinity for the 
15H10 antibody approximately two orders of magnitude weaker than the native 
glycoprotein, leaving significant room for improvement. 
 Of the original three potential epitopes, only the Ebola-2 sequence had the two 
separate amino acid motifs (TDK and FID) predicted by ELISA to have increased 
antibody-binding capabilities.  Original binding studies, however, demonstrated 
significant non-specific binding of the blocking agent, bovine serum albumin (BSA), to 
the peptide-nanoparticle complex, making it impossible to differentiate an antibody-
binding event.  The non-specific binding was ubiquitous for all sources of albumin and 
alternative blocking agents failed to provide sufficient blocking.  This issue is discussed 
further in Chapter V.   
 Efforts to improve antigenicity through epitope binding were focused on 
eliminating the non-specific binding to bovine serum albumin through mutagenesis of the 
Ebola-2 epitope.  Sequence overlay of the three epitopes (Figure 37) identified one region 
(INQI) unique to both Ebola-1 and Ebola-2 believed to be responsible for binding BSA.  
This four amino acid sequence, INQI, was substituted with a SGSG sequence with the 
intentions that this modification would eliminate the BSA-binding without affecting the 
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15H10 epitope.  The new peptide was synthesized with a N-terminal cysteine-PEG6 (C-
PEG-TDKSGSGIHDFIDNPL; MW = 2154 Da) linkage to allow for functionalization  
 
 
 
Figure 37.  Ebola epitope sequence overlay identifies one potential BSA-binding region. 
 
and antibody-sequence accessibility, as previously described in Chapter III.200 After 
place-exchange of the peptide onto a gold nanoparticle, binding detection of the new 
mimic, Ebola2-SGSG, via quartz crystal microbalance indicated complete inhibition of 
BSA binding while retaining the ability to induce antibody recognition (Figure 38).  
 
 
Figure 38.  10 μM Ebola2-SGSG quartz crystal microbalance experiments showing (A) 
non-specific mimic binding to BSA and (B) ~100 ng 15H10/mimic binding. 
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 Successful inhibition of BSA binding via the Ebola2-SGSG nanocluster provided 
the opportunity to explore the Ebola-2 epitope in greater detail.  One such investigation 
examined the concept of multi-valency.  It stands to reason that a cluster displaying a 
high number of epitopes would have better success at antibody recognition than one 
displaying fewer epitopes.  An increase in perceived affinity for the nanocluster system is 
termed avidity.   The actual affinity between antibody and ligand remain constant; 
however, the cluster receives an apparent overall increase in affinity resulting from 
multiple binding sites.  These interactions have previously been studied and quantitated 
for a variety of antibody-antigen systems.205, 206   
 A similar study was performed here utilizing the Ebola2-SGSG mimic.  Three 
separate mimics were synthesized containing an average of 6, 11, and 40 peptides per 
cluster: Ebola2-SGSG6 (MW = 201,646 Da), Ebola2-SGSG11 (MW = 211,590 Da), and 
Ebola2-SGSG40 (MW = 269,352 Da).  Variation in peptide density was obtained by 
adjusting the ratio of tiopronin ligand to incoming peptide, utilizing ratios of 12:1, 7:1, 
and 1.75:1, respectively.  Based on the final compositions, it was calculated that 
approximately 32% of available peptide underwent functionalization.  This incomplete 
exchange is consistent with the observation that ligands with increasing chain lengths 
tend to exchange at a slower rate, thus it is often difficult to achieve 100% 
functionalization of the peptide.174 Characterization of the Ebola2-SGSG peptide and 
nanocluster peptide densities is presented in Figure 39.        
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Figure 39.  Ebola2-SGSG characterization. (A) MALDI spectrum indicating appropriate 
mass for C-PEG-TDKSGSGIHDFIDNPL.  NMR spectra highlight the amino acids used 
in peptide density quantitation for (B) Ebola2-SGSG6, (C) Ebola2-SGSG11, and (D) 
Ebola2-SGSG40.  
 
 
  
 Mimic binding to 15H10 monoclonal antibody was quantitated via the quartz 
crystal microbalance immunosensor described in Chapter III.  Initial control experiments 
confirmed a lack of non-specific binding with BSA allowing for further study.  The total 
mass of mimic that bound to immobilized antibody was determined as a function of 
nanoparticle concentration (Figure 40).  Each mimic shows a saturation of available 
antibody binding sites with increasing mimic concentration, consistent with Langmuir 
adsorption behavior.  Additional control experiments confirmed that this binding was 
specific for the 15H10 antibody and epitope of interest.   
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 Figure 40.  Concentration-dependent binding curves for Ebola2-SGSG6, Ebola2-SGSG11, 
and Ebola2-SGSG40. 
 
 
 Data obtained for some of the higher concentrations indicate particle aggregation 
after monolayer formation, as the amount of bound material exceeded what would be 
expected for a monolayer.  The 65 and 100 μM Ebola2- 
SGSG40 data points offer prime examples of this occurrence, as 1231 ng constitutes the 
maximum amount of this specific nanocluster that would be expected based on the 
number of available antibody binding sites.  As a result, using these values to obtain 
equilibrium constants would skew the equilibrium data towards values consistent with 
particle aggregation. 
     Kinetic data has often been used as both a complement and alternative to 
Langmuir isotherms for calculating equilibrium constants.207-209 By utilizing time-
dependent binding data, one can determine the forward (kf) and reverse (kr) rate constants 
associated with the mimic-antibody binding.  Fitting the time-dependent data to the 
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exponential expression highlighted in Eq. 1, where mt is equal to the mass bound at time 
t, and mi is the mass bound at infinite time, allows for the calculation of a time constant 
(τ-1) for each concentration.   τ-1 is determined by calculating the slope of the linear 
portion of this plot after forcing the y-intercept through zero.  This constant can then be 
plotted vs. the nanoparticle concentration via Eq. 2, to calculate kf (the slope) and kr (the 
y-intercept).  These rate constants can then be used to determine the necessary  
 
ln (1-mt/mi) = - (τ-1)t (Eq. 1) 
τ-1 = kfC + kr (Eq. 2) 
 
equilibrium constants.  The association constant, Ka (M-1), is calculated as the ratio of 
kf/kr and the dissociation constant, Kd (M), is the inverse of this ratio.  The kinetic data 
provides a more reliable measure for this specific case in which high concentrations make 
final mass determinations difficult.  This basis for determining affinity constants 
encompasses an extensive range of concentration- and time-dependent data points, 
offering more precision for the final values, despite the fact that Eq. 1 tends to deviate 
from linearity at the most dilute (slow mass diffusion) and most concentrated 
(aggregation) ends of the range studied. 
 Fitting the data obtained for Ebola2-SGSG6, Ebola2-SGSG11, and Ebola2-SGSG40 
to Eq. 2 renders the plots in Figure 41.  Determination of the rate constants allows for the 
calculation of the disassociation constant, Kd.  Kd is a common measure of antigen-
antibody affinity and can be thought of in a physical sense as the concentration necessary 
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for a material to occupy half of the available binding sites.  Dissociation and rate 
constants for the Ebola2-SGSG mimics are presented in Table 8.       
 
 
 
 
Figure 41.  Kinetic plots for Ebola2-SGSG6, Ebola2-SGSG11, and Ebola2-SGSG40. 
 
 
Table 8.  Equilibrium and kinetic constants for Ebola2-SGSG mimics. 
Mimic System Kd ( x 10-6 M) kf ( x 102 M-1s-1) kr ( x 10-5 s-1) 
Ebola2-SGSG6 0.655 ± 0.05 0.626 ± 0.5 4.10 ± 2.6 
Ebola2-SGSG11 1.49 ± 0.10 0.464 ± 0.3 6.90 ± 1.7 
Ebola2-SGSG40 1.56 ± 0.09 1.13 ± 0.7 17.6 ± 3.8 
 
 
 
 The equilibrium data indicates that binding amongst Ebola2-SGSG mimics 
becomes increasingly weaker as the number of peptides on the surface of the particle 
increases.  This decrease suggests that a crowding effect is exhibited in which a 3 nm 
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particle is unable to withstand an increased number of peptides while maintaining 
sufficient display of the epitope.  The extreme length of the peptide epitope (17 a.a. + 
PEG6) also likely contributes to this crowding as the peptides are likely to sterically 
inhibit antibody interaction with neighboring peptides, effectively reducing the number of 
potential binders.   
 Each mimic system demonstrated considerable improvement in binding relative to 
the previously studied mimic, Ebola-PEG-3.  Even the worst binder of the three, Ebola2-
SGSG40, showed a greater than 5-fold improvement in reported Kd compared to Ebola-
PEG-3 (Kd = (9.0±0.4) x 10-6 M), while the best, Ebola-SGSG6, exhibited greater than 13-
fold improvement.  This suggests that binding is greatly enhanced by the combination of 
the FID and TDK sequences first predicted to be crucial in 15H10 binding.  It is also 
worth noting that the Ebola2-SGSG6 represents the best Ebola glycoprotein antigen 
mimic reported to date with regard to equilibrium constant.  The previously reported Kd 
for the Ebola glycoprotein, (0.100±0.01) x 10-6, falls within the same order of magnitude 
of the Ebola2-SGSG6 mimic, (0.655±0.05) x 10-6, with both demonstrating binding on a 
nanomolar scale. 
  
Bidentate conformational epitope presentation 
 To this point, all antigen mimic studies concerning the Ebola glycoprotein and 
15H10 antibody have focused on the presentation of a linear epitope.  As mentioned 
previously, however, if this specific epitope were conformational in nature, then 
presentation resulting in any conformation other than the one displayed in the native 
protein will result in decreased binding relative to the native state.  Therefore, alternative 
 115
presentation methods must be considered to account for the prospects of conformational 
requirements for antibody binding. 
 A major benefit to using gold nanoclusters as presentation scaffolds is related to 
the concept of ligand mobility.  Hostetler proposed that functionalized ligands have the 
ability to migrate over the surface of the nanoparticle.174 Gerdon et al. used this 
mechanism as an advantage in the presentation of a conformational epitope via a 
bidentate attachment scheme which anchored both ends of the peptide epitope to the 
nanoparticle.170 The concept of ligand mobility would suggest that once bound, the 
peptide would be free to migrate on the surface of the particle until coming into contact 
with an antibody.  In the case of a linear epitope, this has little bearing on an antibody 
binding event, as peptide structure potentially plays little to no role in binding.  A 
conformational epitope, however, must be presented in a manner that would recapitulate 
the structure found in the native protein.  Allowing the peptide to move freely over the 
surface would increase the chance that the two anchors migrate the appropriate distance 
apart, leading to the formation of a loop conformation similar to what is seen in the native 
protein. 
 The possibility that the 15H10-Ebola glycoprotein epitope could be 
conformational in nature was addressed by presenting the peptide in a bidentate fashion 
(Figure 42).  The Ebola2-SGSG peptide was synthesized with cysteine-PEG linkages at 
both termini to allow for nanoparticle attachment points resulting in the following 
sequence: C-PEG- TDKSGSGIHDFIDNPL-PEG-C (MW = 2,592 Da).  Place-exchange 
of this peptide was accomplished by the methods previously described utilizing a 7.5:1 
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 Figure 42.  Diagram illustrating the concept of bidentate epitope presentation and how 
that relates to antibody interaction. 
 
 
 
tiopronin/peptide ratio and resulting in following final composition: Ebola2-BiSGSG21 -   
Au773Tiopronin184BiSGSG21; MW = 236,533 Da.  MALDI mass spectrometry analysis of 
the peptide and an NMR spectrum used to determine degree of exchange are presented in 
Figure 43. 
 
 
Figure 43.  Characterization of Ebola2-BiSGSG including (A) MALDI spectrum of 
purified peptide and (B) NMR spectrum of peptide-functionalized nanoparticles. 
 
 
 Quartz crystal microbalance binding quantitation produced the concentration-
dependent binding curve and kinetic plot displayed in Figure 44.  Very little overall 
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binding was achieved for this conformational mimic, even at increasing concentrations, 
relative to all other previously studied mimics.  However, control experiments did 
validate that the small amount of binding was specific for 15H10 antibody.  Kinetic data 
was used to generate corresponding forward and reverse rate constants of (0.104±0.2) x 
102 M-1s-1 and (7.19±1.0) x 10-5 s-1, respectively, yielding a dissociation constant of Kd 
(6.89±1.4) x 10-6 M. 
 
 
Figure 44.  (A) Concentration-dependent binding curve and (B) kinetic plot for Ebola-
BiSGSG. 
 
 
 
 The data indicate a decrease in binding affinity for the mimic presented in a 
bidentate fashion relative to the linear Ebola2-SGSG epitope.  The most simplistic 
explanation for this diminished activity is that the epitope must exist in a linear form in 
nature.  If this were the case, constricting the conformational freedom of the peptide by 
anchoring both termini would have an adverse effect relative to its native state.  However, 
additional factors may be contributing to the observed decrease in binding.  Restricting 
conformational freedom may play a role in the sense that the lowest energy state 
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occupied by this system may exist in a form that limits surface accessibility to one of the 
crucial binding amino acids (TDK or FID, for example).  Such a scenario would suggest 
that the nanoparticle was presenting the epitope in a conformation different from that 
observed in the native protein.  One solution for this would be to alter the size of the 
nanoparticle, as particle diameter plays a role in Cys-Cys spacing, and thus conformation 
determination. 
 An alternative explanation for the decreased binding may be related to the density 
of peptides displayed on the surface.  As shown earlier, increased peptide density leads to 
a steric effect which manifests itself as diminished interaction with the antibody.  This 
system had approximately 21 peptides per nanocluster which implies a maximum 
exchange of 42 tiopronin ligands after both terminal cysteine thiol groups attach to the 
nanoparticle.  Based on the results for previous Ebola2-SGSG systems, this extreme 
degree of functionalization would most certainly lead to peptide overlap and steric 
inhibition of antibody interaction.        
 
Binary epitope presentation 
 When one examines the nature of a conformational epitope and how the binding 
site is constructed, two distinct scenarios can be envisioned, both of which possess the 
necessary secondary structure element for binding.  The first situation, which has already 
been discussed at length, occurs when the natural secondary structure of the protein 
results in the linear sequence adopting some definitive conformation.  Efforts to mimic 
this type of epitope must account for the entire sequence adopting a particular 
conformation.  A second situation arises when the protein folding brings non-linear 
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portions of the structure within spatial proximity of each other.  In this case, two different 
regions separated by a specific number of irrelevant amino acids are the primary epitope.  
Presentation of the entire sequence in this instance would be superfluous and could 
potentially inhibit binding depending on the situation. 
 A similar scenario exists for this Ebola glycoprotein/15H10 epitope in which two 
primary regions of interaction are separated by a number of residues (albeit a small 
number of residuces in this instance).  Evidence for this hypothesis includes the 
following: (1) the identification of two distinct sequences required for complete antibody 
recognition confirmed via ELISA and QCM measurements, (2) the ability to retain 
antibody recognition despite mutagenesis of a significant portion of the epitope sequence 
(INQI), and (3) the observed loss of binding that occurs when conformationally 
presenting the epitope in a bidentate fashion.   
 In an effort to address this issue, a binary route for epitope presentation was 
developed and studied as a suitable method for antigen mimicry.  By separately 
displaying both the T-D-K and F-I-D sequences, presentation of the non-linear epitope 
can be achieved (Figure 45).  This is not a truly original concept, as two recent 
publications demonstrated the use of mixed peptide-nanoparticle complexes within the 
past six months.210, 211 However, to this author’s knowledge, it has not been demonstrated 
as a method to induce antibody recognition via conformational epitope presentation. 
 The short TDK and FID sequences were individually synthesized with C-terminal 
Cys-PEG linkages and functionalized onto the surface of the gold nanoclusters by the 
methods previously described.  Tiopronin-to-peptide ratios were selected with the 
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intention of exchanging comparable numbers of TDK and FID ligands onto the same 
particle.  Particles displaying just one of the ligands (either C-PEG-TDK or  
 
 
Figure 45.  Diagram of binary conformational presentation of TDK and FID epitopes. 
        
 
C-PEG-FID) were also prepared in order serve as controls.  Two different binary systems 
were synthesized utilizing ratios of 14:1 and 7:1 for each peptide.  These exchange ratios 
produced particles with the following average final compositions: Ebola-TDK14FID15 – 
Au773Tiopronin197TDK14FID15 (MW = 145,819 Da) and Ebola-TDK25FID31 – 
Au773Tiopronin170TDK25FID31 (MW = 164,039 Da).  Characterization of the resulting 
particles is presented in Figure 46. 
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Figure 46.  (A) MALDI spectrum of C-PEG-TDK; MW = 800 Da.  (B) MALDI spectrum 
of C-PEG-FID; MW = 831 Da.  (C) NMR spectrum for TDK14FID15.  (D) NMR 
spectrum for TDK25FID31. 
 
 
 
 Antibody recognition was quantitated for the systems (Ebola-TDK14FID15, Ebola-
TDK25FID31, Ebola-TDK11, and Ebola-FID12) via quartz crystal microbalance as 
described above.  Control experiments demonstrated all observable binding was specific 
for the 15H10 antibody.  Binding and kinetic data for the two binary systems are 
presented in Figure 47 and the calculated equilibrium and rate constants are listed in 
Table 9.  Contrary to what was observed for the Ebola2-SGSG mimics, an increase in 
overall binding was observed with an increase in peptide density.  This can likely be 
attributed to the maximum number of peptides presented in each case.       
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Figure 47.  (A) Concentration-dependent binding curve and (B) kinetic plot for binary 
presentation mimics TDK14FID15 and TDK25FID31. 
 
 
 
Table 9.  Equilibrium and kinetic constants for Ebola-TDK-FID mimics. 
 
Mimic System Kd ( x 10-6 M) kf ( x 102 M-1s-1) kr ( x 10-5 s-1) 
Ebola-TDK14FID15 9.34 ± 0.2 0.580 ± 0.1 54.2 ± 1.1 
Ebola-TDK25FID31 1.55 ± 0.08 0.704 ± 0.4 10.9 ± 2.6 
Ebola-TDK11 8.71 ± 1.3 0.236 ± 0.4 20.6 ± 1.9 
Ebola-FID12 4.75 ± 0.4 0.373 ± 0.3 17.7 ± 1.7 
 
 
Ebola-TDK14-FID15 has a maximum of 14 potential epitopes available for presentation.  
However, the likelihood that all ligands are placed with exactly the proper spacing from a 
corresponding counterpart is extremely small.  Therefore, the effective number of 
epitopes being presented in the proper fashion is much smaller than the maximum value, 
and unfortunately impossible to predict.  The advantage to this system, however, is that 
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the short peptides show no steric effect as the overall functionalization reaches ~56 
peptides per cluster for the Ebola-TDK25FID31 mimic.  This advantage manifests itself as 
a 6-fold increase in binding relative to the Ebola-TDK14FID15 mimic despite displaying 
less than twice as many potential epitopes.   
 The increase in binding for the highly substituted binary mimic compared to both 
the control mimics also speaks the benefit of displaying both TDK and FID sequences.  It 
is also worth mentioning that the binding observed for Ebola-FID relative to Ebola-TDK 
verifies the initial ELISA results reported in Chapter III which showed a higher level of 
binding centered on the FID region. 
 
Conclusions 
 A summary of all the Ebola glycoprotein mimicry data recorded to date is 
presented in Table 10.  These values illustrate the validity of epitope presentation via a 
nanoparticle scaffold as a means of protein antigen mimicry.  The design and synthesis 
methods reported here are likely applicable to most protein-based antigens for which the 
amino acid sequence is known.  Successful nanoparticle-based epitope presentation 
resulted in the molecular recognition of a monoclonal antibody, in some cases (e.g. 
Ebola-SGSG6) on the order observed for the native glycoprotein.  Ebola2-SGSG6 
represents the best mimic produced to date, as its antigenicity most closely resembles that 
of the native protein.  High levels of binding can likely be attributed to the ideal degree of 
functionalization combined with a linear presentation method.  It is of interest to note,  
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Table 10.  Complete summary of mimic binding data.a
Mimic System Kd ( x 10-6 M) kf ( x 102 M-1s-1) kr ( x 10-5 s-1) 
Ebola2-SGSG6 0.655 ± 0.05 0.626 ± 0.5 4.1 ± 2.6 
Ebola2-SGSG11 1.49 ± 0.10 0.464 ± 0.3 6.9 ± 1.7 
Ebola2-SGSG40 1.56 ± 0.09 1.13 ± 0.7 1.8 ± 3.8 
Ebola2-BiSGSG 6.89 ± 1.4 0.104 ± 0.2 71.9 ± 1.0 
Ebola-TDK14FID15 9.34 ± 0.2 0.580 ± 0.1 54.2 ± 1.1 
Ebola-TDK25FID31 1.55 ± 0.08 0.704 ± 0.4 10.9 ± 2.6 
Ebola-TDK11 8.71 ± 1.3 0.236 ± 0.4 20.6 ± 1.9 
Ebola-FID12 4.75 ± 0.4 0.373 ± 0.3 17.7 ± 1.7 
Ebola-PEG-3 8.99 ± 0.4 0.779 ± 0.4 70.0 ± 1.3 
  a Inclusive of data from all chapters.  
 
however, the high level of antigenicity achieved via binary epitope presentation.  This 
successful presentation offers another tool in the ever-expanding antigen mimicry 
“toolkit”.  Such a scheme could potentially be utilized for the mimicry and presentation 
of a truly discontinuous epitope.  For example, Lee et al.’s recently published crystal 
structure of the Ebola glycoprotein-KZ52 neutralizing antibody complex revealed the an 
epitope consisting of three short segments spanning the two separate glycoprotein 
subunits.204  Binary (or tertiary, in this case) presentation offers a method by which to 
construct a glycoprotein mimic that would recognize a neutralizing antibody.  
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CHAPTER V 
 
 
 
INVESTIGATION OF AN ALBUMIN-BINDING PEPTIDE SEQUENCE RELATED 
TO THE EBOLA GLYCOPROTEIN FOR THE DESIGN OF AN ALBUMIN-
TARGETING NANOPARTICLE COMPLEX  
 
 
 
Introduction 
 
 The concept of nanomedicine refers to the application of nanotechnology for 
medicinal purposes.  The potential applications associated with this broad topic are vast 
and offer the promise for improved therapy and diagnostics.  The use of nanoparticles, in 
particular, has emerged as a means by which to specifically target potential drug delivery 
sites, whether by tuning the size and composition of the nanoparticle or through 
modification of their surfaces with target-binding ligands.212, 213 Common ligands used 
for such purposes consist of drug molecules, antibodies, and cell- and protein-binding 
peptide sequences. 
 One potential target is the blood protein, albumin.  Its ubiquitous nature and 
unique binding capabilities make it an increasingly common mode of drug delivery.  
Albumin is a ~65 kDa blood protein whose primary function involves regulating the 
osmotic pressure and pH of blood.214 The protein is triangular in shape and is composed 
of three homologous subunits, which include seven different fatty acid binding sites.215, 
216 For this reason, albumin also serves as the primary transporter of fatty acids to tissues 
throughout the body.217  It is also known to bind a number of other types of species, 
including heavy metals, hemin, and organic molecules, such as bilirubin.214, 218 For this 
reason, drug-delivery systems are emerging that utilize serum albumin as a carrier 
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agent.219, 220 However, the binding capabilities of albumin are typically limited to lower 
molecular weight substances; thus, it is relatively inert with regards to many types of 
biomolecules.  As a result, it is commonly used in laboratory settings as a blocking agent 
for biomolecular assays.   
 A peptide sequence was previously identified in Chapters III and IV, originating 
from the Ebola glycoprotein, which showed an atypical affinity for albumin.  The source 
of this binding was revealed as a specific four amino acid sequence, INQI.  Once 
substituted with a different sequence, the binding activity was lost.  For this reason, 
presentation of the sequence via a nanoparticle scaffold was explored as a means to create 
a high affinity albumin-targeting ligand for possible applications related to drug delivery.  
Achievement of this goal would result in expanding the applicability of albumin-related 
drug delivery to drugs previously unable to bind to the protein.               
 
Experimental 
 
Peptide synthesis and characterization   
 All peptides were synthesized via continuous flow fmoc solid phase peptide 
synthesis methods on an Advanced Chemtech peptide synthesizer, purified by reverse-
phase HPLC, and lyophilized as previously described.171  Identification of the peptides 
was confirmed by MALDI mass spectrometry. 
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Monolayer-Protected Cluster (MPC) synthesis and characterization 
 Tiopronin-protected gold nanoclusters were synthesized as previously described 
by Templeton et al.173 Auric acid (2.7 mmol) was dissolved in an 85:15 solution of 
methanol/glacial acetic acid.  N-(2-Mercaptopropionyl)glycine (C5H9NO3S), commonly 
referred to as tiopronin (8.1 mmol), was added in 3-fold excess to the auric acid.  Sodium 
borohydride (54 mmol) was then slowly added in 20-fold excess to reduce the gold.  
After allowing the solution to stir for 30 min., the methanol was removed under vacuum.  
The pH was adjusted to approximately 1.0 and the clusters were purified by dialysis.  
Dialysis was performed with cellulose ester tubing with a molecular weight cut-off of 
10,000 Da.  The dialysis tubing was added to 4 L of water and was allowed to stir for 
three days.  The water was exchanged approximately every 12 hours over the course of 
the three day period.  The MPCs were then dried under ambient conditions and 
characterized.  
 Transmission electron microscopy (TEM) samples were prepared by dropwise 
addition of an aqueous suspension of particles onto a carbon-coated copper grid (Ted 
Pella, Inc.).  TEM was performed using a Phillips CM20T TEM operating at 200 kV.  
Nuclear magnetic resonance spectroscopy (NMR) samples were prepared by dissolution 
of the particles in a deuterium oxide solvent and was performed on a 300 MHz Bruker 
DPX-300 FT-NMR Spectrometer.  Thermogravimetric analysis (TGA) was performed on 
an Instrument Specialist TGA-1000. 
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Place-exchange reactions     
 All place-exchange reactions were carried out as previously described by 
Hostetler et al.174 In a typical exchange, Au-tiopronin MPC’s were dissolved in a 2 
mg/mL solution of deionized water.  Peptides previously dissolved in 500 μL of 
deionized water were then added to the MPC solution utilizing various tiopronin ligand-
to-peptide ratios.  This solution was allowed to stir at room temperature for three days 
before purification by dialysis as described above.  The extent of exchange was 
determined by analyzing the NMR integration of amino acid peaks from the 
functionalized peptide compared with integration of tiopronin peaks. 
 
Enzyme-linked immunosorbant assays 
 All enzyme-linked immunosorbant assays (ELISAs) were performed in 96-well 
Immulon-coated plates.  The adsorption of Ebola mimics to different forms of albumin 
was investigated by first blocking the wells with 300 μL of a 10% w/v solution composed 
of one of the potential blocking agents (bovine serum albumin, horse serum albumin, 
fetal bovine serum, and lactalbumin) for 2 h at 25 oC.  Three washes were performed after 
this and each subsequent step using phosphate-buffered saline (PBS) containing 0.1% 
Tween-20.  Peptide-presenting nanoclusters dissolved in pH 7.2, 50 mM phosphate buffer 
were then added to the wells at a peptide concentration of 6.4 μM.  These nanoparticles 
were allowed to incubate for 1 h at 37 oC.  Murine monoclonal 15H10 antibody was 
received as a gift via SERCEB and was isolated and purified as previously described.172  
15H10 antibody was added as primary antibody at 7 μg/mL and incubated for 1 h at 37 
oC.  Samples were treated with goat anti-mouse horseradish peroxidase secondary 
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antibodies (diluted 1:5000 in PBS) and were allowed to incubate for 1 h at 37 oC.  After 
addition of TMB substrate, the enzymatic reaction was quenched using 1 M H2SO4.  The 
wells were then measured spectrophotometrically at 450 nm.  Each assay was performed 
in triplicate.    
 
Quartz crystal microbalance studies 
 Three different types of QCM experiments were used in these analyses.  The first 
involved the typical layered immunosensor previously described in Chapters III and IV.  
The second involved immobilization of nanoparticles followed by addition of the 
antibody.  Each experiment involved the use of a 5-MHz quartz crystal with gold 
electrodes plated on both sides and was performed under continuous flow.  The crystal 
was cleaned before each experiment with a solution of piranha (3:1 H2SO4/30% H2O2).  
After allowing the system to equilibrate in pH 7.2, 50 mM phosphate buffer for at least 1 
h, a 0.05 μM solution of polyelectrolyte immobilization component, 
poly(diallyldimethylammonium chloride), was allowed to flow over the crystal until a 
maximum amount of adsorption of the electrolyte to the gold electrode had occurred.  A 
10 min. phosphate buffer equilibration step was performed after this and each subsequent 
step.  Bovine serum albumin was then added to the system for blocking purposes.  A 4 
mg/mL solution of peptide-functionalized nanoparticles dissolved in phosphate buffer 
was then added for at least ten minutes or until monolayer formation had occurred.  The 
following buffer step was then allowed to proceed until any unbound material had been 
washed away, followed by addition of 1 mg/mL solution of BSA for 5-10 min. while 
binding was monitored. 
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 Peptide binding in the absence of a nanoparticle scaffold was studied through the 
formation of two-dimensional self-assembled monolayers.  Monolayers were self-
assembled on the gold QCM electrode by incubating a 1 mM peptide solution in ethanol 
with a clean electrode overnight.  Cyclic voltammetry was performed on the electrode to 
ensure complete monolayer coverage.  QCM experiments were then used to study 
albumin adsorption to the protein monolayer via the previously described methods. 
 
Results and Discussion 
 
Initial albumin binding observations 
 Previous experiments discussed in Chapter III indicated some degree of non-
specific binding of the bovine serum albumin blocking agent to the Ebola-1 and Ebola-2 
mimics.  Data from one of these experiments is presented in Figure 48A.  Though one 
can certainly suspect some level of specific binding interaction was occurring between 
antibody and mimic, the error introduced by the albumin interference rendered the 
obtained binding values unreliable.  Control experiments indicated that a major portion of 
the binding was due to this non-specific interaction with albumin protein (Figure 48B).     
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 Figure 48.  (A) Initial binding indicating Ebola-2 antibody recognition.  (B) Control 
experiment showing mimic-BSA interaction. 
  
  
 
 In an effort to study better understand this albumin interaction, enzyme-linked 
immunoassays were utilized to probe the possibility that this binding was universal for all 
forms of albumin, or whether specificity existed with regards to the bovine form.  
Sequence homology between bovine serum albumin and human serum albumin is only 
76%, so it is not unrealistic to expect different binding characteristics based on the 
albumin source.221 A modified indirect binding ELISA was performed by first adding the 
albumin to a well, serving to block the entire well from future binding.  This initial 
blocking was then followed by the ELISA utilizing the Ebola-2 nanoparticle-peptide 
complex.  This design of this assay would only allow for positive binding if the peptide 
epitope (or nanoparticle) bound to the blocking agent to some degree.   
 Four different types of albumin proteins were surveyed for binding, the results of 
which are presented in Figure 49.  The data indicated the mimic binding shows no 
preference to the type of albumin.  Lactalbumin did show diminished binding capabilities 
relative to bovine, fetal bovine, and human albumins, but the interaction still exceeded all 
reasonable expected levels of binding for a blocking agent.       
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Figure 49.  ELISA results probing the binding between Ebola-2 mimic and albumin from 
various sources. 
  
 
  
 As discussed in Chapters III and IV, this interaction was shown to be specific for 
the Ebola-1 and Ebola-2 sequences, whereas Ebola-3 did not bind the protein (Figure 50).  
Control ELISAs implicated the peptide sequences were responsible for BSA interaction, 
as non-functionalized Au-tiopronin particles exhibited negligible binding.  In an effort to 
determine the specific source of this interaction, sequence overlay identified a four amino 
acid region (INQI) unique to Ebola-1 and Ebola-2, but absent in Ebola-3, indicating the 
sequence as a potential binding site for albumin.  Modification of this region to the less 
interactive Ebola2-SGSG sequence discussed in Chapter IV, resulted in complete 
inhibition of BSA binding, implicating the INQI as the primary mode of interaction. 
     
 133
 Figure 50.  ELISA results showing Ebola mimic-BSA binding. 
 
Synthesis of albumin-binding peptide-nanoparticle complex  
 Synthesis of an albumin-binding nanoparticle system was performed by 
functionalizing the INQI sequence onto the surface of a tiopronin-protected gold 
nanoparticle.  Both a monodentate sequence with an N-terminal Cys-PEG6 linker and a 
bidentate sequence with Cys-PEG6 linkers on both termini were synthesized and 
exchanged onto the surface of Au773Tiopronin226 clusters.  In each case, the INQI 
sequence was expanded one amino acid in each direction (K-INQI-I) based on the 
original Ebola sequence, so as not to induce a terminal charge on one of the binding 
residues.  A tiopronin-to-ligand ratio of 7:1 rendered the resulting compositions: 
Au773Tiopronin212INQI14 (MW = 202,967 Da) and Au773Tiopronin156BiINQI35 (MW = 
233,700 Da).  NMR characterization for these systems is presented in Figure 51. 
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Figure 51.  NMR characterization of (A) MonoKINQII and (B) BiKINQII. 
 
 
 
 Two different types of QCM experiments were utilized to monitor BSA-
nanoparticle interaction.  The first entailed saturating the gold electrode with BSA 
followed by addition of peptide-presenting clusters.  The second involved the 
electrostatic immobilization of the nanoparticles using a positively-charged polymer, 
poly(diallyldimethylammonium chloride), adsorbed to the gold electrode.  Once particles 
were adsorbed to the surface, BSA was added and monitored for binding. 
 Unfortunately, binding was never observed for either INQI system, regardless of 
QCM method.  Up to 10 mg/mL of nanoparticle complex were added, equating to ~43 
and 49 μM, respectively, for the mono- and bidentate systems; yet only a minimal 
amount of binding was detected (Figure 52).  This binding is attributed to the average 
background associated with any QCM experiment.  The polyelectrolyte method allowed 
for the saturation of the electrode with nanoparticles, effectively presenting a monolayer 
of peptides off the surface to interact with the protein.  This locally high concentration of 
peptide ligand was intended to provide better albumin interaction; however, no binding 
was observed.   
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Figure 52.  QCM experiments for (A) mono- and (B) bidentate functionalized KINQII-
nanoparticles.  Both experiments were run using nanoparticle concentrations of 10 
mg/mL and resulted in minimal binding to albumin protein.   
 
 
 In order to better understand these results and uncover methods to improve 
binding, the principal sequence was reevaluated.  Site-directed mutagenesis studies were 
used to investigate the nature of the binding phenomena and the role of each amino acid.  
Understanding exactly where and how this unique protein binding occurs would offer 
more ideas on how to recapitulate the interaction. 
 Peptides were designed to analyze various aspects of the sequence including 
changing one or both of the positive charges to negative charges (IDQI, INEI, IDEI), 
changing the nature of the positive charge (IKQI, INKI, IKKI), or altering the 
hydrophobicity by substituting alanine residues for individual amino acids (ANQI, IAQI, 
INAI, INQA).  Variations of the Ebola-2 sequence (CTDK-INQI-IHDFIDNPL) were 
then synthesized to account for these alterations.  BSA binding to each sequence was 
measured after assembling each peptide as a monolayer on the surface of QCM chip’s 
gold electrode via the thiol linkage from an N-terminal cysteine residue.  Two-
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dimensional monolayer assembly coupled with quartz crystal microbalance detection has 
previously been used as a valuable technique for quantitating binding interactions 
between peptides and other biomolecules.169 The results of these binding studies are 
summarized in Table 11.       
 The original sequence –INQI- elicited ~49 ng of albumin binding.  Conversely, 
the lowest binding sequence was the complete substitution of –SGSG-, consistent with 
earlier observations, showing ~11 ng of binding.  One conclusion that can be drawn from 
this data is that the charged glutamine plays a crucial role in binding.  A significant drop 
in binding occurred when charge was removed from that residue via the addition of an 
alanine.  Extending the charge out away from the backbone of the peptide seemed to have 
an adverse effect on binding as well, as was observed after substitution with a lysine (5 vs 
4 atom side chain backbone).  The most interesting observation, however, is related to the 
substitution of anionic residues.  Each case, regardless of the location of the substitution 
saw the level of binding increase almost two-fold.  This is somewhat unexpected, as one 
would speculate the two cationic residues would likely play a role in binding, and thus by 
exchanging these residues you would inhibit binding.  In fact, the opposite holds true, 
suggesting that binding might be improved by the incorporation of a negatively charged 
residue into the albumin binding sequence.  These results offer insight into future 
approaches that could lead to a peptide-nanoscale complex which actually binds albumin 
protein.  Although our results are inconclusive, these data do provide ideas to better 
improve the interaction in the future.    
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Table 11.  Level of albumin binding detected for various mutagens. 
Ebola-2 Sequence Variation Average Mass of BSA Bound (ng) 
-INQI- 49 
  
-IEQI- 83 
-INEI- 80 
-IDEI- 90 
  
-IKQI- 68 
-INKI- 40 
-IKKI- 24 
  
-ANQI- 56 
-IAQI- 49 
-INAI- 28 
-INQA- 29 
  
-SGSG- 11 
 
 
Conclusions 
 A sequence related to the Ebola glycoprotein was identified as a potential 
albumin-binding protein.  However, nanoparticle presentation of a short region of that 
sequence was incapable of binding the protein regardless of the method of detection.  
Based on these results, future attempts into designing a peptide-functionalized 
nanoparticle with an affinity for albumin would likely center on expanding the epitope 
beyond the KINQII region, even incorporating a source of negative charge into the 
epitope sequence. 
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APPENDIX A 
 
MICROWAVE SYNTHESIS OF NANOPALLADIUM CATALYST FOR DIRECT 
FORMIC ACID FUEL CELLS 
 
 
 
Introduction 
 
 Polymer electrolyte membrane fuel cells have emerged as promising candidates 
for use as power sources in portable electronics.  These fuel cells are utilized for the 
direct conversion of a chemical fuel into electricity using a proton conducting polymer 
membrane.222  Typical fuels are compose of electrolytic liquids, as they offer a means by 
which to facilitate electron and proton transfer within the anode.223  Previously, methanol 
has been employed as a liquid fuel; however, problems related to toxicity and fuel 
crossover through the membrane has been shown to diminish the fuel cell potential, 
leading researchers to explore other potential fuels.  Recently, formic acid has been 
investigated as a possible fuel alternative.  Formic acid offers a non-toxic replacement 
which, in a fuel cell partially dissociates into formate ions, which are repelled by the 
anionic polymer membrane, thus limiting crossover potential.  This lack of crossover 
allows for the use of increased fuel concentration, thus generating overall improved fuel 
cell performance. 
 Formic acid oxidation is thought to proceed via two pathways: a dehydration 
pathway and a direct dehydrogenation reaction.223 The dehydration pathway results in the 
generation of a CO intermediate, an undesirable product that effectively poisons the 
reaction.  To eliminate the formation of this intermediate, alternative methods were 
designed that emphasized the direct oxidation pathway.  Fuel cell catalysis incorporating 
 139
either metal nanocomposites or carbon-supported metal nanocomposites have been 
shown as effective alternatives, as both are capable of promoting the dehydrogenation 
reactions.224, 225  
 Palladium-based catalysis, specifically, has previously been shown as an effective 
candidate for direct formic acid fuel cells.226 Palladium has been shown to catalyze the 
following direct oxidation of formic acid: 
  
HCOOH Æ CO2 + 2H+ + 2e- (Eq. 3) 
 
Pd catalysis results in a fuel cell that outperforms traditional direct methanol fuel cells by 
attaining open circuit voltages up to 0.9 V and generating power densities 2.5 times 
greater than the expected requirements.227 These results highlight the potential for Pd-
based catalysts in direct formic acid fuel cells and indicate the need for synthesis methods 
directed towards these materials. 
 Catalytic activity is known to be related to the amount of surface metal present.  
Thus, methods which lead to small particles are desirable.  Wet chemical, reduction-
based synthesis methods of palladium generally produce larger particles and it is often 
difficult to control the monodispersity of the sample.  As a result, methods of synthesis 
involving alternative palladium precursors are being explored.228-231
 This appendix reports a microwave irradiation preparation for palladium 
nanoparticle catalysts.  Microwave synthesis has been demonstrated to produce 
monodisperse, nanoscale particles in a short amount of time.232  The method reported 
herein was shown to produce carbon-supported Pd catalysts of high weight percent (~40 
 140
%) as an improved performance fuel cell when compared to commercial catalytic 
standards. 
 
Experimental 
 
Chemicals and General Methods  
 The precursor compound tris(dibenzylideneacetone) dipalladium (0) [Pd2(dba)3] 
was purchased from Strem Chemicals, Inc.  Vulcan carbon powder XC-72R was 
purchased from Cabot.  All chemicals and solvents were used as received.  Transmission 
electron microscopy (TEM) characterization was performed on a Phillips CM20T 
instrument operating at 200 kV.  Samples were prepared by suspending the 
nanocomposite in methylene chloride, placing a drop of the suspension on a holey 
carbon-coated copper grid, and allowing the solvent to evaporate.  Powder X-ray 
diffraction analysis (XRD) was performed using a Scintag X1 θ/θ automated powder 
diffractometer with a Cu target, a Peltier-cooled solid-state detector, and a zero-
background, Si(510) sample support.  All fuel cell testing was performed by Lynntech, 
Inc. and was compared to a Pd black standard catalyst. 
 
Microwave Synthesis 
 Metal precursor was absorbed onto Vulcan carbon support following dissolution 
in 50-mL of acetone solvent.  Amounts of precursor and support material were chosen to 
give a final metal loading of 15 or 40 wt%.  After allowing the mixture to stir overnight, 
the solvent was removed by rotary evaporation.  Thermal treatment was performed as a 
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modified version of the method first reported by Boxall and Lukehart which utilized 
dielectric loss heating via a commercial microwave oven.232 As in the Boxall procedure, 
the dried sample was placed inside a ½-dram vial.  This vial was then placed inside a 
larger 2-dram vial which had been previously filled with Vulcan-carbon powder.  Heating 
occurs via dielectric loss of the Vulcan carbon support, which has been shown to reach 
temperatures > 500 oC in a matter of seconds.  Thus, the support allows for the thermal 
degradation of the palladium precursor, with the carbon located in the 2-dram vial serving 
as an additional external heating bath.  Two microwave heating protocols were employed.  
Protocol A consisted of a 15-s on, 45-s off, 10-s on heating cycle, while B utilized 3-s on, 
45-s off, 7-s on.  These methods have previously been shown to produce temperatures of 
approximately 390 oC.232 After heating, the sample was allowed to cool and was collected 
for characterization.  
 
Results and Discussion 
 The microwave heating of palladium-containing molecular precursors in the 
presence of a carbon support resulted in the formation of spherical nanoscale palladium 
particles scattered throughout the support.  A pre-synthesis loading of ~15% Pd metal 
formed particles with an average diameter of 5.27 ± 0.99 nm (Figure 53).  Increasing the 
metal loading to 40% had only a slight effect on the overall size of the particles, resulting 
in particles with and average diameter of 5.31 ± 1.10 nm (Figure 54).  Powder X-ray 
diffraction confirmed both the composition and nanoscale nature of these particles 
(Figure 55).   
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 Figure 53.  (A) TEM and (B) histogram of 15 wt. % Pd nanoparticle/carbon support 
sample. 
 
 
Figure 54.  (A) TEM and (B) histogram of 40 wt. % Pd nanoparticle/carbon support 
sample. 
 
 
 
Figure 55.  Powder XRD scan of 40% Pd on Vulcan carbon support (pdf: 46-1043).  
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 Microwave heating is generated via dielectric loss, providing the opportunity to 
achieve remarkably high temperatures in a matter of seconds.  Heating occurs uniformly 
throughout the reaction material, thus resulting in more homogenous nucleation than can 
be achieved via conventional heating methods.233 The homogeneity of the product 
combined with the intense heating exhibited by the Vulcan carbon support provides a 
valuable method for the rapid formation of monodisperse particles.    
 The metal precursor also plays a crucial role in the final particle size.  As a 
control, an alternative palladium salt, Na2PdCl4, was used to test the role of the precursor. 
It was shown that the average diameters (18.7 nm) of the nanoparticles synthesized from 
this precursor were 350% larger than the particles formed from [Pd2(dba)3].  This 
difference is likely due to the nature of the Pd atom in each precursor.  In Pd2(dba)3, the 
Pd atoms are already in the zero oxidation state, thus particle formation is likely 
dominated by nucleation, thus limiting particle growth potential.  The reduction step 
necessary with the Na2PdCl4 precursor results in a slower nucleation step, leading to 
increased particle growth.   
 Heating time was also shown to play a small role in influencing particle size.  
Two different heating protocols were investigated.  Protocol A consisted of a 15-s on, 45-
s off, 10-s off heating cycle, while Protocol B employed 3-s on, 45-s off, 7-s on.  Particles 
produced by Protocol B showed an overall decrease in size of ~5%.  The increased 
heating times and higher final reaction temperatures of Protocol A allow more 
opportunity for particle growth.  Although varying the heating method of the precursor 
did not affect the product as significantly as varying the metal precursor, an overall 
change in particle size was observed. 
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 Material from three samples performed using the protocol described above, along 
with a fourth synthesis performed by Matthew Wellons utilizing a serial deposition 
method were combined and sent to Lynntech, Inc. for fuel cell testing (Fig. 56).  Fuel 
cells utilizing the Pd/C nanocomposite showed improved performance compared to cells  
 
 
Figure 56.  Fuel cell polarization curve showing the improved performance of a Pd/C 
nanocomposite catalyst vs. a standard Pd black catalyst. 
 
 
 
tested using a standard Pd black catalyst.  Specifically, the nanocomposite showed 
improved performance within the typical operating range of fuel cell (0.7-0.45 V).226 The 
improvement likely results from the ability to achieve a very high surface area of metal 
catalyst related to the high loading percentages of nanometer-sized particles.  This 
performance highlights the potential for further research into both microwave synthesis 
and nano-Pd-based catalysts. 
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APPENDIX B 
 
BUFFER EFFECTS ON DENDRIMER-TEMPLATED SYNTHESIS OF TITANIUM 
DIOXIDE 
 
 
 
Introduction 
 
 Traditional synthesis methods for metal oxide materials generally require harsh 
conditions such as high temperatures and pressures, and extreme pH.  Nature, however, 
has developed genetically controlled processes to synthesize these materials under 
ambient conditions while maintaining remarkable control over the size, shape, and 
composition of the material.  Syntheses such as this, referred to as biomineralization, 
have sparked the emergence of an entire field of research directed at deducing the means 
by which they occur.   
 One such study involves the cell wall of the diatom Cylindrotheca fusiformis.  
Diatoms possess intricately designed cell walls composed of SiO2.  It was discovered that 
these organisms direct the formation of the cell walls through a series of precipitation 
reactions, originating from a biological template.  One of these templates consist of a 
series of positively-charged proteins, termed silaffins.9, 38, 234  A biomimetic analogue of 
one of these proteins,the R5 peptide (SSKKSGSYSGSKGSKRRIL), was also shown to 
form networks of spherical SiO2 in the presence of silicic acid.9  It was later postulated 
that this templating effect arises from the R5 peptide’s ability to self-assemble in 
solution.11 This self-assembly process occurs in a manner which provides a locally high 
amine concentration, promoting the condensation of monosilicic acid, resulting in 
growing particles of SiO2. 
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 This work has since expanded to incorporate a number of different templates and 
substrates.  For example, poly-L-lysine and amine-terminated dendrimers have been 
utilized to capitalize on the molecules’ high degree of positive charge, similar to both 
silaffins and the R5 peptide.235-237  Both templates have proven capable of promoting the 
formation of SiO2 in aqueous solution.  Non-traditional syntheses incorporating these 
templates have offered approaches for the biomineralization of non-silica metal oxides, 
including TiO2 and GeO2.13, 238 The work herein seeks to shed light onto one of these 
processes, examining the role of buffer composition on polyamidoamine (PAMAM) 
dendrimer-templated TiO2 production. 
 
Experimental 
 
Chemicals and General Methods 
 Generation 4 polyamidoamine (PAMAM) dendrimer was purchased from Sigma 
Aldrich.  Titanium precursor, titanium (IV) bis(ammonium lactate) dihydroxide 
(TBALDH), was purchased from Sigma Aldrich.   
 
TiO2 Precipitation 
 For each precipitation experiment, TBALDH (40 μL of a 1M solution) was added 
to 200 μL of G4 PAMAM dendrimer, which had been diluted in buffer to give a final 
primary amine concentration of 35 μM.  The type, pH, and concentration of the buffer 
were varied depending on the study.  After mixing, the samples were shaken for 5 min., 
centrifuged at 10,000 rpm, and washed three times with deionized water. 
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TiO2 Quantitation Assay 
 TiO2 quantitation was achieved using the 5-chlorosalicylic assay.239 Each sample 
was dissolved in 1 mL of concentrated H2SO4 and placed in a water bath at 95 oC for 2 h.  
To the samples was added 2.5 mL of 2.5% 5-chlorosalicylic acid in ethanol, 2.5 mL of 1 
M sodium perchlorate, 7.5 mL of ethanol, and 10 mL of deionized water.  The pH of the 
resulting solution was adjusted to 4.0 using concentrated NH4OH and diluted to 50 mL 
with deionized water.  The absorbance of the colored product was then measured at 355 
nm using an Agilent 8453 UV-vis spectrophotometer and quantitated via a standard 
curve. 
 
Scanning Electron Microscopy 
 Scanning Electron Microscopy was performed on a Hitachi S4200 SEM operating 
at variable voltages.  Samples were prepared in suspensions of ethanol and drop casted 
onto an aluminum SEM puck (Ted Pella, Inc.).  After allowing the solvent to evaporate, 
each sample was sputter-coated with a thin layer of gold using a Pelco Model 3 
Sputtering Instrument to avoid charging.    
 
Results and Discussion 
 A number of previous studies have demonstrated the effects of buffers on metal 
oxide nanoparticle size and aggregation.237, 240 In the case of dendrimer-templated silica 
formation, the increasing presence of cations in solution led to the formation of particles 
with increasing diameter.  It was suggested that the cations serve the purpose of 
neutralizing the growing negative charge associated with the silanol group on the 
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growing silica particle.237 This charge repulsion is thought to promote particle 
aggregation, increasing average particle size.  Once the growing particles finally reach a 
critical size, the charge stabilization from the cations becomes insufficient to allow the 
particles to stay in solution, resulting in precipitation. 
 In an effort to elucidate similar mechanistic details related to titania synthesis, 
dendrimer-templated TiO2 was formed in the presence of various buffer conditions: 
including phosphate buffer, salt solutions, and variable pH.  In each case, the primary 
amine concentration from the G4 PAMAM dendrimer was kept constant; so as to only 
observe changes related to buffer composition.  The amount of TiO2 formation and 
particle size was first monitored in the presence of phosphate buffer.  In each case TiO2 
production activity remained constant (between 13,000 and 17,000 nanomoles), with the 
lowest value observed in the absence of phosphate (Figure 57A).  Particle size, however, 
showed a linear increase between 20 and 100 mM (Figure 57B).  Knecht et al. made 
similar observations regarding silica formation, indicating similar pathways of metal 
oxide particle growth.  In this case, sodium cations associated with phosphate salt likely 
provide the charge stabilization necessary to promote increased particle growth. 
 
 149
 Figure 57.  TiO2 (A) quantitation and (B) particle size as a function of phosphate buffer.  
Inset: SEM images of TiO2 particles at selected concentrations of phosphate buffer (scale 
bar = 550 nm). 
 
   
 To further test this “charge stabilization” theory, TiO2 formation was monitored in 
the presence of various NaCl concentrations.  Reactions were performed in the absence of 
phosphate, with the only external source of ions coming from the NaCl salt.  As was 
observed with phosphate buffer, TiO2 production was constant throughout the range of 
salt concentration (0-100 mM), and particle size grew with increased cation concentration 
(Figure 58).  However, the particle sizes observed were approximately half an order of 
magnitude smaller than was observed for phosphate buffer (100-140 nm vs. 550-700).  
The exact basis for the observed distribution in sizes is still unknown; however, the data 
could indicate the involvement of the anion in the mechanism of larger particle 
formation.  This hypothesis is supported by IR data which confirmed the association of 
the phosphate anion with the mineralized TiO2, matching similar results related to R5 
production of titania.13, 238   
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 The final study involved TiO2 formation at varied pH.  Previously, R5-mediated 
TiO2 formation was shown to have a maximum production between pH 6.0 and 7.5, with 
a significant drop in production occurring below pH 6.0.  This particular study examined 
a pH range of 5.0-8.5 with a phosphate-citrate buffer responsible for pH 5 and 5.5, 
phosphate buffer for pH 6.0-8.0, and borate buffer for pH 8.5.  Unlike R5-mediated 
production, the dendrimer-mediated formation of TiO2 was shown to be constant 
throughout the pH range, with each producing approximately 12,000 nanomoles of 
 
 
Figure 58. TiO2 (A) quantitation and (B) particle size as a function of NaCl 
concentration.  Inset: scanning electron microscopy images of TiO2 in selected NaCl 
concentrations (scale bar = 300 nm). 
 
 
 
material (Figure 59).  G4 PAMAM-mediated formation of SiO2 followed a similar trend 
throughout the same pH range, with only a small decrease in silica production occurring 
with increased pH (3,590-3,150 nanomoles).  Particle size increased as the solution 
became more basic.  This trend, however, may not be solely pH dependent, as the 
increase was non-linear and appeared to be influenced as much by the specific buffer type 
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as it was the pH.  Both the pH 5.0 and 5.5 citrate-phosphate buffer produced 
nanoparticles having and average diameter of approximately 40 nm.  The pH 6.0-8.0 
phosphate buffer showed a linear increase in particle size from 360 nm to 570 nm 
throughout the range; and the pH 8.5 borate buffer produced 1,200 nm particles.  This 
non-linear change lends credence to the idea that the specific type of anion plays a role in 
particle size determination of dendrimer-mediated TiO2.  
 
 
Figure 59. TiO2 (A) quantitation and (B) particle size as a function of buffer pH. 
 
Conclusions 
 In each case, TiO2 production was maintained at levels between 12,000 and 
16,000 nanomoles.  This results in 30-40% conversion of titanium precursor to metal 
oxide particle, suggesting the dendrimer template acts as a limiting reagent.  Particle size 
followed similar trends as dendrimer-mediated silica production.  Each case saw 
increasing particle size with an increase in positive charge in solution, suggesting a 
similar mechanism regarding particle growth in which positive charge neutralizes the 
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growing negatively-charged TiO2 particles.  This neutralization is thought to reduce 
electrostatic repulsion between particles, allowing aggregation to occur. 
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APPENDIX C 
 
SYNTHESIS OF VIRAL PEPTIDES FOR THE IDENTIFICATION OF HUMAN 
LEUKOCYTE ANTIGEN-BINDING EPITOPES 
 
 
 In an effort to study T-cell responses to respiratory syncytial virus (RSV), 
metapneumovirus (MPV), and smallpox, potential peptide epitopes were synthesized.  
The peptides had previously been predicted as possible epitopes for three different human 
leukocyte antigen alleles (A1, A2, B7) with three separate antigenic prediction 
algorithms.  Each peptide was synthesized using standard continuous flow fmoc solid 
phase protocols on an Advanced Chemtech Automated Peptide Synthesizer, purified by 
reverse-phase high performance liquid chromatography (HPLC) on a Waters Prep HPLC, 
lyophilized, and identified using MALDI mass spectrometry.  Tables 11-14 list each 
peptide that was synthesized for the A1, A2, B7, and smallpox epitope mapping, 
respectively.  Each table includes the peptide sequence, protein of origin, molecular 
weight, and hydrophobicity of the peptides listed.  A portion of this work was assisted by 
and Malgorzata Broncel and Dr. Catherine E. Prudom 
 
Table 12. Synthesized RSV and MPV epitopes for HLA-A01. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
1 MPV-F YMVQLPIFGV 1166.5 90 
2 RSV-L YLSELLNSL 1051.2 56 
3 RSV-L FLYGDYILKL 1244.5 80 
4 RSV-L FIMSLILNI 1063.4 78 
5 RSV-L YLLSSLSML 1026.3 67 
6 MPV-L MLYDVKFLSL 1228.5 70 
7 MPV-F FVLGAIALGV 959.2 100 
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Table 12, continued. 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
8 RSV-G FISSCLYKL 1073.3 67 
9 MPV-L FIMSEILRI 1121.4 67 
10 MPV-M2-2 YLENIEIIYV 1268.5 70 
11 RSV-L KLFPQYLSV 1094.3 67 
12 MPV-M2-1 YLLIRSNYLL 1267.5 70 
13 RSV-L FLTEAIVHSV 1115.3 80 
14 MPV-SH ILALLTFLTV 1103.4 100 
15 RSV-L YMVESTYPYL 1265.4 80 
16 MPV-SH KLILALLTFL 1144.5 90 
17 RSV-L TLSGFQFIL 1025.2 78 
18 MPV-L SMMLENLGLL 1120.4 70 
19 MPV-F FIIVIILIAV 1113.5 100 
20 RSV-F YVVQLPLYGV 1150.4 90 
21 MPV-N TLLCGEILYA 1095.3 90 
22 MPV-L FMDFKIFLCV 1262.6 80 
23 MPV-L YMILLPWQHV 1299.6 90 
24 MPV-L SLFCWLHLI 1131.4 89 
25 RSV-NS2 FLVNYEMKL 1156.4 67 
26 RSV-F IMITTIIIV 1016.4 100 
27 MPV-L GLLSRILSV 957.2 67 
28 RSV-L ISFGLSLMSV 1053.3 70 
29 RSV-L AILTYIDLV 1020.2 89 
30 RSV-F ILLSLIAVGL 1011.3 90 
31 RSV-L YLLALNSLKL 1147.4 70 
32 MPV-L GLLSRILSVV 1056.3 70 
33 RSV-L FQNCISFGL 1028.2 67 
34 RSV-L KLYLDILKV 1104.4 67 
35 MPV-M2-1 KLAKLIIDL 1026.3 67 
36 RSV-SH HMITTIISL 1028.3 89 
37 MPV-M2-1 YLLIRSNYL 1154.4 67 
38 MPV-L FLTEAISHV 1016.2 78 
39 MPV-L SLFCWLHLIV 1230.5 90 
40 RSV-NS2 RLMITDMRPL 1245.6 70 
41 RSV-G LIIAAIIFI 986.3 100 
42 RSV-F YMLTNSELL 1083.3 67 
43 RSV-L KLNTYPSLL 1048.2 67 
44 MPV-L SLILRNFWL 1161.4 67 
45 MPV-L KLMKDLNLKV 1201.5 50 
46 MPV-SH LILALLTFL 1016.3 100 
47 RSV-F MLTNSELLSL 1120.3 60 
48 MPV-L QLIEQSLFL 1090.3 56 
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Table 12, continued. 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
49 MPV-G ILIGITTLSI 1043.3 90 
50 MPV-L FILRIIKGFV 1205.6 80 
51 RSV-L MLFGGGDPNL 1020.2 80 
52 RSV-F KLMSNNVQI 1046.3 44 
53 RSV-L SLFSWLHLTI 1216.4 80 
54 MPV-L KLSEGLDEV 989.1 44 
55 MPV-M2-1 LLIRSNYLL 1104.4 67 
56 MPV-L SMMLENLGL 1007.2 67 
57 RSV-L KLWTIEAISL 1173.4 70 
58 RSV-N KILRDAGYHV 1171.4 70 
59 MPV-SH ALLTFLTVTI 1091.4 100 
60 RSV-L KLFHNEGFYI 1267.5 70 
61 RSV-G ILASTTPGV 858 89 
62 MPV-M YLVDTYQGI 1071.2 78 
63 RSV-NS2 YLINHECIV 1103.3 78 
64 RSV-L FLFRIFGHPM 1264.6 90 
65 RSV-L FILNQYGCIV 1169.4 80 
66 RSV-NS1 GLLDDNCEI 991.1 66 
67 RSV-SH IMIAILNKL 1028.4 78 
68 MPV-L KLYETVDYML 1274.5 70 
69 RSV-L FLTWKDISL 1122.3 67 
70 RSV-SH LLIIISIMI 1028.4 80 
71 MPV-L MMLENLGLL 1033.3 78 
72 RSV-M2orf GIIEDIYTI 1036.2 78 
73 RSV-M2 AMSKLLTEL 1005.2 67 
74 MPV-P KLSMILGLL 987.3 78 
75 MPV-L YLNDKDHIV 1116.2 56 
76 RSV-F FLLGVGSAIA 947.1 90 
77 RSV-L DLYNLFPMVV 1210.5 80 
78 RSV-NS2 RQATFTFLV 1082.3 78 
79 MPV-L KLWTMEAISL 1191.5 70 
80 RSV-L TLLIRILPL 1051.4 89 
81 RSV-L AQADYLLAL 977.1 78 
82 RSV-G SLIIAAIIFI 1073.4 90 
83 RSV-L FIYRIIKGFV 1255.6 80 
84 MPV-L YLPDSYLKGV 1154.3 70 
85 RSV-L LLLRTVVEL 1055.3 78 
86 RSV-P KLSEILGML 1003.3 67 
87 RSV-N GMIILCIAAL 1017.4 100 
88 RSV-NS1 YMNQLSELL 1110.3 56 
89 RSV-F ALLSTNKAVV 1015.2 70 
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Table 12, continued. 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
90 RSV-L ILLSKFLKL 1074.4 67 
91 MPV-F KLMLENRAMV 1204.5 60 
92 MPV-L KLLGDTLRCI 1131.4 70 
93 MPV-L ILRNFWLYNL 1351.6 70 
94 RSV-M2 FMLNRILKSM 1252.6 60 
95 RSV-F FLLGVGSAI 876.1 89 
96 MPV-L FMSVNFLHRL 1263.5 70 
97 RSV-L YLTDSYLKGV 1158.3 70 
98 RSV-N TLASLTTEI 984.1 88 
99 RSV-NS1 KLNGIVFVHV 1125.4 80 
100 RSV-SH SLLIIISIMI 1115.5 80 
101 RSV-NS2 FLVNYEMKLL 1269.6 70 
102 MPV-L KLNMICDWL 1135.4 67 
103 RSV-L KLYLDILKVL 1217.6 70 
104 MPV-L YLQLIEQSL 1106.3 56 
105 RSV-F KLMSNNVQIV 1145.4 50 
106 MPV-L KLPFFVRSV 1092.3 67 
107 MPV-L IMLYDVKFL 1141.4 78 
108 RSV-L ILDDFKVSL 1049.2 56 
109 MPV-F VLGSTMILV 932.2 89 
110 MPV-G TLSIALNIYL 1120.4 80 
111 RSV-G FIASANHKV 986.1 67 
112 MPV-M VLLDQLKTL 1042.3 67 
113 RSV-L LLYKEYAGI 1069.3 78 
114 MPV-L SLCCNEGFSL 1072.2 60 
115 RSV-L YMPSHIQNYI 1265.5 70 
116 RSV-N KMLKEMGEV 1064.3 56 
117 RSV-L YLSVNYLHRL 1277.5 70 
118 RSV-L KLWFLKRLNV 1316.7 60 
119 MPV-G SLILIGITTL 1043.3 90 
120 RSV-P ILGMLHTLVV 1095.4 100 
121 RSV-L KLDWVYASI 1094.3 67 
122 RSV-L SLIFRNVWL 1147.4 67 
123 MPV-L KLMCDNALFT 1155.4 70 
124 RSV-F SLIAVGLLL 898.2 89 
125 RSV-L TLYMNLPML 1095.4 89 
126 MPV-L SLLNGDNQSI 1060.1 40 
127 RSV-L YILSQDASL 1009.1 56 
128 MPV-F VLGAIALGV 812 100 
129 MPV-L KLSGSECYI 999.2 56 
130 MPV-L ILLKISANI 984.2 67 
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Table 12, continued. 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
131 MPV-L SLGKLVFVV 961.2 78 
132 MPV-N LQMLDIHGV 1025.2 78 
133 RSV-L SLFVCDAEL 996.1 67 
134 MPV-F AVLGSTMILV 1003.3 90 
135 MPV-L FVFSSTGCKV 1074.3 70 
136 RSV-NS1 KLIHLTNAL 1022.3 78 
137 RSV-L RLNKFLTCI 1107.4 67 
138 MPV-L LLSRILSVV 999.3 67 
139 RSV-G ILAMIISTSL 1061.4 80 
140 MPV-L SLLSGLRIPI 1068.3 70 
141 RSV-M2 ALLVRQNFML 1204.5 70 
142 RSV-N GMLYAMSRL 1041.3 78 
143 MPV-L IIADNITPV 955.1 78 
144 RSV-L YIGDHIVDL 1044.2 78 
145 RSV-L FIGEGAGNLL 990.1 80 
146 MPV-F SLLITPQHGL 1078.3 80 
147 RSV-SH MITTIISLL 1004.3 89 
148 RSV-N MIILCIAAL 948.3 100 
149 RSV-L KLIKITGSL 972.2 67 
150 RSV-F LLSLIAVGL 898.2 89 
151 MPV-L GLTDQLTKL 988.1 67 
152 MPV-N SLQQEITLL 1044.2 56 
 
 
Table 13.  Synthesized RSV and MPV epitopes for HLA-A02. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
153 RSV-NS1 LSDSTMTNY 1031.1 56 
154 RSV-L ISDYFHNTY 1159.2 67 
155 RSV-L NIDTALTLY 1023.2 78 
156 MPV-N VSDDSQNDY 1042 22 
157 RSV-L NVDEQSGLY 1024.1 44 
158 RSV-M VTDNKGAFKY 1142.3 60 
159 MPV-L IADNITPVY 1005.1 78 
160 RSV-L STELNYNHLY 1253.3 60 
161 RSV-F NVDIFNPKY 1109.2 56 
162 RSV-L FSECNALGSY 1090.2 60 
 
 
 
 158
Table 13, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
163 RSV-L YTSNLFYINY 1297.4 70 
164 RSV-M2orf IIEDIYTIY 1142.3 78 
165 RSV-N FTGLIGMLY 1014.3 100 
166 MPV-L NLENAAELY 1036.1 56 
167 RSV-M YLEKESIYY 1207.3 56 
168 MPV-SH LTVTITINY 1037.2 67 
169 RSV-F LIAVGLLLY 974.3 100 
170 RSV-L TSNLFYINY 1134.3 67 
171 MPV-L CTTYGTDLY 1036.1 89 
172 MPV-G NSDTNPSSQY 1112.1 30 
173 MPV-L ITTCMDVIY 1058.3 89 
174 MPV-L KIEEQSGLY 1066.2 44 
175 MPV-M KTLTITTLY 1053.3 89 
176 RSV-L LTYYKLNTY 1178.4 78 
177 RSV-F VSVGNTLYY 1015.1 78 
178 RSV-NS2 ATFTFLVNY 1075.2 89 
179 RSV-L LSDDRLNKF 1107.2 33 
180 MPV-SH FLTVTITINY 1184.4 90 
181 RSV-L GSLTQELEY 1039.1 56 
182 RSV-L STGCKISIEY 1100.3 60 
183 RSV-L KSLIPFLCY 1083.4 78 
184 MPV-L GLDEVKADY 1009.1 56 
185 MPV-M LTQAKIAPY 1004.1 78 
186 RSV-M STYTAAVQY 1003.1 78 
187 RSV-L ATNNIHWSY 1105.2 67 
188 RSV-M AITNAKIIPY 1103.3 80 
189 MPV-G STEGSTLYF 1004.1 67 
190 RSV-L SSAMIRTNY 1042.2 56 
191 MPV-M2-2 YLENIEIIY 1169.3 56 
192 MPV-L ISDHAFMDF 1082.2 67 
193 RSV-L VLELIDSSY 1038.2 56 
194 RSV-F LSALRTGWY 1066.2 78 
195 MPV-G QSTEGSTLY 985 56 
196 RSV-L LSITELSKY 1053.2 56 
197 MPV-P FTPNEPGKY 1052.2 67 
198 MPV-M ALTQAKIAPY 1075.3 80 
199 MPV-L GTVLENNDY 1024.1 56 
200 RSV-L FLEQKVIKY 1167.4 56 
201 RSV-L ITQSLISKY 1052.2 56 
202 RSV-F TVSVGNTLY 953.1 78 
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Table 13, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
203 RSV-L HSVFILSYY 1128.3 78 
204 RSV-L VILTQLFLY 946.2 87 
205 RSV-L ALNSLKLLY 1034.3 67 
206 RSV-P DTAGNKPNY 881.9 50 
207 RSV-N ITEDANHKF 1074.2 56 
208 RSV-L SSGIIIEKY 1009.2 56 
209 RSV-M ITNAKIIPY 1032.2 78 
210 RSV-L KTIQHNGVYY 1222.4 70 
211 MPV-M2-1 QSITKAAACY 1126.3 73 
212 RSV-L KTIQHNGVY 1059.2 67 
213 RSV-F DTVSVGNTLY 1068.1 70 
214 RSV-L SIGTLGLTY 924.1 89 
215 RSV-L LVHNSTSLY 1033.1 67 
216 MPV-F DTVTIDNTVY 1140.2 70 
217 MPV-F LSVLRTGWY 1094.3 78 
218 MPV-L VSNWFSNWY 1202.3 56 
219 RSV-M GSTYTAAVQY 1060.1 80 
220 MPV-G SMEASTSTTY 1077.1 60 
221 RSV-L HALCNNKLY 1075.3 67 
222 RSV-M2 AAELDRTEEY 1196.2 50 
223 MPV-L LKDDLDHHY 1155.2 65 
224 MPV-L CLGSLGISY 912.1 78 
225 RSV-L ISSGIIIEKY 1122.3 60 
226 MPV-G TTLSIALNIY 1108.3 80 
227 RSV-L WLIHWFNLY 1291.5 89 
228 RSV-L VVSGDILSY 952.1 67 
229 RSV-L ATDATNNIHW 1142.2 70 
230 MPV-L KIAACNDFY 1044.2 67 
231 MPV-SH TTPNHDITQY 1189.2 70 
232 MPV-L ITFERLKNY 1182.6 56 
233 MPV-M2-1 GSECKFNHNY 1197.5 50 
234 RSV-G LLFISSCLY 1057.5 78 
235 RSV-N EMEQVVEVY 1124.5 56 
236 RSV-L NLNNLSELY 1078.5 44 
237 RSV-L SLIFRNVWLY 1309.7 70 
238 MPV-L NLENAAELYY 1198.5 60 
239 MPV-G TLSIALNIY 1006.5 78 
240 RSV-L NTAKSNQLY 1037.5 44 
241 RSV-L SLVHNSTSLY 1119.5 60 
242 RSV-L ELENNYNKLY 1299.4 40 
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Table 13, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
243 MPV-L DLDHHYPLEY 1301.4 70 
244 MPV-N YAAEIGIQY 1026.5 78 
245 MPV-L KSYVVKQEY 1143.3 44 
246 RSV-F STCSAVSKGY 1001.4 60 
247 MPV-L NSPKGELNY 1020.5 44 
248 MPV-L VLSCRICTTY 1157.5 80 
249 RSV-L KSSAMIRTNY 1170.4 50 
250 RSV-L LPDKISLTQY 1177.4 60 
251 RSV-N FAGLFMNAY 1032.5 89 
252 RSV-NS2 ITDMRPLSL 1044.5 67 
253 MPV-N GIHLSDLSY 1003.5 67 
254 RSV-L GSYIFNGPY 1016.4 78 
255 RSV-F KTFSNGCDY 1033.4 56 
256 RSV-L VLPLRWLTYY 1322.7 90 
257 MPV-L YTDMAHALTR 1177.5 80 
258 MPV-N FVNIFMQAY 1131.5 78 
259 MPV-M2-1 GSTNVVQGY 923.4 67 
260 RSV-N GTPRNQDLY 1063.1 56 
261 RSV-L ETYISRDMQF 1288.6 50 
262 RSV-NS1 KLSDSTMTNY 1158.5 50 
263 RSV-L ILAHKISDY 1058.6 67 
264 MPV-F NINISTTNY 1038.5 56 
265 RSV-SH IAILNKLCEY 1178.6 70 
266 RSV-M SLDERSKLAY 1181.3 40 
267 MPV-L WTMYFKAKSY 1324.6 70 
268 MPV-N TLLCGEILY 1023.5 89 
269 MPV-L ETYISRDLQF 1270.6 50 
270 MPV-M2-1 LSDSKHVAL 969.1 56 
271 RSV-L SIMYTMDIKY 1264.5 70 
272 RSV-L CTYRHAPPY 1106.5 89 
273 RSV-L GISNKSNRY 1038.1 33 
274 MPV-G ALNIYLIINY 1208.6 80 
275 RSV-L IMYTMDIKY 1177.5 78 
276 RSV-L LSMLRGAFIY 1170.4 80 
277 MPV-L LSCRICTTY 1058.5 78 
278 MPV-L SITTCMDVIY 1144.5 80 
279 RSV-F LTRTDRGWY 1167.3 67 
280 RSV-L VVELHPDIRY 1240.4 70 
281 RSV-F TVSVGNTLYY 1116.2 80 
282 MPV-F YLSVLRTGWY 1257.5 80 
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Table 13, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
283 RSV-L KSNRYNDNY 1173.2 22 
284 MPV-L GSCLLKRPY 1035.5 67 
285 RSV-L ITDHMFINL 1103.3 78 
286 MPV-M NATVALDEY 995.1 67 
287 MPV-M2-1 ALHNLVLSY 1029.2 78 
288 RSV-F SLIAVGLLLY 1060.6 90 
289 RSV-M2orf KIMILPDKY 1120.4 67 
290 RSV-M2orf ITSRCRVTMY 1228.6 70 
291 RSV-F YLSALRTGWY 1228.6 80 
292 MPV-F ESCSTITEGY 1088.4 60 
293 MPV-L LTDQLTKLK 1058.6 56 
294 MPV-F SCSTITEGY 959.4 67 
295 MPV-N VLSDALKRY 1064.3 56 
296 RSV-L RTNYSKQDLY 1287.4 40 
297 MPV-L LSEQDFLEL 1092.5 44 
298 RSV-L VCPWVVNIDY 1206.6 80 
299 MPV-M TVCEVKTVY 1040.5 78 
300 MPV-L TSDDTSILSF 1085.1 50 
301 RSV-M2orf HLGIIEDIY 1072.2 78 
302 RSV-M2orf TSRCRVTMY 1116.3 67 
 
 
Table 14. Synthesized RSV and MPV epitopes for HLA-B07. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
303 MPV-F NPRQSRFVL 1116.3 44 
304 RSV-F LPRFMNYTL 1154.4 78 
305 RSV-L MPVYNRQVL 1119.4 67 
306 MPV-L VPVYNRQIL 1101.3 67 
307 RSV-L YPASIKKVL 1018.3 67 
308 MPV-L WPKIKNLKVL 1238.6 60 
309 RSV-M NPTHDIIAL 993.1 78 
310 RSV-L HPTHMKAIL 1047.3 89 
311 MPV-M2-1 LPREKLKKL 1124.4 44 
312 MPV-N SPKAGLLSL 885.1 67 
313 RSV-M2orf YPCSITSIL 996.2 78 
314 MPV-M2-2 MPCKTVKAL 990.3 78 
315 RSV-N NPKASLLSL 942.1 56 
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Table 14, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
316 RSV-N FPHFSSVVL 1032.2 78 
317 RSV-M TPCEIKACSL 1064.3 70 
318 MPV-L SPVIEHVRL 1049.2 67 
319 MPV-M APYAGLIMIM 1079.4 100 
320 RSV-M MPADLLIKEL 1142.4 70 
321 MPV-L HPTPIKKIL 1046.3 78 
322 MPV-L FPKITFERL 1150.4 67 
323 RSV-P KPNYQRKPL 1143.4 44 
324 RSV-L HPMVDERQAM 1213.4 60 
325 MPV-N CPNFASVVL 949.1 78 
326 MPV-L IPTKSNGRL 985.2 56 
327 MPV-P KPTILSEPKL 1125.4 60 
328 RSV-L WPTLRNAIVL 1182.4 80 
329 RSV-N SPDCGMIIL 948.2 78 
330 RSV-L IPKLNEIHL 1076.3 67 
331 RSV-M TPKGPSLRVM 1085.3 70 
332 RSV-F TPVTLSKDQL 1101.3 60 
333 MPV-F MPTSAGQIKL 1045.3 70 
334 MPV-L HPMVDERDAM 1200.4 60 
335 MPV-L SPMVNLTQVI 1101.3 70 
336 MPV-L LPRFMSVNF 1110.3 67 
337 RSV-L FPRNYMPSHI 1261.5 70 
338 MPV-L RLRVHGTVL 1050.3 78 
339 RSV-P SPITSNSTII 1032.2 60 
340 MPV-M APYAGLIMI 948.2 100 
341 MPV-L KPVKLSEGL 970.2 56 
342 RSV-L MPKKADKESI 1146.4 40 
343 MPV-M TPPAVLLDQL 1066.3 80 
344 MPV-F GPSLIKTEL 957.1 67 
345 RSV-L NPNAEFVTL 1004.1 67 
346 MPV-N APDTPIILL 952.2 89 
347 MPV-M2-1 TPASLINNL 942.1 67 
348 RSV-M2 LPADVLKKTI 1097.4 70 
349 RSV-NS2 KPTKHTPII 1034.3 78 
350 RSV-L APPYIGDHIV 1081.2 90 
351 MPV-N RPSAPDTPI 953.1 67 
352 MPV-L TPIPSPMVNL 1068.3 80 
353 RSV-L FPMVVIDRII 1202.5 80 
354 MPV-P KPSHKRSQSI 1167.3 30 
355 RSV-SH WPYFTLIHM 1207.5 100 
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Table 14, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
356 RSV-L LPLLSNKKL 1025.3 56 
357 MPV-N TVRRANRVL 1084.3 56 
358 MPV-F KPTGAPPEL 909.1 78 
359 MPV-G SPPWAMTRTV 1145.3 80 
360 RSV-M2 SPKIRVYNTV 1176.4 60 
361 MPV-F RPVSSSFDPV 1090.2 50 
362 RSV-P SPITSNSTI 919 56 
363 RSV-NS2 TPQRLMITDM 1205.5 70 
364 RSV-L YVRERSWSL 1195.3 44 
365 RSV-G SVAQITLSIL 1044.3 70 
366 MPV-M2-1 HVALHNLVL 1015.2 89 
367 RSV-M KPQSQFIVDL 1174.4 50 
368 RSV-N NPKDNDVEL 1043.1 33 
369 MPV-L KTRCQMTSL 1067.3 56 
370 RSV-L RPCEFPASI 1019.2 67 
371 RSV-M SVRNKDLNTL 1159.3 40 
372 MPV-N RGRVPNTEL 1041.2 56 
373 MPV-N RPSAPDTPII 1066.2 70 
374 RSV-NS2 TPIIYKYDL 1125.3 78 
375 MPV-SH TIKDHSGKVL 1097.3 60 
376 MPV-L LTRLIRKKL 1140.5 56 
377 MPV-L RICTTYGTDL 1142.3 80 
378 MPV-L YPKNYLPETI 1237.4 70 
379 MPV-L SPDKIDMLTL 1132.3 60 
380 MPV-G ASRTKTSPAV 1017.2 60 
381 RSV-G KPNNDFHFEV 1246.3 50 
382 RSV-F KARSTPVTL 972.2 67 
383 MPV-M NPKGIFKKL 1044.3 56 
384 RSV-L CNRDKREIL 1146.3 33 
385 RSV-L RKRFYNSML 1214.5 44 
386 MPV-M2-1 LKRLPREKL 1152.4 44 
387 MPV-L RPMEFPASV 1033.2 67 
388 RSV-L LPKKVDLEM 1072.3 56 
389 MPV-N SSTGSKAESL 966 40 
390 RSV-M RSISVRNKDL 1187.4 30 
391 RSV-G NPSEITSQI 988.1 44 
392 RSV-L KSRRVLEYYL 1326.6 50 
393 RSV-L TPETLENIL 1029.2 67 
394 MPV-L VPEKTNLEM 1060 56 
395 MPV-L ALACHWCGIL 1086.3 100 
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Table 14, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
396 MPV-L IHRVSKDAL 1038.2 56 
397 RSV-G KPQTTKSKEV 1145.3 40 
398 MPV-SH KPAVEVHHIV 1128.3 80 
399 RSV-L MPSHIQNYI 1102.3 67 
400 RSV-NS2 RPLSLETII 1041.3 67 
401 MPV-L LPFHKAEKVV 1167.4 70 
402 MPV-N YPRMDIPKI 1132.4 67 
403 RSV-L WPTLRNAIV 1069.3 78 
404 RSV-L APPYIGDHI 982.1 89 
405 MPV-L SPMVNLTQV 988.2 67 
406 RSV-L LPKKVDLEMI 1185.5 60 
407 RSV-G LAMIISTSL 948.2 78 
408 MPV-M IPYTAAVQV 961.1 89 
409 MPV-M LPASLTIWF 1047.3 89 
410 RSV-NS2 RLMITDMRPL 1245.6 70 
411 RSV-NS2 LMITDMRPL 1089.4 78 
412 MPV-G RTVRRTTTL 1103.3 67 
413 RSV-M2orf SPNQTFNEI 1049.1 44 
414 MPV-L TPDFLTEAI 1006.1 78 
415 RSV-N VIRRANNVL 1054.3 56 
416 MPV-P ISRPAKPTIL 1095.4 70 
417 MPV-F FPEDQFNVAL 1179.3 60 
418 RSV-L TLRNAIVLPL 1109.4 80 
419 RSV-N AVIRRANNVL 1125.3 60 
420 MPV-L STRFRNTLL 1107.3 56 
421 RSV-N LPKDIANSF 1004.2 56 
422 RSV-M NSRSAVLAQM 1076.2 50 
423 RSV-L LPWHHINRF 1219.4 78 
424 RSV-P GPTSARDGI 872.9 67 
425 RSV-L LPFYKAEKIV 1207.5 70 
426 MPV-L LPRFMSVNFL 1223.5 70 
427 MPV-L SPPKRLIWSV 1182.4 60 
428 RSV-M IPYSGLLLVI 1087.4 90 
429 RSV-M2orf LPDKYPCSI 1035.2 67 
430 MPV-N VVLTRTYSL 1051.3 78 
431 MPV-N IARSSNNIM 1005.2 44 
432 MPV-L KTRRVLEYYL 1340.6 60 
433 MPV-L AICADVADEL 1019.1 70 
434 MPV-N GPESGLLHL 922 78 
435 MPV-L YPLEYQRVI 1180.4 67 
 
 165
Table 14, continued. 
 
Number Protein Sequence MW (g/mol) % Hydrophobicity 
436 RSV-L YIRIANSEL 1078.2 56 
437 MPV-M KPYGMVSKFV 1155.4 70 
438 MPV-L YPMYEVVLKL 1254.6 80 
439 RSV-L EPTYFQSLL 1097.2 67 
440 MPV-P GPTAARDGI 856.9 78 
441 MPV-N KIKNNKGEDL 1158.3 30 
442 RSV-N LAAGDRSGL 859 67 
443 MPV-M IPAFIKSVSI 1074.3 70 
444 MPV-L IPSWVSNWF 1135.3 67 
445 RSV-L IPAYRTTNY 1098.2 78 
446 RSV-F MPITNDQKKL 1187.4 50 
447 MPV-G SPVSPQTSA 872.9 56 
448 MPV-L TPVYPHGLRV 1138.3 90 
449 RSV-L TPDFLTEAI 1006.1 78 
450 MPV-N IPKIARSFY 1094.3 67 
451 RSV-G KPPSKPNNDF 1143.3 40 
452 MPV-L LTRNYMILL 1136.4 78 
 
 
 
Table 15.  Synthesized smallpox epitopes for HLA-A02 and HLA-B07. 
 
Number HLA Allele Sequence MW (g/mol) % Hydrophobicity 
453 A02 LIQEIVHEV 1078.6 67 
454 A02 ILNDEQLNL 1070.5 44 
455 A02 YITALNHLV 1042.6 89 
456 A02 VLNDQYAKV 1048.5 56 
457 A02 IVIEAHTV 880.5 87 
458 A02 KLSDSKITV 989.6 44 
459 A02 KVLDIDEIL 1056.6 56 
460 A02 FVEPEELNL 1088.5 56 
461 A02 FIFLKKNEL 1150.6 56 
462 A02 LLIDILILL 1037.7 89 
463 A02 ILFPDDVQEL 1187.6 60 
464 A02 YIDISDVKV 1050.5 56 
465 A02 SLSNLDFRL 1063.5 44 
466 A02 KLTELNAEL 1029.5 56 
467 A02 KVDDTFYYV 1148.5 67 
468 A02 YVNAILYQI 1095.6 78 
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Table 15, continued. 
 
Number HLA Allele Sequence MW (g/mol) % Hydrophobicity 
469 A02 NLFDIPLLTV 1143.6 80 
470 A02 FLTSVINRV 1047.6 67 
471 A02 ILDDNLYKV 1091.6 56 
472 A02 KIDYYIPYV 1172.6 78 
473 A02 FLNISWFYI 1201.6 78 
474 A02 GLNDYLHSV 1016.5 67 
475 A02 SMHFYGWSL 1126.5 78 
476 A02 ILSDENYLL 1078.5 56 
477 A02 FLVIAINAM 990.5 89 
478 A02 YLYTEYFLFI 1370.7 90 
479 A02 MMLVPLITV 1015.6 100 
480 A02 FILGIIITV 987.6 100 
481 A02 RLYDYFTRV 1231.6 67 
482 A02 GLFDFVNFV 1056.5 78 
483 A02 RTLLGLILFV 1143.7 90 
484 A02 SLSAYIIRV 1020.6 67 
485 A02 HVDGKILFV 1026.6 78 
486 A02 VLYDEFVTI 1097.6 78 
487 A02 RVYEALYYV 1174.6 78 
488 A02 YLPEVISTI 1033.5 78 
489 A02 FLIVSLCPT 991.5 89 
490 A02 IIIPFIAYFV 1194.7 100 
491 A02 ILMIFISSFL 1182.6 80 
492 A02 LMYDIINSV 1066.5 67 
493 B07 PPLISILMI 995.6 89 
494 B07 GPKSNIDFKI 1117.6 50 
495 B07 EPVVKDKIKL 1167.7 50 
496 B07 KPITYPKAL 1029.6 78 
497 B07 FPTNTLTSI 992.5 78 
498 B07 EPIRGYVIIL 1171.7 80 
499 B07 LPCQLMYAL 1050.5 89 
500 B07 TPVIVVPVI 935.6 100 
501 B07 LPNSNINII 996.5 56 
502 B07 RPIGIGVQGL 1008.6 80 
503 B07 EPLELVRYI 1130.6 67 
504 B07 VPITGSKLIL 1039.6 80 
505 B07 LPMIIGEPI 981.5 89 
506 B07 APASSLLPAL 938.5 80 
507 B07 LPASLKKNI 982.6 56 
508 B07 YPSNKNYEI 1126.5 44 
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Table 15, continued. 
 
Number HLA Allele Sequence MW (g/mol) % Hydrophobicity 
509 B07 RPNQHHTIDL 1229.6 60 
510 B07 RPRDAIRFL 1142.7 56 
511 B07 KPKPAVRFAI 1125.7 70 
512 B07 APNPNRFVI 1026.5 67 
513 B07 RPMSLRSTII 1172.6 60 
514 B07 MPAYIRNTL 1077.5 78 
515 B07 HPRHYATVM 1110.5 89 
516 B07 LPRPDTRHL 1103.6 67 
517 B07 KPFNNILNL 1071.6 56 
518 B07 RPSTRNFFEL 1265.6 50 
519 B07 GESKSYCEL 1014.4 44 
520 B07 DELVDPINY 1076.5 56 
521 B07 TEYDDHINL 1118.5 56 
522 B07 CLYTEYILWV 1301.6 90 
 
 
 
 As previously described, peptides were separated from their fragments via 
reverse-phase semi-preparative HPLC and were collected based on their absorbance at 
210 nm, corresponding to the absorbance of an amide bond.  The molecular weights of 
the collected fragments were then determined via matrix-assisted laser desorption 
ionization (MALDI) mass spectrometry and only fractions corresponding to the correct 
mass were collected for lyophilization.  The chromatograms and mass spectroscopic data 
for three separate peptides listed above have been provided in Figures 60-62 as examples 
of purification and characterization, respectively. 
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Figure 60.  (A) Chromatogram and (B) mass spectrum of Peptide 290 (YLSALRTGWY, 
MW = 1,228 g/mol). 
 
 
 
 
Figure 61.  (A) Chromatogram and (B) mass spectrum of Peptide 333 (MPTSAGQIKL, 
MW = 1,045 g/mol). 
 
 
 
 
Figure 62.  (A) Chromatogram and (B) mass spectrum of Peptide 408 (IPYTAAVQV, 
MW = 961 g/mol). 
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